35
Average Days in Review
97%
Percent of Research Articles Cited within Two Years of Publication
10
Average Days to Publication from Acceptance
Annual HTML+PDF Usage

CURRENT ISSUE

Volume 89Issue 8July 2021

EDITOR IN CHIEF: Dr. Andreas J. Bäumler

Explore IAI

Editor in Chief

IAI EiC Baumler
Dr. Andreas J. Bäumler

Editor in Chief (2022) | University of California at Davis

Andreas J. Bäumler is Professor and Vice Chair of Research of the Department of Medical Microbiology and Immunology at the University of California at Davis. His laboratory studies the interaction between enteric pathogens, the host, and its gut microbiota.

Editorial Board

  • Infection and ImmunityArticle
    Sex Matters: Male Hamsters Are More Susceptible to Lethal Infection with Lower Doses of Pathogenic Leptospira than Female Hamsters

    Sex Matters: Male Hamsters Are More Susceptible to Lethal Infection with Lower Doses of Pathogenic Leptospira than Female Hamsters

    ABSTRACT

    A somewhat contradictory published body of evidence suggests that sex impacts severity outcomes of human leptospirosis. In this study, we used an acute animal model of disease to analyze leptospirosis in male and female hamsters infected side by side with low but increasing doses of Leptospira interrogans serovar Copenhageni. We found that male hamsters were considerably more susceptible to leptospirosis, given that only 6.3% survived infection, whereas 68.7% of the females survived the same infection doses. In contrast to the females, male hamsters had high burdens of L. interrogans in kidney and high histopathological scores after exposure to low infection doses (∼103 bacteria). In hamsters infected with higher doses of L. interrogans (∼104 bacteria), differences in pathogen burdens as well as cytokine and fibrosis transcript levels in kidney were not distinct between sexes. Our results indicate that male hamsters infected with L. interrogans are more susceptible to severe leptospirosis after exposure to lower infectious doses than females.

    REFERENCES

    1.
    Levett PN. 2001. Leptospirosis. Clin Microbiol Rev 14:296–326.
    2.
    Haake DA, Levett PN. 2015. Leptospirosis in humans. Curr Top Microbiol Immunol 387:65–97.
    3.
    Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, Stein C, Abela-Ridder B, Ko AI. 2015. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis 9:e0003898.
    4.
    Fish EN. 2008. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 8:737–744.
    5.
    vom Steeg LG, Klein SL. 2016. SeXX matters in infectious disease pathogenesis. PLoS Pathog 12:e1005374.
    6.
    Guerra-Silveira F, Abad-Franch F. 2013. Sex bias in infectious disease epidemiology: patterns and processes. PLoS One 8:e62390.
    7.
    Raoult D, Mailloux M, De Chanville F, Chaudet H. 1985. Seroepidemiologic study on leptospirosis in the Camargue region. Bull Soc Pathol Exot Filiales 78:439–445. (In French.)
    8.
    Everard CO, Bennett S, Edwards CN, Nicholson GD, Hassell TA, Carrington DG, Everard JD. 1992. An investigation of some risk factors for severe leptospirosis on Barbados. J Trop Med Hyg 95:13–22.
    9.
    Goris MG, Kikken V, Straetemans M, Alba S, Goeijenbier M, van Gorp EC, Boer KR, Wagenaar JF, Hartskeerl RA. 2013. Towards the burden of human leptospirosis: duration of acute illness and occurrence of post-leptospirosis symptoms of patients in the Netherlands. PLoS One 8:e76549.
    10.
    Kawaguchi L, Sengkeopraseuth B, Tsuyuoka R, Koizumi N, Akashi H, Vongphrachanh P, Watanabe H, Aoyama A. 2008. Seroprevalence of leptospirosis and risk factor analysis in flood-prone rural areas in Lao PDR. Am J Trop Med Hyg 78:957–961.
    11.
    Thai KT, Binh TQ, Giao PT, Phuong HL, Hung LQ, Nam NV, Nga TT, Goris MG, de Vries PJ. 2006. Seroepidemiology of leptospirosis in southern Vietnamese children. Trop Med Int Health 11:738–745.
    12.
    Goris MG, Boer KR, Duarte TA, Kliffen SJ, Hartskeerl RA. 2013. Human leptospirosis trends, the Netherlands, 1925-2008. Emerg Infect Dis 19:371–378.
    13.
    Traxler RM, Callinan LS, Holman RC, Steiner C, Guerra MA. 2014. Leptospirosis-associated hospitalizations, United States, 1998-2009. Emerg Infect Dis 20:1273–1279.
    14.
    Ristow P, Bourhy P, da Cruz McBride FW, Figueira CP, Huerre M, Ave P, Girons IS, Ko AI, Picardeau M. 2007. The OmpA-like protein Loa22 is essential for leptospiral virulence. PLoS Pathog 3:e97.
    15.
    Croda J, Figueira CP, Wunder EA, Jr, Santos CS, Reis MG, Ko AI, Picardeau M. 2008. Targeted mutagenesis in pathogenic Leptospira species: disruption of the LigB gene does not affect virulence in animal models of leptospirosis. Infect Immun 76:5826–5833.
    16.
    Lambert A, Picardeau M, Haake DA, Sermswan RW, Srikram A, Adler B, Murray GA. 2012. FlaA proteins in Leptospira interrogans are essential for motility and virulence but are not required for formation of the flagellum sheath. Infect Immun 80:2019–2025.
    17.
    Eshghi A, Lourdault K, Murray GL, Bartpho T, Sermswan RW, Picardeau M, Adler B, Snarr B, Zuerner RL, Cameron CE. 2012. Leptospira interrogans catalase is required for resistance to H2O2 and for virulence. Infect Immun 80:3892–3899.
    18.
    Kassegne K, Hu W, Ojcius DM, Sun D, Ge Y, Zhao J, Yang XF, Li L, Yan J. 2014. Identification of collagenase as a critical virulence factor for invasiveness and transmission of pathogenic Leptospira species. J Infect Dis 209:1105–1115.
    19.
    Wunder EA, Jr, Figueira CP, Benaroudj N, Hu B, Tong BA, Trajtenberg F, Liu J, Reis MG, Charon NW, Buschiazzo A, Picardeau M, Ko AI. 2016. A novel flagellar sheath protein, FcpA, determines filament coiling, translational motility and virulence for the Leptospira spirochete. Mol Microbiol 101:457–470.
    20.
    Gomes-Solecki M, Santecchia I, Werts C. 2017. Animal models of leptospirosis: of mice and hamsters. Front Immunol 8:58.
    21.
    Lourdault K, Matsunaga J, Haake DA. 2016. High-throughput parallel sequencing to measure fitness of Leptospira interrogans transposon insertion mutants during acute infection. PLoS Negl Trop Dis 10:e0005117.
    22.
    Fontana C, Lambert A, Benaroudj N, Gasparini D, Gorgette O, Cachet N, Bomchil N, Picardeau M. 2016. Analysis of a spontaneous non-motile and avirulent mutant shows that FliM is required for full endoflagella assembly in Leptospira interrogans. PLoS One 11:e0152916.
    23.
    King AM, Pretre G, Bartpho T, Sermswan RW, Toma C, Suzuki T, Eshghi A, Picardeau M, Adler B, Murray GL. 2014. High-temperature protein G is an essential virulence factor of Leptospira interrogans. Infect Immun 82:1123–1131.
    24.
    Clayton JA, Collins FS. 2014. Policy: NIH to balance sex in cell and animal studies. Nature 509:282–283.
    25.
    Collins FS, Tabak LA. 2014. Policy: NIH plans to enhance reproducibility. Nature 505:612–613.
    26.
    Jansen A, Stark K, Schneider T, Schoneberg I. 2007. Sex differences in clinical leptospirosis in Germany: 1997-2005. Clin Infect Dis 44:e69–e72.
    27.
    Van CT, Thuy NT, San NH, Hien TT, Baranton G, Perolat P. 1998. Human leptospirosis in the Mekong delta, Viet Nam. Trans R Soc Trop Med Hyg 92:625–628.
    28.
    Leal-Castellanos CB, Garcia-Suarez R, Gonzalez-Figueroa E, Fuentes-Allen JL, Escobedo-de la Penal J. 2003. Risk factors and the prevalence of leptospirosis infection in a rural community of Chiapas, Mexico. Epidemiol Infect 131:1149–1156.
    29.
    Morgan J, Bornstein SL, Karpati AM, Bruce M, Bolin CA, Austin CC, Woods CW, Lingappa J, Langkop C, Davis B, Graham DR, Proctor M, Ashford DA, Bajani M, Bragg SL, Shutt K, Perkins BA, Tappero JW, Leptospirosis Working Group. 2002. Outbreak of leptospirosis among triathlon participants and community residents in Springfield, Illinois, 1998. Clin Infect Dis 34:1593–1599.
    30.
    Tomizawa R, Sugiyama H, Sato R, Ohnishi M, Koizumi N. 2017. Male-specific pulmonary hemorrhage and cytokine gene expression in golden hamster in early-phase Leptospira interrogans serovar Hebdomadis infection. Microb Pathog 111:33–40.
    31.
    Ganoza CA, Matthias MA, Collins-Richards D, Brouwer KC, Cunningham CB, Segura ER, Gilman RH, Gotuzzo E, Vinetz JM. 2006. Determining risk for severe leptospirosis by molecular analysis of environmental surface waters for pathogenic Leptospira. PLoS Med 3:e308.
    32.
    National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
    33.
    Richer L, Potula HH, Melo R, Vieira A, Gomes-Solecki M. 2015. Mouse model for sublethal Leptospira interrogans infection. Infect Immun 83:4693–4700.
    34.
    Fujita R, Koizumi N, Sugiyama H, Tomizawa R, Sato R, Ohnishi M. 2015. Comparison of bacterial burden and cytokine gene expression in golden hamsters in early phase of infection with two different strains of Leptospira interrogans. PLoS One 10:e0132694.
    35.
    Matsui M, Roche L, Geroult S, Soupe-Gilbert ME, Monchy D, Huerre M, Goarant C. 2016. Cytokine and chemokine expression in kidneys during chronic leptospirosis in reservoir and susceptible animal models. PLoS One 11:e0156084.
    36.
    Potula HH, Richer L, Werts C, Gomes-Solecki M. 2017. Pre-treatment with Lactobacillus plantarum prevents severe pathogenesis in mice infected with Leptospira interrogans and may be associated with recruitment of myeloid cells. PLoS Negl Trop Dis 11:e0005870.

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 86Number 10October 2018
    eLocator: e00369-18
    Editor: Guy H. Palmer
    Washington State University

    History

    Received: 14 May 2018
    3 June 2018
    Accepted: 9 July 2018
    Published online: 16 July 2018

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. Leptospira interrogans
    2. acute leptospirosis
    3. hamster
    4. sex
    5. acute
    6. lethal
    7. male

    Contributors

    Authors

    Charles K. Gomes
    Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    Immuno Technologies, Inc., Memphis, Tennessee, USA
    Universidade Federal de Pelotas, Pelotas, RS, Brazil
    Mariana Guedes
    Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    Immuno Technologies, Inc., Memphis, Tennessee, USA
    Hari-Hara Potula
    Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    Present address: Hari-Hara Potula, Stanford BioADD Laboratory, Palo Alto, California, USA.
    Odir A. Dellagostin
    Universidade Federal de Pelotas, Pelotas, RS, Brazil
    Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    Immuno Technologies, Inc., Memphis, Tennessee, USA

    Editor

    Guy H. Palmer
    Editor
    Washington State University

    Notes

    Address correspondence to Maria Gomes-Solecki, [email protected].
    C.K.G. and M.G. contributed equally.

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    Sequestration and Scavenging of Iron in Infection

    Sequestration and Scavenging of Iron in Infection

    ABSTRACT

    The proliferative capability of many invasive pathogens is limited by the bioavailability of iron. Pathogens have thus developed strategies to obtain iron from their host organisms. In turn, host defense strategies have evolved to sequester iron from invasive pathogens. This review explores the mechanisms employed by bacterial pathogens to gain access to host iron sources, the role of iron in bacterial virulence, and iron-related genes required for the establishment or maintenance of infection. Host defenses to limit iron availability for bacterial growth during the acute-phase response and the consequences of iron overload conditions on susceptibility to bacterial infection are also examined. The evidence summarized herein demonstrates the importance of iron bioavailability in influencing the risk of infection and the ability of the host to clear the pathogen.

    REFERENCES

    1.
    Graf E, Mahoney JR, Bryant RG, and Eaton JW. 1984. Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J. Biol. Chem. 259:3620–3624.
    2.
    Bergeron F, Auvre F, Radicella JP, and Ravanat JL. 2010. HO* radicals induce an unexpected high proportion of tandem base lesions refractory to repair by DNA glycosylases. Proc. Natl. Acad. Sci. U. S. A. 107:5528–5533.
    3.
    Schmitt TH, Frezzatti WA Jr, and Schreier S. 1993. Hemin-induced lipid membrane disorder and increased permeability: a molecular model for the mechanism of cell lysis. Arch. Biochem. Biophys. 307:96–103.
    4.
    Shaklai N, Avissar N, Rabizadeh E, and Shaklai M. 1986. Disintegration of red cell membrane cytoskeleton by hemin. Biochem. Int. 13:467–477.
    5.
    Shikama K. 2006. Nature of the FeO2 bonding in myoglobin and hemoglobin: a new molecular paradigm. Prog. Biophys. Mol. Biol. 91:83–162.
    6.
    Giulivi C and Cadenas E. 1998. Heme protein radicals: formation, fate, and biological consequences. Free Radic. Biol. Med. 24:269–279.
    7.
    Reeder BJ and Wilson MT. 2005. Hemoglobin and myoglobin associated oxidative stress: from molecular mechanisms to disease States. Curr. Med. Chem. 12:2741–2751.
    8.
    Bothwell T, Charlton R, Cook J, and Finch C. 1979. Iron metabolism in man. Blackwell, Oxford, England.
    9.
    Hahn PF, Bale WF, Lawrence EO, and Whipple GH. 1939. Radioactive Iron and its metabolism in anemia: its absorption, transportation, and utilization. J. Exp. Med. 69:739–753.
    10.
    Hahn PF, Bale WF, Hettig RA, Kamen MD, and Whipple GH. 1939. Radioactive iron and its excretion in urine, bile, and feces. J. Exp. Med. 70:443–451.
    11.
    McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E, Mudaly M, Richardson C, Barlow D, Bomford A, Peters TJ, Raja KB, Shirali S, Hediger MA, Farzaneh F, and Simpson RJ. 2001. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291:1755–1759.
    12.
    Choi J, Masaratana P, Latunde-Dada GO, Arno M, Simpson RJ, and McKie AT. 2012. Duodenal reductase activity and spleen iron stores are reduced and erythropoiesis is abnormal in Dcytb knockout mice exposed to hypoxic conditions. J. Nutr. 142:1929–1934.
    13.
    Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, and Hediger MA. 1997. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388:482–488.
    14.
    Kosman DJ. 2010. Redox cycling in iron uptake, efflux, and trafficking. J. Biol. Chem. 285:26729–26735.
    15.
    Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J, and Anderson GJ. 1999. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet. 21:195–199.
    16.
    Cherukuri S, Tripoulas NA, Nurko S, and Fox PL. 2004. Anemia and impaired stress-induced erythropoiesis in aceruloplasminemic mice. Blood Cells Mol. Dis. 33:346–355.
    17.
    Yang F, Lum JB, McGill JR, Moore CM, Naylor SL, van Bragt PH, Baldwin WD, and Bowman BH. 1984. Human transferrin: cDNA characterization and chromosomal localization. Proc. Natl. Acad. Sci. U. S. A. 81:2752–2756.
    18.
    Aisen P and Leibman A. 1972. Lactoferrin and transferrin: a comparative study. Biochim. Biophys. Acta 257:314–323.
    19.
    Mazurier J and Spik G. 1980. Comparative study of the iron-binding properties of human transferrins. I. Complete and sequential iron saturation and desaturation of the lactotransferrin. Biochim. Biophys. Acta 629:399–408.
    20.
    Masson PL, Heremans JF, and Schonne E. 1969. Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J. Exp. Med. 130:643–658.
    21.
    Miyazaki E, Kato J, Kobune M, Okumura K, Sasaki K, Shintani N, Arosio P, and Niitsu Y. 2002. Denatured H-ferritin subunit is a major constituent of haemosiderin in the liver of patients with iron overload. Gut 50:413–419.
    22.
    Pereira CG, Silva AL, de Castilhos P, Mastrantonio EC, Souza RA, Romao RP, Rezende RJ, Pena JD, Beletti ME, and Souza MA. 2009. Different isolates from Leishmania braziliensis complex induce distinct histopathological features in a murine model of infection. Vet. Parasitol. 165:231–240.
    23.
    Wang Y, Juan LV, Ma X, Wang D, Ma H, Chang Y, Nie G, Jia L, Duan X, and Liang XJ. 2010. Specific hemosiderin deposition in spleen induced by a low dose of cisplatin: altered iron metabolism and its implication as an acute hemosiderin formation model. Curr. Drug Metab. 11:507–515.
    24.
    Ward RJ, Legssyer R, Henry C, and Crichton RR. 2000. Does the haemosiderin iron core determine its potential for chelation and the development of iron-induced tissue damage? J. Inorg. Biochem. 79:311–317.
    25.
    Ozaki M, Kawabata T, and Awai M. 1988. Iron release from haemosiderin and production of iron-catalysed hydroxyl radicals in vitro. Biochem. J. 250:589–595.
    26.
    Donohue DM, Gabrio BW, and Finch CA. 1958. Quantitative measurement of hematopoietic cells of the marrow. J. Clin. Invest. 37:1564–1570.
    27.
    Larsen L and Milman N. 1975. Normal iron absorption determined by means of whole body counting and red cell incorporation of 59Fe. Acta Med. Scand. 198:271–274.
    28.
    Fleming RE and Ponka P. 2012. Iron overload in human disease. N. Engl. J. Med. 366:348–359.
    29.
    Osaki S, Johnson DA, and Frieden E. 1971. The mobilization of iron from the perfused mammalian liver by a serum copper enzyme, ferroxidase I. J. Biol. Chem. 246:3018–3023.
    30.
    Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, and Adermann K. 2000. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480:147–150.
    31.
    Park CH, Valore EV, Waring AJ, and Ganz T. 2001. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 276:7806–7810.
    32.
    Mazur A, Feillet-Coudray C, Romier B, Bayle D, Gueux E, Ruivard M, Coudray C, and Rayssiguier Y. 2003. Dietary iron regulates hepatic hepcidin 1 and 2 mRNAs in mice. Metabolism 52:1229–1231.
    33.
    Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, and Vaulont S. 2002. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110:1037–1044.
    34.
    Vokurka M, Krijt J, Sulc K, and Necas E. 2006. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol. Res. 55:667–674.
    35.
    Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, and Kaplan J. 2004. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–2093.
    36.
    Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, and Sadler PJ. 1989. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J. Biol. Chem. 264:4417–4422.
    37.
    Bullen JJ, Rogers HJ, and Griffiths E. 1978. Role of iron in bacterial infection. Curr. Top. Microbiol. Immunol. 80:1–35.
    38.
    Chaberek S and Martell AE. 1959. Organic sequestering agents. John Wiley & Sons, Inc, New York, NY.
    39.
    Andrews SC, Robinson AK, and Rodriguez-Quinones F. 2003. Bacterial iron homeostasis. FEMS Microbiol. Rev. 27:215–237.
    40.
    Hartmann A and Braun V. 1981. Iron uptake and iron limited growth of Escherichia coli K-12. Arch. Microbiol. 130:353–356.
    41.
    Higgs PI, Myers PS, and Postle K. 1998. Interactions in the TonB-dependent energy transduction complex: ExbB and ExbD form homomultimers. J. Bacteriol. 180:6031–6038.
    42.
    Krieg S, Huche F, Diederichs K, Izadi-Pruneyre N, Lecroisey A, Wandersman C, Delepelaire P, and Welte W. 2009. Heme uptake across the outer membrane as revealed by crystal structures of the receptor-hemophore complex. Proc. Natl. Acad. Sci. U. S. A. 106:1045–1050.
    43.
    Gudmundsdottir A, Bell PE, Lundrigan MD, Bradbeer C, and Kadner RJ. 1989. Point mutations in a conserved region (TonB box) of Escherichia coli outer membrane protein BtuB affect vitamin B12 transport. J. Bacteriol. 171:6526–6533.
    44.
    Torres VJ, Pishchany G, Humayun M, Schneewind O, and Skaar EP. 2006. Staphylococcus aureus IsdB is a hemoglobin receptor required for heme iron utilization. J. Bacteriol. 188:8421–8429.
    45.
    Dryla A, Gelbmann D, von Gabain A, and Nagy E. 2003. Identification of a novel iron regulated staphylococcal surface protein with haptoglobin-haemoglobin binding activity. Mol. Microbiol. 49:37–53.
    46.
    Sebbane F, Jarrett C, Gardner D, Long D, and Hinnebusch BJ. 2010. Role of the Yersinia pestis yersiniabactin iron acquisition system in the incidence of flea-borne plague. PLoS One 5(12):e14379.
    47.
    Wagegg W and Braun V. 1981. Ferric citrate transport in Escherichia coli requires outer membrane receptor protein fecA. J. Bacteriol. 145:156–163.
    48.
    Noinaj N, Easley NC, Oke M, Mizuno N, Gumbart J, Boura E, Steere AN, Zak O, Aisen P, Tajkhorshid E, Evans RW, Gorringe AR, Mason AB, Steven AC, and Buchanan SK. 2012. Structural basis for iron piracy by pathogenic Neisseria. Nature 483:53–58.
    49.
    Noinaj N, Cornelissen CN, and Buchanan SK. 2013. Structural insight into the lactoferrin receptors from pathogenic Neisseria. J. Struct. Biol. [Epub ahead of print.] doi:
    50.
    Lau CK, Ishida H, Liu Z, and Vogel HJ. 2013. Solution structure of Escherichia coli FeoA and its potential role in bacterial ferrous iron transport. J. Bacteriol. 195:46–55.
    51.
    Wyckoff EE, Mey AR, Leimbach A, Fisher CF, and Payne SM. 2006. Characterization of ferric and ferrous iron transport systems in Vibrio cholerae. J. Bacteriol. 188:6515–6523.
    52.
    Kammler M, Schon C, and Hantke K. 1993. Characterization of the ferrous iron uptake system of Escherichia coli. J. Bacteriol. 175:6212–6219.
    53.
    Stojiljkovic I, Cobeljic M, and Hantke K. 1993. Escherichia coli K-12 ferrous iron uptake mutants are impaired in their ability to colonize the mouse intestine. FEMS Microbiol. Lett. 108:111–115.
    54.
    Velayudhan J, Hughes NJ, McColm AA, Bagshaw J, Clayton CL, Andrews SC, and Kelly DJ. 2000. Iron acquisition and virulence in Helicobacter pylori: a major role for FeoB, a high-affinity ferrous iron transporter. Mol. Microbiol. 37:274–286.
    55.
    Tsolis RM, Baumler AJ, Heffron F, and Stojiljkovic I. 1996. Contribution of TonB- and Feo-mediated iron uptake to growth of Salmonella typhimurium in the mouse. Infect. Immun. 64:4549–4556.
    56.
    Vartivarian SE and Cowart RE. 1999. Extracellular iron reductases: identification of a new class of enzymes by siderophore-producing microorganisms. Arch. Biochem. Biophys. 364:75–82.
    57.
    Barchini E and Cowart RE. 1996. Extracellular iron reductase activity produced by Listeria monocytogenes. Arch. Microbiol. 166:51–57.
    58.
    Chatfield CH and Cianciotto NP. 2007. The secreted pyomelanin pigment of Legionella pneumophila confers ferric reductase activity. Infect. Immun. 75:4062–4070.
    59.
    Larson JA, Howie HL, and So M. 2004. Neisseria meningitidis accelerates ferritin degradation in host epithelial cells to yield an essential iron source. Mol. Microbiol. 53:807–820.
    60.
    Whitby PW, Vanwagoner TM, Springer JM, Morton DJ, Seale TW, and Stull TL. 2006. Burkholderia cenocepacia utilizes ferritin as an iron source. J. Med. Microbiol. 55:661–668.
    61.
    Daou N, Buisson C, Gohar M, Vidic J, Bierne H, Kallassy M, Lereclus D, and Nielsen-LeRoux C. 2009. IlsA, a unique surface protein of Bacillus cereus required for iron acquisition from heme, hemoglobin and ferritin. PLoS Pathog. 5(11):e1000675.
    62.
    Gupta R, Shah P, and Swiatlo E. 2009. Differential gene expression in Streptococcus pneumoniae in response to various iron sources. Microb. Pathog. 47:101–109.
    63.
    Bracken CS, Baer MT, Abdur-Rashid A, Helms W, and Stojiljkovic I. 1999. Use of heme-protein complexes by the Yersinia enterocolitica HemR receptor: histidine residues are essential for receptor function. J. Bacteriol. 181:6063–6072.
    64.
    Perkins-Balding D, Baer MT, and Stojiljkovic I. 2003. Identification of functionally important regions of a haemoglobin receptor from Neisseria meningitidis. Microbiology 149:3423–3435.
    65.
    Bates CS, Montanez GE, Woods CR, Vincent RM, and Eichenbaum Z. 2003. Identification and characterization of a Streptococcus pyogenes operon involved in binding of hemoproteins and acquisition of iron. Infect. Immun. 71:1042–1055.
    66.
    Mocny JC, Olson JS, and Connell TD. 2007. Passively released heme from hemoglobin and myoglobin is a potential source of nutrient iron for Bordetella bronchiseptica. Infect. Immun. 75:4857–4866.
    67.
    Morton DJ, Van Wagoner TM, Seale TW, Whitby PW, and Stull TL. 2006. Utilization of myoglobin as a heme source by Haemophilus influenzae requires binding of myoglobin to haptoglobin. FEMS Microbiol. Lett. 258:235–240.
    68.
    Otto BR, Sijbrandi R, Luirink J, Oudega B, Heddle JG, Mizutani K, Park SY, and Tame JR. 2005. Crystal structure of hemoglobin protease, a heme binding autotransporter protein from pathogenic Escherichia coli. J. Biol. Chem. 280:17339–17345.
    69.
    Drago-Serrano ME, Parra SG, and Manjarrez-Hernandez HA. 2006. EspC, an autotransporter protein secreted by enteropathogenic Escherichia coli (EPEC), displays protease activity on human hemoglobin. FEMS Microbiol. Lett. 265:35–40.
    70.
    Mazmanian SK, Skaar EP, Gaspar AH, Humayun M, Gornicki P, Jelenska J, Joachmiak A, Missiakas DM, and Schneewind O. 2003. Passage of heme-iron across the envelope of Staphylococcus aureus. Science 299:906–909.
    71.
    Wu R, Skaar EP, Zhang R, Joachimiak G, Gornicki P, Schneewind O, and Joachimiak A. 2005. Staphylococcus aureus IsdG and IsdI, heme-degrading enzymes with structural similarity to monooxygenases. J. Biol. Chem. 280:2840–2846.
    72.
    Andrade MA, Ciccarelli FD, Perez-Iratxeta C, and Bork P. 2002. NEAT: a domain duplicated in genes near the components of a putative Fe3+ siderophore transporter from Gram-positive pathogenic bacteria. Genome Biol. 3:RESEARCH0047.
    73.
    Maresso AW, Garufi G, and Schneewind O. 2008. Bacillus anthracis secretes proteins that mediate heme acquisition from hemoglobin. PLoS Pathog. 4(8):e1000132.
    74.
    Fabian M, Solomaha E, Olson JS, and Maresso AW. 2009. Heme transfer to the bacterial cell envelope occurs via a secreted hemophore in the Gram-positive pathogen Bacillus anthracis. J. Biol. Chem. 284:32138–32146.
    75.
    Wilks A and Schmitt MP. 1998. Expression and characterization of a heme oxygenase (Hmu O) from Corynebacterium diphtheriae. Iron acquisition requires oxidative cleavage of the heme macrocycle. J. Biol. Chem. 273:837–841.
    76.
    Skaar EP, Gaspar AH, and Schneewind O. 2004. IsdG and IsdI, heme-degrading enzymes in the cytoplasm of Staphylococcus aureus. J. Biol. Chem. 279:436–443.
    77.
    Reniere ML, Ukpabi GN, Harry SR, Stec DF, Krull R, Wright DW, Bachmann BO, Murphy ME, and Skaar EP. 2010. The IsdG-family of haem oxygenases degrades haem to a novel chromophore. Mol. Microbiol. 75:1529–1538.
    78.
    Matsui T, Nambu S, Ono Y, Goulding CW, Tsumoto K, and Ikeda-Saito M. 2013. Heme degradation by Staphylococcus aureus IsdG and IsdI liberates formaldehyde rather than carbon monoxide. Biochemistry 52:3025–3027.
    79.
    Suits MD, Pal GP, Nakatsu K, Matte A, Cygler M, and Jia Z. 2005. Identification of an Escherichia coli O157:H7 heme oxygenase with tandem functional repeats. Proc. Natl. Acad. Sci. U. S. A. 102:16955–16960.
    80.
    Wyckoff EE, Lopreato GF, Tipton KA, and Payne SM. 2005. Shigella dysenteriae ShuS promotes utilization of heme as an iron source and protects against heme toxicity. J. Bacteriol. 187:5658–5664.
    81.
    Kaur AP, Lansky IB, and Wilks A. 2009. The role of the cytoplasmic heme-binding protein (PhuS) of Pseudomonas aeruginosa in intracellular heme trafficking and iron homeostasis. J. Biol. Chem. 284:56–66.
    82.
    Lansky IB, Lukat-Rodgers GS, Block D, Rodgers KR, Ratliff M, and Wilks A. 2006. The cytoplasmic heme-binding protein (PhuS) from the heme uptake system of Pseudomonas aeruginosa is an intracellular heme-trafficking protein to the delta-regioselective heme oxygenase. J. Biol. Chem. 281:13652–13662.
    83.
    Bibb LA and Schmitt MP. 2010. The ABC transporter HrtAB confers resistance to hemin toxicity and is regulated in a hemin-dependent manner by the ChrAS two-component system in Corynebacterium diphtheriae. J. Bacteriol. 192:4606–4617.
    84.
    Torres VJ, Stauff DL, Pishchany G, Bezbradica JS, Gordy LE, Iturregui J, Anderson KL, Dunman PM, Joyce S, and Skaar EP. 2007. A Staphylococcus aureus regulatory system that responds to host heme and modulates virulence. Cell Host Microbe 1:109–119.
    85.
    Hudson AJ, Andrews SC, Hawkins C, Williams JM, Izuhara M, Meldrum FC, Mann S, Harrison PM, and Guest JR. 1993. Overproduction, purification and characterization of the Escherichia coli ferritin. Eur. J. Biochem. 218:985–995.
    86.
    Andrews SC, Smith JM, Hawkins C, Williams JM, Harrison PM, and Guest JR. 1993. Overproduction, purification and characterization of the bacterioferritin of Escherichia coli and a C-terminally extended variant. Eur. J. Biochem. 213:329–338.
    87.
    Andrews SC, Smith JM, Yewdall SJ, Guest JR, and Harrison PM. 1991. Bacterioferritins and ferritins are distantly related in evolution. Conservation of ferroxidase-centre residues. FEBS Lett. 293:164–168.
    88.
    Yasmin S, Andrews SC, Moore GR, and Le Brun NE. 2011. A new role for heme, facilitating release of iron from the bacterioferritin iron biomineral. J. Biol. Chem. 286:3473–3483.
    89.
    Zhao G, Ceci P, Ilari A, Giangiacomo L, Laue TM, Chiancone E, and Chasteen ND. 2002. Iron and hydrogen peroxide detoxification properties of DNA-binding protein from starved cells. A ferritin-like DNA-binding protein of Escherichia coli. J. Biol. Chem. 277:27689–27696.
    90.
    Gabay C and Kushner I. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340:448–454.
    91.
    Bode JG, Albrecht U, Haussinger D, Heinrich PC, and Schaper F. 2012. Hepatic acute phase proteins: regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur. J. Cell Biol. 91:496–505.
    92.
    Quinton LJ, Blahna MT, Jones MR, Allen E, Ferrari JD, Hilliard KL, Zhang X, Sabharwal V, Algul H, Akira S, Schmid RM, Pelton SI, Spira A, and Mizgerd JP. 2012. Hepatocyte-specific mutation of both NF-κB RelA and STAT3 abrogates the acute phase response in mice. J. Clin. Invest. 122:1758–1763.
    93.
    Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, Taga T, and Kishimoto T. 1993. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260:1808–1810.
    94.
    Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, and Ganz T. 2003. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101:2461–2463.
    95.
    Ganz T. 2011. Hepcidin and iron regulation, 10 years later. Blood 117:4425–4433.
    96.
    Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, and Ganz T. 2004. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113:1271–1276.
    97.
    Armitage AE, Eddowes LA, Gileadi U, Cole S, Spottiswoode N, Selvakumar TA, Ho LP, Townsend AR, and Drakesmith H. 2011. Hepcidin regulation by innate immune and infectious stimuli. Blood 118:4129–4139.
    98.
    Feng Q, Migas MC, Waheed A, Britton RS, and Fleming RE. 2012. Ferritin upregulates hepatic expression of bone morphogenetic protein 6 and hepcidin in mice. Am. J. Physiol. Gastrointest Liver Physiol. 302:G1397–G1404.
    99.
    Besson-Fournier C, Latour C, Kautz L, Bertrand J, Ganz T, Roth MP, and Coppin H. 2012. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood 120:431–439.
    100.
    Wang RH, Li C, Xu X, Zheng Y, Xiao C, Zerfas P, Cooperman S, Eckhaus M, Rouault T, Mishra L, and Deng CX. 2005. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2:399–409.
    101.
    De Domenico I, Zhang TY, Koening CL, Branch RW, London N, Lo E, Daynes RA, Kushner JP, Li D, Ward DM, and Kaplan J. 2010. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J. Clin. Invest. 120:2395–2405.
    102.
    Ross SL, Tran L, Winters A, Lee KJ, Plewa C, Foltz I, King C, Miranda LP, Allen J, Beckman H, Cooke KS, Moody G, Sasu BJ, Nemeth E, Ganz T, Molineux G, and Arvedson TL. 2012. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab. 15:905–917.
    103.
    Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, and Lafuse WP. 2007. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. J. Leukoc. Biol. 82:934–945.
    104.
    Nairz M, Theurl I, Schroll A, Theurl M, Fritsche G, Lindner E, Seifert M, Crouch ML, Hantke K, Akira S, Fang FC, and Weiss G. 2009. Absence of functional Hfe protects mice from invasive Salmonella enterica serovar Typhimurium infection via induction of lipocalin-2. Blood 114:3642–3651.
    105.
    Naz N, Moriconi F, Ahmad S, Amanzada A, Khan S, Mihm S, Ramadori G, and Malik IA. 2013. Ferritin L is the sole serum ferritin constituent and a positive hepatic acute-phase protein. Shock 39:520–526.
    106.
    Sammarco MC, Ditch S, Banerjee A, and Grabczyk E. 2008. Ferritin L and H subunits are differentially regulated on a post-transcriptional level. J. Biol. Chem. 283:4578–4587.
    107.
    Birgegard G and Caro J. 1984. Increased ferritin synthesis and iron uptake in inflammatory mouse macrophages. Scand. J. Haematol. 33:43–48.
    108.
    Lamothe J, Huynh KK, Grinstein S, and Valvano MA. 2007. Intracellular survival of Burkholderia cenocepacia in macrophages is associated with a delay in the maturation of bacteria-containing vacuoles. Cell. Microbiol. 9:40–53.
    109.
    Broadley C and Hoover RL. 1989. Ceruloplasmin reduces the adhesion and scavenges superoxide during the interaction of activated polymorphonuclear leukocytes with endothelial cells. Am. J. Pathol. 135:647–655.
    110.
    Goldstein IM, Kaplan HB, Edelson HS, and Weissmann G. 1979. Ceruloplasmin: a scavenger of superoxide anion radicals. J. Biol. Chem. 254:4040–4045.
    111.
    Haber F and Weiss J. 1934. The catalytic decomposition of hydrogen peroxide by iron salts. Proc. R Soc. Lond. A 147:332–351.
    112.
    Chiarla C, Giovannini I, and Siegel JH. 2009. Hypotransferrinemia and changes in plasma lipid and metabolic patterns in sepsis. Amino Acids 36:327–331.
    113.
    Fleming RE and Bacon BR. 2005. Orchestration of iron homeostasis. N. Engl. J. Med. 352:1741–1744.
    114.
    Prince OD, Langdon JM, Layman AJ, Prince IC, Sabogal M, Mak HH, Berger AE, Cheadle C, Chrest FJ, Yu Q, Andrews NC, Xue QL, Civin CI, Walston JD, and Roy CN. 2012. Late stage erythroid precursor production is impaired in mice with chronic inflammation. Haematologica 97:1648–1656.
    115.
    Ahmad G, Sial GZ, Ramadori P, Dudas J, Batusic DS, and Ramadori G. 2011. Changes of hepatic lactoferrin gene expression in two mouse models of the acute phase reaction. Int. J. Biochem. Cell Biol. 43:1822–1832.
    116.
    Topham MK, Carveth HJ, McIntyre TM, Prescott SM, and Zimmerman GA. 1998. Human endothelial cells regulate polymorphonuclear leukocyte degranulation. FASEB J. 12:733–746.
    117.
    Flores-Villasenor H, Canizalez-Roman A, Reyes-Lopez M, Nazmi K, de la Garza M, Zazueta-Beltran J, Leon-Sicairos N, and Bolscher JG. 2010. Bactericidal effect of bovine lactoferrin, LFcin, LFampin and LFchimera on antibiotic-resistant Staphylococcus aureus and Escherichia coli. Biometals 23:569–578.
    118.
    Appelmelk BJ, An YQ, Geerts M, Thijs BG, de Boer HA, MacLaren DM, de Graaff J, and Nuijens JH. 1994. Lactoferrin is a lipid A-binding protein. Infect. Immun. 62:2628–2632.
    119.
    Theilgaard-Monch K, Jacobsen LC, Nielsen MJ, Rasmussen T, Udby L, Gharib M, Arkwright PD, Gombart AF, Calafat J, Moestrup SK, Porse BT, and Borregaard N. 2006. Haptoglobin is synthesized during granulocyte differentiation, stored in specific granules, and released by neutrophils in response to activation. Blood 108:353–361.
    120.
    Buehler PW, Abraham B, Vallelian F, Linnemayr C, Pereira CP, Cipollo JF, Jia Y, Mikolajczyk M, Boretti FS, Schoedon G, Alayash AI, and Schaer DJ. 2009. Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification. Blood 113:2578–2586.
    121.
    Morgan WT, Liem HH, Sutor RP, and Muller-Ebergard U. 1976. Transfer of heme from heme-albumin to hemopexin. Biochim. Biophys. Acta 444:435–445.
    122.
    Hvidberg V, Maniecki MB, Jacobsen C, Hojrup P, Moller HJ, and Moestrup SK. 2005. Identification of the receptor scavenging hemopexin-heme complexes. Blood 106:2572–2579.
    123.
    Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, Tsuchihashi Z, Sigal E, Bjorkman PJ, and Schatzman RC. 1998. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc. Natl. Acad. Sci. U. S. A. 95:1472–1477.
    124.
    Niederkofler V, Salie R, and Arber S. 2005. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J. Clin. Invest. 115:2180–2186.
    125.
    Christopher GW. 1985. Escherichia coli bacteremia, meningitis, and hemochromatosis. Arch. Intern. Med. 145:1908.
    126.
    Fernandez JM, Serrano M, De Arriba JJ, Sanchez MV, Escribano E, and Ferreras P. 2000. Bacteremic cellulitis caused by non-01, non-0139 Vibrio cholerae: report of a case in a patient with hemochromatosis. Diagn. Microbiol. Infect. Dis. 37:77–80.
    127.
    Hopfner M, Nitsche R, Rohr A, Harms D, Schubert S, and Folsch UR. 2001. Yersinia enterocolitica infection with multiple liver abscesses uncovering a primary hemochromatosis. Scand. J. Gastroenterol. 36:220–224.
    128.
    Manso C, Rivas I, Peraire J, Vidal F, and Richart C. 1997. Fatal Listeria meningitis, endocarditis and pericarditis in a patient with haemochromatosis. Scand. J. Infect. Dis. 29:308–309.
    129.
    Bullen JJ, Spalding PB, Ward CG, and Gutteridge JM. 1991. Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch. Intern. Med. 151:1606–1609.
    130.
    Wang L, Harrington L, Trebicka E, Shi HN, Kagan JC, Hong CC, Lin HY, Babitt JL, and Cherayil BJ. 2009. Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J. Clin. Invest. 119:3322–3328.
    131.
    Olakanmi O, Schlesinger LS, and Britigan BE. 2007. Hereditary hemochromatosis results in decreased iron acquisition and growth by Mycobacterium tuberculosis within human macrophages. J. Leukoc. Biol. 81:195–204.
    132.
    Pippard MJ, Callender ST, Warner GT, and Weatherall DJ. 1979. Iron absorption and loading in beta-thalassaemia intermedia. Lancet ii:819–821.
    133.
    Chambers CE and Sokol PA. 1994. Comparison of siderophore production and utilization in pathogenic and environmental isolates of Yersinia enterocolitica. J. Clin. Microbiol. 32:32–39.
    134.
    Chan GC, Chan S, Ho PL, and Ha SY. 2009. Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin 33:352–360.
    135.
    Chiesa C, Pacifico L, Renzulli F, Midulla M, and Garlaschi L. 1987. Yersinia hepatic abscesses and iron overload. JAMA 257:3230–3231.
    136.
    Gangaidzo IT, Moyo VM, Mvundura E, Aggrey G, Murphree NL, Khumalo H, Saungweme T, Kasvosve I, Gomo ZA, Rouault T, Boelaert JR, and Gordeuk VR. 2001. Association of pulmonary tuberculosis with increased dietary iron. J. Infect. Dis. 184:936–939.
    137.
    Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, Lonnroth K, Patra J, Poznyak V, and Popova S. 2009. The association between alcohol use, alcohol use disorders and tuberculosis (TB): a systematic review. BMC Public Health 9:450.
    138.
    Zaridze D, Brennan P, Boreham J, Boroda A, Karpov R, Lazarev A, Konobeevskaya I, Igitov V, Terechova T, Boffetta P, and Peto R. 2009. Alcohol and cause-specific mortality in Russia: a retrospective case-control study of 48,557 adult deaths. Lancet 373:2201–2214.
    139.
    Baker MA, Wilson D, Wallengren K, Sandgren A, Iartchouk O, Broodie N, Goonesekera SD, Sabeti PC, and Murray MB. 2012. Polymorphisms in the gene that encodes the iron transport protein ferroportin 1 influence susceptibility to tuberculosis. J. Infect. Dis. 205:1043–1047.
    140.
    Masaisa F, Breman C, Gahutu JB, Mukiibi J, Delanghe J, and Philippe J. 2012. Ferroportin (SLC40A1) Q248H mutation is associated with lower circulating serum hepcidin levels in Rwandese HIV-positive women. Ann. Hematol. 91:911–916.
    141.
    Runyen-Janecky LJ, Reeves SA, Gonzales EG, and Payne SM. 2003. Contribution of the Shigella flexneri Sit, Iuc, and Feo iron acquisition systems to iron acquisition in vitro and in cultured cells. Infect. Immun. 71:1919–1928.
    142.
    Sun X, Ge R, Chiu JF, Sun H, and He QY. 2008. Lipoprotein MtsA of MtsABC in Streptococcus pyogenes primarily binds ferrous ion with bicarbonate as a synergistic anion. FEBS Lett. 582:1351–1354.
    143.
    Ferguson AD, Chakraborty R, Smith BS, Esser L, van der Helm D, and Deisenhofer J. 2002. Structural basis of gating by the outer membrane transporter FecA. Science 295:1715–1719.
    144.
    Luck SN, Turner SA, Rajakumar K, Sakellaris H, and Adler B. 2001. Ferric dicitrate transport system (Fec) of Shigella flexneri 2a YSH6000 is encoded on a novel pathogenicity island carrying multiple antibiotic resistance genes. Infect. Immun. 69:6012–6021.
    145.
    Morton DJ, Turman EJ, Hensley PD, VanWagoner TM, Seale TW, Whitby PW, and Stull TL. 2010. Identification of a siderophore utilization locus in nontypeable Haemophilus influenzae. BMC Microbiol. 10:113.
    146.
    Clancy A, Loar JW, Speziali CD, Oberg M, Heinrichs DE, and Rubens CE. 2006. Evidence for siderophore-dependent iron acquisition in group B streptococcus. Mol. Microbiol. 59:707–721.
    147.
    Cotton JL, Tao J, and Balibar CJ. 2009. Identification and characterization of the Staphylococcus aureus gene cluster coding for staphyloferrin A. Biochemistry 48:1025–1035.
    148.
    McMahon MD, Rush JS, and Thomas MG. 2012. Analyses of MbtB, MbtE, and MbtF suggest revisions to the mycobactin biosynthesis pathway in Mycobacterium tuberculosis. J. Bacteriol. 194:2809–2818.
    149.
    Wyckoff EE, Stoebner JA, Reed KE, and Payne SM. 1997. Cloning of a Vibrio cholerae vibriobactin gene cluster: identification of genes required for early steps in siderophore biosynthesis. J. Bacteriol. 179:7055–7062.
    150.
    Liu J, Duncan K, and Walsh CT. 1989. Nucleotide sequence of a cluster of Escherichia coli enterobactin biosynthesis genes: identification of entA and purification of its product 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase. J. Bacteriol. 171:791–798.
    151.
    Lawlor KM and Payne SM. 1984. Aerobactin genes in Shigella spp. J. Bacteriol. 160:266–272.
    152.
    Pollack JR and Neilands JB. 1970. Enterobactin, an iron transport compound from Salmonella typhimurium. Biochem. Biophys. Res. Commun. 38:989–992.
    153.
    Loosmore SM, Yang YP, Coleman DC, Shortreed JM, England DM, Harkness RE, Chong PS, and Klein MH. 1996. Cloning and expression of the Haemophilus influenzae transferrin receptor genes. Mol. Microbiol. 19:575–586.
    154.
    Modun B, Kendall D, and Williams P. 1994. Staphylococci express a receptor for human transferrin: identification of a 42-kilodalton cell wall transferrin-binding protein. Infect. Immun. 62:3850–3858.
    155.
    Biswas GD and Sparling PF. 1995. Characterization of lbpA, the structural gene for a lactoferrin receptor in Neisseria gonorrhoeae. Infect. Immun. 63:2958–2967.
    156.
    Schryvers AB. 1988. Characterization of the human transferrin and lactoferrin receptors in Haemophilus influenzae. Mol. Microbiol. 2:467–472.
    157.
    Parrow NL, Abbott J, Lockwood AR, Battisti JM, and Minnick MF. 2009. Function, regulation, and transcriptional organization of the hemin utilization locus of Bartonella quintana. Infect. Immun. 77:307–316.
    158.
    Henderson DP and Payne SM. 1994. Characterization of the Vibrio cholerae outer membrane heme transport protein HutA: sequence of the gene, regulation of expression, and homology to the family of TonB-dependent proteins. J. Bacteriol. 176:3269–3277.
    159.
    Cope LD, Yogev R, Muller-Eberhard U, and Hansen EJ. 1995. A gene cluster involved in the utilization of both free heme and heme:hemopexin by Haemophilus influenzae type b. J. Bacteriol. 177:2644–2653.
    160.
    Torres AG and Payne SM. 1997. Haem iron-transport system in enterohaemorrhagic Escherichia coli O157:H7. Mol. Microbiol. 23:825–833.
    161.
    Mills M and Payne SM. 1997. Identification of shuA, the gene encoding the heme receptor of Shigella dysenteriae, and analysis of invasion and intracellular multiplication of a shuA mutant. Infect. Immun. 65:5358–5363.
    162.
    Stojiljkovic I, Larson J, Hwa V, Anic S, and So M. 1996. HmbR outer membrane receptors of pathogenic Neisseria spp.: iron-regulated, hemoglobin-binding proteins with a high level of primary structure conservation. J. Bacteriol. 178:4670–4678.
    163.
    Dryla A, Hoffmann B, Gelbmann D, Giefing C, Hanner M, Meinke A, Anderson AS, Koppensteiner W, Konrat R, von Gabain A, and Nagy E. 2007. High-affinity binding of the staphylococcal HarA protein to haptoglobin and hemoglobin involves a domain with an antiparallel eight-stranded beta-barrel fold. J. Bacteriol. 189:254–264.
    164.
    Maciver I, Latimer JL, Liem HH, Muller-Eberhard U, Hrkal Z, and Hansen EJ. 1996. Identification of an outer membrane protein involved in utilization of hemoglobin-haptoglobin complexes by nontypeable Haemophilus influenzae. Infect. Immun. 64:3703–3712.
    165.
    Lewis LA and Dyer DW. 1995. Identification of an iron-regulated outer membrane protein of Neisseria meningitidis involved in the utilization of hemoglobin complexed to haptoglobin. J. Bacteriol. 177:1299–1306.
    166.
    Owens CP, Du J, Dawson JH, and Goulding CW. 2012. Characterization of heme ligation properties of Rv0203, a secreted heme binding protein involved in Mycobacterium tuberculosis heme uptake. Biochemistry 51:1518–1531.
    167.
    Ghigo JM, Letoffe S, and Wandersman C. 1997. A new type of hemophore-dependent heme acquisition system of Serratia marcescens reconstituted in Escherichia coli. J. Bacteriol. 179:3572–3579.
    168.
    Otto BR, van Dooren SJ, Nuijens JH, Luirink J, and Oudega B. 1998. Characterization of a hemoglobin protease secreted by the pathogenic Escherichia coli strain EB1. J. Exp. Med. 188:1091–1103.
    169.
    Torres VJ, Attia AS, Mason WJ, Hood MI, Corbin BD, Beasley FC, Anderson KL, Stauff DL, McDonald WH, Zimmerman LJ, Friedman DB, Heinrichs DE, Dunman PM, and Skaar EP. 2010. Staphylococcus aureus fur regulates the expression of virulence factors that contribute to the pathogenesis of pneumonia. Infect. Immun. 78:1618–1628.
    170.
    Goldberg MB, DiRita VJ, and Calderwood SB. 1990. Identification of an iron-regulated virulence determinant in Vibrio cholerae, using TnphoA mutagenesis. Infect. Immun. 58:55–60.
    171.
    Paulley JT, Anderson ES, and Roop RM II. 2007. Brucella abortus requires the heme transporter BhuA for maintenance of chronic infection in BALB/c mice. Infect. Immun. 75:5248–5254.
    172.
    Bearden SW and Perry RD. 1999. The Yfe system of Yersinia pestis transports iron and manganese and is required for full virulence of plague. Mol. Microbiol. 32:403–414.
    173.
    Fetherston JD, Kirillina O, Bobrov AG, Paulley JT, and Perry RD. 2010. The yersiniabactin transport system is critical for the pathogenesis of bubonic and pneumonic plague. Infect. Immun. 78:2045–2052.
    174.
    Pradel E, Guiso N, Menozzi FD, and Locht C. 2000. Bordetella pertussis TonB, a Bvg-independent virulence determinant. Infect. Immun. 68:1919–1927.
    175.
    Hsieh PF, Lin TL, Lee CZ, Tsai SF, and Wang JT. 2008. Serum-induced iron-acquisition systems and TonB contribute to virulence in Klebsiella pneumoniae causing primary pyogenic liver abscess. J. Infect. Dis. 197:1717–1727.
    176.
    Troxell B, Sikes ML, Fink RC, Vazquez-Torres A, Jones-Carson J, and Hassan HM. 2011. Fur negatively regulates hns and is required for the expression of HilA and virulence in Salmonella enterica serovar Typhimurium. J. Bacteriol. 193:497–505.
    177.
    Morton DJ, Seale TW, Bakaletz LO, Jurcisek JA, Smith A, VanWagoner TM, Whitby PW, and Stull TL. 2009. The heme-binding protein (HbpA) of Haemophilus influenzae as a virulence determinant. Int. J. Med. Microbiol. 299:479–488.
    178.
    Negre VL, Bonacorsi S, Schubert S, Bidet P, Nassif X, and Bingen E. 2004. The siderophore receptor IroN, but not the high-pathogenicity island or the hemin receptor ChuA, contributes to the bacteremic step of Escherichia coli neonatal meningitis. Infect. Immun. 72:1216–1220.

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 81Number 10October 2013
    Pages: 3503 - 3514
    Editor: A. T. Maurelli

    History

    Published online: 8 July 2013

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Nermi L. Parrow
    Division of Molecular and Clinical Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Robert E. Fleming
    Department of Pediatrics, Saint Louis University School of Medicine, St. Louis, Missouri, USA
    Michael F. Minnick
    Division of Biological Sciences, The University of Montana, Missoula, Montana, USA

    Editor

    A. T. Maurelli
    Editor

    Notes

    Address correspondence to Michael F. Minnick, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework

    Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework

    ABSTRACT

    Historically, the nature and extent of host damage by a microbe were considered highly dependent on virulence attributes of the microbe. However, it has become clear that disease is a complex outcome which can arise because of pathogen-mediated damage, host-mediated damage, or both, with active participation from the host microbiota. This awareness led to the formulation of the damage response framework (DRF), a revolutionary concept that defined microbial virulence as a function of host immunity. The DRF outlines six classifications of host damage outcomes based on the microbe and the strength of the immune response. In this review, we revisit this concept from the perspective of Candida albicans, a microbial pathogen uniquely adapted to its human host. This fungus commonly colonizes various anatomical sites without causing notable damage. However, depending on environmental conditions, a diverse array of diseases may occur, ranging from mucosal to invasive systemic infections resulting in microbe-mediated and/or host-mediated damage. Remarkably, C. albicans infections can fit into all six DRF classifications, depending on the anatomical site and associated host immune response. Here, we highlight some of these diverse and site-specific diseases and how they fit the DRF classifications, and we describe the animal models available to uncover pathogenic mechanisms and related host immune responses.

    REFERENCES

    1.
    Casadevall A, Pirofski L-A. 1999. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect Immun 67:3703–3713.
    2.
    Calderone RA. 2012. Candida and candidiasis. ASM Press, Washington, DC.
    3.
    Williams D, Jordan R, Wei X-Q, Alves C, Wise M, Wilson M, Lewis M. 21 October 2013. Interactions of Candida albicans with host epithelial surfaces. J Oral Microbiol doi:
    4.
    Naglik JR, Fidel PL, Odds FC. 2008. Animal models of mucosal Candida infection. FEMS Microbiol Lett 283:129–139.
    5.
    Naglik JR, Challacombe SJ, Hube B. 2003. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67:400–428.
    6.
    Tournu H, Serneels J, Van Dijck P. 2012. Candida biofilms and the host: models and new concepts for eradication. Int J Microbiol 2012:845352.
    7.
    Szabo EK, MacCallum DM. 2011. The contribution of mouse models to our understanding of systemic candidiasis. FEMS Microbiol Lett 320:1–8.
    8.
    Casadevall A, Pirofski L-A. 2015. What is a host? Incorporating the microbiota into the damage-response framework. Infect Immun 83:2–7.
    9.
    Casadevall A, Pirofski L-A. 2003. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 1:17–24.
    10.
    Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163.
    11.
    Ganguly S, Mitchell A. 2011. Mucosal biofilms of Candida albicans. Curr Opin Microbiol 14:380–385.
    12.
    Ellis M. 2002. Invasive fungal infections: evolving challenges for diagnosis and therapeutics. Mol Immunol 38:947–957.
    13.
    Mason K, Erb-Downward J, Mason K, Falkowski N, Eaton K, Kao J, Young V, Huffnagle G. 2012. Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy. Infect Immun 80:3371–3380.
    14.
    Liu M-B, Xu S-R, He Y, Deng G-H, Sheng H-F, Huang X-M, Ouyang C-Y, Zhou H-W. 2013. Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis. PLoS One 8:e79812.
    15.
    Southern P, Horbul J, Maher D, Davis DA. 2008. C. albicans colonization of human mucosal surfaces. PLoS One 3:e2067.
    16.
    Fidel P, Jr. 2002. Immunity to Candida. Oral Dis 8(Suppl 2):69–75.
    17.
    Pirofski L-A, Casadevall A. 2009. Rethinking T cell immunity in oropharyngeal candidiasis. J Exp Med 206:269.
    18.
    Finkel J, Mitchell A. 2011. Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 9:109–118.
    19.
    Mathe L, Van Dijck P. 2013. Recent insights into Candida albicans biofilm resistance. Curr Genet 59:251–264.
    20.
    Perlroth J, Choi B, Spellberg B. 2007. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 45:321–346.
    21.
    Filioti J, Spiroglou K, Panteliadis CP, Roilides E. 2007. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, mangement, and outcome. Intensive Care Med 33:1272–1283.
    22.
    Nett J, Andes D. 2006. Candida albicans biofilm development, modeling a host-pathogen interaction. Curr Opin Microbiol 9:340–345.
    23.
    Jabra-Rizk MA, Falkler WA, Jr, Meiller TF. 2004. Fungal biofilms and drug resistance. Emerg Infect Dis 10:14–19.
    24.
    Tsui CKE, Jabra-Rizk MA. 2016. Pathogenesis of Candida albicans biofilm. Pathog Dis 74:ftw018.
    25.
    Costerton JW, Montanaro L, Arciola CR. 2005. Biofilm in implant infections: its production and regulation. Int J Artif Organs 28:1062–1068.
    26.
    Lewis K. 2001. Riddle of biofilm resistance. Antimicrob Agents Chemother 45:999–1007.
    27.
    Ghannoum M, Roilides E, Katragkou A, Petraitis V, Walsh T. 2015. The role of echinocandins in Candida biofilm-related vascular catheter infections: in vitro and in vivo model systems. Clin Infect Dis 61(Suppl 6):S618–S621.
    28.
    Taff HT, Mitchell KF, Edward JA, Andes DR. 2013. Mechanisms of Candida biofilm drug resistance. Future Microbiol 8:1325–1337.
    29.
    Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in U.S. hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309–317.
    30.
    Williams D, Lewis M. 28 January 2011. Pathogenesis and treatment of oral candidosis. J Oral Microbiol doi:
    31.
    Garcia-Cuesta C, Sarrion-Pérez M, Bagán J. 2014. Current treatment of oral candidiasis: a literature review. J Clin Exp Dent 6:e576–e582.
    32.
    Lo H-L, Kohler J, DiDomenico D, Loebenberg D, Cacciapuoti A, Fink G. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90:939–949.
    33.
    Cleary IA, Reinhard SM, Lazzell AL, Monteagudo C, Thomas DP, Lopez-Ribot JL, Saville SP. 2016. Examination of the pathogenic potential of Candida albicans filamentous cells in an animal model of haematogenously disseminated candidiasis. FEMS Yeast Res 16:fow011.
    34.
    Hoyer LL. 2001. The ALS gene family of Candida albicans. Trends Microbiol 9:176–180.
    35.
    Naglik JR, Albrecht A, Bader O, Hube B. 2004. Candida albicans proteinases and host/pathogen interactions. Cell Microbiol 6:915–926.
    36.
    Peters ES, Jr, Eisenberg E. 1990. Oral candidiasis: the clinical diagnostic spectrum. J Conn State Dent Assoc 66:34–37.
    37.
    Fidel PL, Jr. 2011. Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis. Adv Dent Res 23:45–49.
    38.
    Fidel PL, Jr. 2006. Candida-host interactions in HIV disease: relationships in oropharyngeal candidiasis. Adv Dent Res 19:80–84.
    39.
    Redding SW, Zellars RC, Kirkpatrick WR, McAtee RK, Caceres MA, Fothergill AG, Lopez-Ribot JL, Bailey CW, Rinaldi MG, Paterson TF. 1999. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol 37:3896–3900.
    40.
    Naglik JR, Newport G, White TC, Fernandes-Naglik LL, Greenspan JS, Greenspan D, Sweet SP, Challacombe SJ, Agabian N. 1999. In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. Infect Immun 67:2482–2490.
    41.
    Kong EF TC, Boyce H, Ibrahim A, Hoag SW, Karlsson AJ, Meiller TF, Jabra-Rizk MA. 2015. Development and in vivo evaluation of a novel histatin-5 bioadhesive hydrogel formulation against oral candidiasis. Antimicrob Agents Chemother 60:881–889.
    42.
    Khan S, Fidel P, Jr, Al Thunayyan A, Meiller T, Jabra-Rizk M. 2013. Impaired histatin-5 level and salivary antimicrobial activity against C. albicans in HIV-infected individuals. J Acquir Immune Defic Syndr Clin Res 4:1–6.
    43.
    Edgerton M, Koshlukova SE, Lo TE, Chrzan BG, Straubinger RM, Raj PA. 1998. Candidacidal activity of salivary histatins. J Biol Chem 272:20438–20447.
    44.
    Peters B, Shirtliff M, Jabra-Rizk M. 2010. Antimicrobial peptides: primeval molecules or future drugs? PLoS Pathog 6:e1001067.
    45.
    Ashman R, Farah C, Wanasaengsakul S, Hu V, Pang G, Clancy R. 2004. Innate versus adaptive immunity in Candida albicans infection. Immunol Cell Biol 82:196–204.
    46.
    Farah C, Elahi S, Drysdale K, Pang G, Gotjamanos T, Seymour G, Clancy R, Ashman R. 2002. Primary role for CD4(+) T lymphocytes in recovery from oropharyngeal candidiasis. Infect Immun 70:724–731.
    47.
    Solis N, Filler S. 2012. Mouse model of oropharyngeal candidiasis. Nat Protoc 7:637–642.
    48.
    Kong E, Kucharíková S, Van Dijck P, Peters B, Shirtliff M, Jabra-Rizk M. 2015. Clinical implications of oral candidiasis: host tissue damage and disseminated bacterial disease. Infect Immun 83:604–613.
    49.
    de Repentigny L, Aumont F, Ripeau J-S, Fiorillo M, Kay D, Hanna Z, Jolicoeur P. 2002. Mucosal candidiasis in transgenic mice expressing human immunodeficiency virus type 1. J Infect Dis 185:1103–1114.
    50.
    Gaffen SL, Hernandez-Santos N, Peterson A. 2011. IL-17 signaling in host defense against Candida albicans. Immunol Res 50:181–187.
    51.
    Conti H, Shen F, Nayyar N, Stocum E, Sun J, Lindemann M, Ho A, Hai J, Yu J, Jung J, Filler S, Masso-Welch P, Edgerton M, Gaffen S. 2009. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206:299–311.
    52.
    Liang S, Tan X, Luxenberg D, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser L. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203:2271–2279.
    53.
    Harriott M, Lilly E, Rodriguez T, Fidel P, Jr, Noverr M. 2010. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 156:3635–3644.
    54.
    Hernández-Santos N, Huppler A, Peterson A, Khader S, McKenna K, Gaffen S. 2013. Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections. Mucosal Immunol 6:900–910.
    55.
    Clancy CJ, Nguyen MH. 2013. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56:1284–1292.
    56.
    Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329.
    57.
    Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections. Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29:996–1011.
    58.
    Lewis RE, Cahyame-Zuniga L, Leventakos K, Chamilos G, Ben-Ami R, Tamboli P, Tarrand J, Bodey GP, Luna M, Kontoyiannis DP. 2013. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 56:638–645.
    59.
    Parker JC, Jr, McCloskey JJ, Knauer KA. 1976. Pathobiologic features of human candidiasis. A common deep mycosis of the brain, heart and kidney in the altered host. Am J Clin Pathol 65:991–1000.
    60.
    Louria D, Stiff D, Bennett B. 1962. Disseminated moniliasis in the adult. Medicine 41:307–338.
    61.
    Morrell M, Fraser V, Kollef M. 2005. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640–3645.
    62.
    Pasqualotto AC, Nedel WL, Machado TS, Severo LC. 2006. Risk factors and outcome for nosocomial breakthrough candidaemia. J Infect 52:216–222.
    63.
    Eggimann P, Pittet D. 2014. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med 40:1429–1448.
    64.
    Spellberg B. 2008. Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge. PLoS Pathog 4:e38.
    65.
    Vonk A, Netea M, van der Meer J, Kullberg B. 2006. Host defence against disseminated Candida albicans infection and implications for antifungal immunotherapy. Expert Opin Biol Ther 6:891–903.
    66.
    Pappas PG. 2006. Invasive candidiasis. Infect Dis Clin North Am 20:485–506.
    67.
    MacCallum D, Odds F. 2005. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 48:151–161.
    68.
    MacCallum D. 2009. Massive induction of innate immune response to Candida albicans in the kidney in a murine intravenous challenge model. FEMS Yeast Res 9:1111–1122.
    69.
    Castillo LMD, Brown AJ, Gow NA, Odds FC. 2011. Differential regulation of kidney and spleen cytokine responses in mice challenged with pathology-standardized doses of Candida albicans mannosylation mutants. Infect Immun 79:146–152.
    70.
    Spellberg B, Ibrahim A, Edwards J, Jr, Filler S. 2005. Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis 192:336–343.
    71.
    Lazzell A, Chaturvedi A, Pierce C, Prasad D, Uppuluri P, Lopez-Ribot J. 2009. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother 64:567–570.
    72.
    Schinabeck MK, Long LA, Hossain MA, Chandra J, Mukherjee PK, Mohamed S, Ghannoum MA. 2004. Rapid model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother 48:1727–1732.
    73.
    Andes D, Nett J, Pschel P, Albrecht R, Marchillo K, Pitula A. 2004. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 72:6023–6031.
    74.
    Netea M, Gow N, Munro C, Bates S, Collins C, Ferwerda G, Hobson R, Bertram G, Hughes H, Jansen T, Jacobs L, Buurman E, Gijzen K, Williams D, Torensma R, McKinnon A, MacCallum D, Odds F, Van der Meer J, Brown A, Kullberg B. 2006. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 116:1642–1650.
    75.
    Van de Veerdonk F, Kullberg B, Verschueren I, Hendriks T, van der Meer J, Joosten L, Netea M. 2010. Differential effects of IL-17 pathway in disseminated candidiasis and zymosan-induced multiple organ failure. Shock 34:407–411.
    76.
    Huang W, Na L, Fidel P, Jr, Schwarzenberger P. 2004. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190:624–631.
    77.
    Onishi R, Gaffen S. 2010. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129:311–321.
    78.
    Maher CO, Dunne K, Comerford R, O'Dea S, Loy A, Woo J, Rogers TR, Mulcahy F, Dunne PJ, Doherty DG. 2015. Candida albicans stimulates IL-23 release by human dendritic cells and downstream IL-17 secretion by Vδ1 T cells. J Immunol 194:5953–5960.
    79.
    Dejima T, Shibata K, Yamada H, Hara H, Iwakura Y, Naito S, Yoshikai Y. 2011. Protective role of naturally occurring interleukin-17A-producing γδ T cells in the lung at the early stage of systemic candidiasis in mice. Infect Immun 79:4503–4510.
    80.
    Quintin J, Voigt J, van der Voort R, Jacobsen ID, Verschueren I, Hube B, Giamarellos-Bourboulis EJ, van der Meer JW, Joosten LA, Kurzai O, Netea MG. 2014. Differential role of NK cells against Candida albicans infection in immunocompetent or immunocompromised mice. Eur J Immunol 44:2405–2414.
    81.
    Koh A. 2013. Murine models of Candida gastrointestinal colonization and dissemination. Eukaryot Cell 12:1416–1422.
    82.
    Clemons K, Gonzalez G, Singh G, Imai J, Espiritu M, Parmar R, Stevens D. 2006. Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs. Antimicrob Agents Chemother 50:2650–2657.
    83.
    Koh A, Köhler J, Coggshall K, Van Rooijen N, Pier G. 2008. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog 8:e35.
    84.
    Balish E, Warner T, Nicholas P, Paulling E, Westwater C, Schofield D. 2005. Susceptibility of germfree phagocyte oxidase- and nitric oxide synthase 2-deficient mice, defective in the production of reactive metabolites of both oxygen and nitrogen, to mucosal and systemic candidiasis of endogenous origin. Infect Immun 73:1313–1320.
    85.
    Lionakis M. 2014. New insights into innate immune control of systemic candidiasis. Med Mycol 52:555–564.
    86.
    Raaijmakers R, Schroder C, Monnens L, Cornelissen E, Warris A. 2007. Fungal periotonitis in children on peritoneal dialysis. Pediatr Nephrol 22:288–293.
    87.
    Rebolledo M, Sarria J. 2013. Candida peritonitis intra-abdominal fungal infections. Curr Opin Infect Dis 26:441–446.
    88.
    Montravers P, Dupont H, Eggimann P. 2013. Intra-abdominal candidiasis: the guidelines—forgotten non-candidemic invasive candidiasis. Intensive Care Med 39:2226–2230.
    89.
    Cheng S, Clancy C, Xu W, Schneider F, Hao B, Mitchell A, Nguyen M-H. 2013. Profiling of Candida albicans gene expression during intra-abdominal candidiasis identifies biologic processes involved in pathogenesis. J Infect Dis 208:1529–1537.
    90.
    Vergidis P, Clancy CJ, Shields RK, Park SY, Wildfeuer BN, Simmons RL, Nguyen MH. 2016. Intra-abdominal candidiasis: the importance of early source control and antifungal treatment. PLoS One 11:e0153247.
    91.
    Wojtowicz A, Tissot F, Lamoth F, Orasch C, Eggimann P, Siegemund M, Zimmerli S, Flueckiger UM, Bille J, Calandra T, Marchetti O, Bochud PY, Fungal Infection Network of Switzerland. 2014. Polymorphisms in tumor necrosis factor-alpha increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients. Crit Care Med 42:e304–e308.
    92.
    Dupont H, Paugam-Burtz C, Muller-Serieys C, Fierobe L, Chosidow D, Marmuse JP, Mantz J, Desmonts JM. 2002. Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg 137:1341–1346.
    93.
    Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. 1996. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 23:486–494.
    94.
    Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. 1989. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet ii:1437–1440.
    95.
    Blot SI, Vandewoude KH, De Waele JJ. 2007. Candida peritonitis. Curr Opin Crit Care 13:195–199.
    96.
    Nash E, Peters B, Palmer G, Fidel P, Jr, Noverr M. 2014. Morphogenesis is not required for Candida albicans-Staphylococcus aureus intra-abdominal infection-mediated dissemination and lethal sepsis. Infect Immun 82:3426–3435.
    97.
    Peters B, Noverr M. 2013. Candida albicans-Staphylococcus aureus polymicrobial peritonitis modulates host innate immunity. Infect Immun 81:2178–2189.
    98.
    Nash E, Peters B, Fidel P, Jr, Noverr M. 2015. Morphology-independent virulence of Candida species during polymicrobial intra-abdominal infections with Staphylococcus aureus. Infect Immun 84:90–98.
    99.
    Felk A, Kretschmar M, Albrecht A, Schaller M, Beinhauser S, Nichterlein T, Sanglard D, Korting H, Schäfer W, Hube B. 2002. Candida albicans hyphal formation and the expression of the Efg1-regulated proteinases Sap4 to Sap6 are required for the invasion of parenchymal organs. Infect Immun 70:3689–3700.
    100.
    Koh A. 2013. Gastrointestinal colonization of fungi. Curr Fungal Infect Rep 7:144–151.
    101.
    Rashid MU, Rosenborg S, Panagiotidis G, Soderberg-Lofdal K, Weintraub A, Nord CE. 2015. Ecological effect of ceftaroline-avibactam on the normal human intestinal microbiota. Antimicrob Agents Chemother 59:4504–4509.
    102.
    Lacour M, Zunder T, Huber R, Sander A, Daschner F, Frank U. 2002. The pathogenetic significance of intestinal Candida colonization: a systematic review from an interdisciplinary and environmental medical point of view. Int J Hyg Environ Health 205:257–268.
    103.
    Wheeler ML, Limon JJ, Bar AS, Leal CA, Gargus M, Tang J, Brown J, Funari VA, Wang HL, Crother TR, Arditi M, Underhill DM, Iliev ID. 2016. Immunological consequences of intestinal fungal dysbiosis. Cell Host Microbe 19:865–873.
    104.
    Erdogan A, Rao S. 2015. Small intestinal fungal overgrowth. Curr Gastroenterol Rep 17:16.
    105.
    Schulze J, Sonnenborn U. 2009. Yeasts in the gut: from commensals to infectious agents. Dtsch Arztebl Int 106:837–842.
    106.
    Cantorna M, Balish E. 1991. Acquired immunity to systemic candidiasis in immunodeficient mice. J Infect Dis 164:936–943.
    107.
    Vazquez-Torres A, Jones-Carson J, Warner T, Balish E. 1995. Nitric oxide enhances resistance of SCID mice to mucosal candidiasis. J Infect Dis 172:192–198.
    108.
    Cantorna M, Balish E. 1990. Mucosal and systemic candidiasis in congenitally immunodeficient mice. Infect Immun 58:1093–1100.
    109.
    Balish E, Jensen J, Warner T, Brekke J, Leonard B. 1993. Mucosal and disseminated candidiasis in gnotobiotic SCID mice. J Med Vet Mycol 31:143–154.
    110.
    Balish E, Balish M, Salkowski C, Lee K, Bartizal K. 1984. Colonization of congenitally athymic, gnotobiotic mice by Candida albicans. Appl Environ Microbiol 47:647–652.
    111.
    Cenci E, Mencacci A, Spaccapelo R, Tonnetti L, Mosci P, Enssle K, Puccetti P, Romani L, Bistoni F. 1995. T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis 171:1279–1288.
    112.
    Jones-Carson J, Vazquez-Torres A, Warner T, Balish E. 2000. Disparate requirement for T cells in resistance to mucosal and acute systemic candidiasis. Infect Immun 68:2363–2365.
    113.
    Noverr M, Noggle R, Toews G, Huffnagle G. 2004. Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect Immun 72:4996–5003.
    114.
    Noverr M, Falkowski N, McDonald R, McKenzie A, Huffnagle G. 2005. Development of allergic airway disease in mice following antibiotic therapy and fungal microbiota increase: role of host genetics, antigen, and interleukin-13. Infect Immun 73:30–38.
    115.
    Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, Brown J, Becker CA, Fleshner PR, Dubinsky M, Rotter JI, Wang HL, McGovern DP, Brown GD, Underhill DM. 2012. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 336:1314–1317.
    116.
    Jawhara S, Thuru X, Standaert-Vitse A, Jouault T, Mordon S, Sendid B, Desreumaux P, Poulain D. 2008. Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. J Infect Dis 197:972–980.
    117.
    Xin L, Jiang T, Chaturvedi V, Kinder J, Ertelt J, Rowe J, Steinbrecher K, Way S. 2014. Commensal microbes drive intestinal inflammation by IL-17-producing CD4+ T cells through ICOSL and OX40L costimulation in the absence of B7-1 and B7-2. Proc Natl Acad Sci U S A 111:10672–10677.
    118.
    Ott S, Kuhbacher T, Musfeldt M, Rosenstiel P, Hellmig S, Rehman A, Drews O, Weichert W, Timmis K, Schreiber S. 2008. Fungi and inflammatory bowel diseases: alterations of composition and diversity. Scand J Gastroenterol 43:831–841.
    119.
    Enache-Angoulvant A, Bourget M, Brisse S, Stockman-Pannier C, Diancourt L, Francois N, Rimek D, Fairhead C, Poulain D, Hennequin C. 2010. Multilocus microsatellite markers for molecular typing of Candida glabrata: application to analysis of genetic relationships between bloodstream and digestive system isolates. J Clin Microbiol 48:4028–4034.
    120.
    Webb BC, Thomas CJ, Willcox MDP, Harty DWS, Knox KW. 1998. Candida-associated denture stomatitis. Aetiology and management: a review. Part 3. Treatment of oral candidosis. Austr Dent J 43:244–249.
    121.
    Ramage G, Tomsett K, Wickes BL, Lopez-Ribot JL, Redding SW. 2004. Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:53–59.
    122.
    Budtz-Jörgensen E. 1974. The significance of Candida albicans in denture stomatitis. Eur J Oral Sci 82:151–190.
    123.
    Johnson C, Yu A, Lee H, Fidel PL, Noverr MC. 2012. Development of a contemporary animal model of Candida albicans-associated denture stomatitis using a novel intraoral denture system. Infect Immun 80:1736–1743.
    124.
    Lee H, Yu A, Johnson CC, Lilly EA, Noverr MC, Fidel PL, Jr. 2011. Fabrication of a multi-applicable removable intraoral denture system for rodent research. J Oral Rehabil 38:686–690.
    125.
    Lee H, Alika Y, Fidel P. June 2014. Removable rodent intraoral device. US Patent 8,753,113 B2.
    126.
    Tobouti PL, Casaroto AR, de Almeida RS, de Paula Ramos S, Dionísio TJ, Porto VC, Santos CF, Lara VS. 2016. Expression of secreted aspartyl proteinases in an experimental model of Candida albicans-associated denture stomatitis. J Prosthodont 25:127–134.
    127.
    Miranda LN, van der Heijden IM, Costa SF, Sousa AP, Sienra RA, Gobara S, Santos CR, Lobo RD, Pessoa VP, Jr, Levin AS. 2009. Candida colonisation as a source for candidaemia. J Hosp Infect 72:9–16.
    128.
    Bergendal T, Holmberg K, Nord C-E. 1979. Yeast colonization in the oral cavity and feces in patients with denture stomatitis. Acta Odontol Scand 37:37–45.
    129.
    Gasparoto T, de Oliveira C, Vieira N, Porto V, Gasparoto C, Campanelli A, Lara V. 2012. The pattern recognition receptors expressed on neutrophils and the associated cytokine profile from different aged patients with Candida-related denture stomatitis. Exp Gerontol 47:741–748.
    130.
    Peters B, Yano J, Noverr M, Fidel P. 2014. Candida vaginitis: when opportunism knocks, the host responds. PLoS Pathog 10:e1003965.
    131.
    Sobel J, Faro S, Foxman B, Ledge W, Nyirjesy P, Reed B, Summers P. 1998. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 178:203–211.
    132.
    Sobel J, Chaim W. 1996. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol 34:2497–2499.
    133.
    McClelland R, Richardson B, Hassan W, Graham S, Kiarie J, Baeten J, Mandaliya K, Jaoko W, Ndinya-Achola J, Holmes K. 2009. Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. J Infect Dis 199:1883–1890.
    134.
    Fidel PL, Jr, Barousse M, Espinosa T, Ficarra M, Sturtevant J, Martin DH, Quayle AJ, Dunlap K. 2004. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 72:2939–2946.
    135.
    Fidel P, Jr. 2004. History and new insights into host defense against vaginal candidiasis. Trends Microbiol 12:220–227.
    136.
    Sobel J. 1992. Pathogenesis and treatment of recurrent vulvovagnial candidiasis. Clin Infect Dis 14:S148–S153.
    137.
    Sobel JD, Muller G, Buckley HR. 1984. Critical role of germ tube formation in the pathogenesis of candidal vaginitis. Infect Immun 44:576–580.
    138.
    Zhou X, Westman R, Hickey R, Hansmann M, Kennedy C, Osborn T, Forney L. 2009. Vaginal microbiota of women with frequent vulvovaginal candidiasis. Infect Immun 77:4130–4135.
    139.
    Yano J, Fidel P, Jr. 2011. Protocols for vaginal inoculation and sample collection in the experimental mouse model of Candida vaginitis. J Vis Exp 58:3382.
    140.
    de Bernardis F, Arancia S, Morelli L, Hube B, Sanglard D, Schafer W, Cassone A. 1990. Evidence that members of the secretory aspartyl proteinases gene family (SAP), in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 179:201–208.
    141.
    de Bernardis F, Cassone A, Sturtevant J, Calderone R. 1995. Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect Immun 63:1887–1892.
    142.
    Lian CH, Liu WD. 2007. Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis. Mycoses 50:383–390.
    143.
    Naglik JR, Moyes D, Makwana J, Kanzaria P, Tsichlaki E, Weindl G, Tappuni AR, Rodgers CA, Woodman AJ, Challacombe SJ, Schaller M, Hube B. 2008. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 154:3266–3280.
    144.
    Fidel PL, Jr, Vazquez JA, Sobel JD. 1999. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 12:80–96.
    145.
    Nash EE, Peters BM, Lilly EA, Noverr MC, Fidel PL, Jr. 2016. A murine model of Candida glabrata vaginitis shows no evidence of an inflammatory immunopathogenic response. PLoS One 11:e0147969.
    146.
    Yano J, Noverr MC, Fidel PL, Jr. 2012. Cytokines in the host response to Candida vaginitis: identifying a role for non-classical immune mediators, S100 alarmins. Cytokine 58:118–128.
    147.
    Yano J, Lilly E, Barousse M, Fidel PL, Jr. 2010. Epithelial cell-derived S100 calcium-binding proteins as key mediators in the hallmark acute neutrophil response during Candida vaginitis. Infect Immun 78:5126–5137.
    148.
    Bruno VM, Wang Z, Marjani SL, Euskirchen GM, Martin J, Sherlock G, Snyder M. 2010. Comprehensive annotation of the transcriptome of the human fungal pathogen Candida albicans using RNA-seq. Genome Res 20:1451–1458.
    149.
    Steele C, Fidel P, Jr. 2002 Cytokine and chemokine production by human oral and vaginal epithelial cells in response to Candida albicans. Infect Immun 70:577–583.
    150.
    Fidel PJ. 2003. Immune regulation and its role in the pathogenesis of candida vaginitis. Curr Infect Dis Rep 5:488–493.
    151.
    De Bernardis F, Arancia S, Sandini S, Graziani S, Norelli S. 2015. Studies of immune responses in Candida vaginitis. Pathogens 4:697–707.
    152.
    Cassone A. 2015. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG 122:785–794.
    153.
    Pietrella D, Rachini A, Pines M, Pandey N, Mosci P, Bistoni F, d'Enfert C, Vecchiarelli A. 2011. Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS One 6:e22770.
    154.
    Drell T, Lillsaar T, Tummeleht L, Simm J, Aaspollu A, Vain E, Saarma I, Salumets A, Donders G, Metsis M. 2013. Characterization of the vaginal micro- and mycobiome in asymptomatic reproductive-age Estonian women. PLoS One 8:e54379.
    155.
    Vitali B, Pugliese C, Biagi E, Candela M, Turroni S, Bellen G, Donders G, Brigidi P. 2007. Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR. Appl Environ Microbiol 73:5731–5741.
    156.
    van de Wijgert J, Borgdorff H, Verhelst R, Crucitti T, Francis S, Verstraelen H, Jespers V. 2014. The vaginal microbiota: what have we learned after a decade of molecular characterization? PLoS One 9:e105998.
    157.
    Sender R, Fuchs S, Milo R. 2016. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 164:337–340.
    158.
    Ursell L, Metcalf J, Parfrey L, Knight R. 2012. Defining the human microbiome. Nutr Rev 70:S38–S44.
    159.
    Belizario JE, Napolitano M. 2015. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Front Microbiol 6:1050.
    160.
    Mushin R, Dubos R. 1965. Colonization of the mouse intestine with Escherichia coli. J Exp Med 122:745.
    161.
    Francino MP. 2015. Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. Front Microbiol 6:1543.
    162.
    Dethlefsen L, McFall-Ngai M, Relman DA. 2007. An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449:811–818.
    163.
    Wagner RD, Pierson C, Warner T, Dohnalek M, Hilty M, Balish E. 2000. Probiotic effects of feeding heat-killed Lactobacillus acidophilus and Lactobacillus casei to Candida albicans-colonized immunodeficient mice. J Food Prot 63:638–644.
    164.
    Rooks MG, Garrett WS. 2016. Gut microbiota, metabolites and host immunity. Nat Rev Immunol 16:341–352.
    165.
    Blumberg R, Powrie F. 2012. Microbiota, disease, and back to health: a metastable journey. Sci Transl Med 4:137rv137.
    166.
    Kong EF, Fidel P, Jabra-Rizk MA. 2015. Candida albicans: love-hate relationship with its human host. Microbe Mag 10:413–418.

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 84Number 10October 2016
    Pages: 2724 - 2739
    Editor: A. T. Maurelli
    University of Florida

    History

    Published online: 18 July 2016

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Mary Ann Jabra-Rizk
    Department of Oncology and Diagnostic Sciences, Dental School, University of Maryland, Baltimore, Maryland, USA
    Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland, USA
    Eric F. Kong
    Department of Oncology and Diagnostic Sciences, Dental School, University of Maryland, Baltimore, Maryland, USA
    Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland, USA
    Graduate Program in Life Sciences, Molecular Microbiology and Immunology Program, University of Maryland, Baltimore, Maryland, USA
    Christina Tsui
    Department of Oncology and Diagnostic Sciences, Dental School, University of Maryland, Baltimore, Maryland, USA
    M. Hong Nguyen
    Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cornelius J. Clancy
    Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Infectious Diseases Section, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA
    Paul L. Fidel Jr.,
    Center of Excellence in Oral and Craniofacial Biology, Louisiana State University Health Sciences Center School of Dentistry, New Orleans, Louisiana, USA
    Mairi Noverr
    Center of Excellence in Oral and Craniofacial Biology, Louisiana State University Health Sciences Center School of Dentistry, New Orleans, Louisiana, USA

    Editor

    A. T. Maurelli
    Editor
    University of Florida

    Notes

    Address correspondence to Mary Ann Jabra-Rizk, [email protected].
    M.A.J.-R., E.F.K., P.L.F., and M.N. contributed equally to this work.

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    Bacterial Guanine Nucleotide Exchange Factors SopE-Like and WxxxE Effectors

    Bacterial Guanine Nucleotide Exchange Factors SopE-Like and WxxxE Effectors

    ABSTRACT

    Subversion of Rho family small GTPases, which control actin dynamics, is a common infection strategy used by bacterial pathogens. In particular, Salmonella enterica serovar Typhimurium, Shigella flexneri, enteropathogenic Escherichia coli (EPEC), and enterohemorrhagic Escherichia coli (EHEC) translocate type III secretion system (T3SS) effector proteins to modulate the Rho GTPases RhoA, Cdc42, and Rac1, which trigger formation of stress fibers, filopodia, and lamellipodia/ruffles, respectively. The Salmonella effector SopE is a guanine nucleotide exchange factor (GEF) that activates Rac1 and Cdc42, which induce “the trigger mechanism of cell entry.” Based on a conserved Trp-xxx-Glu motif, the T3SS effector proteins IpgB1 and IpgB2 of Shigella, SifA and SifB of Salmonella, and Map of EPEC and EHEC were grouped together into a WxxxE family; recent studies identified the T3SS EPEC and EHEC effectors EspM and EspT as new family members. Recent structural and functional studies have shown that representatives of the WxxxE effectors share with SopE a 3-D fold and GEF activity. In this minireview, we summarize contemporary findings related to the SopE and WxxxE GEFs in the context of their role in subverting general host cell signaling pathways and infection.

    REFERENCES

    1.
    Alto, N. M., F. Shao, C. S. Lazar, R. L. Brost, G. Chua, S. Mattoo, S. A. McMahon, P. Ghosh, T. R. Hughes, C. Boone, and J. E. Dixon.2006. Identification of a bacterial type III effector family with G protein mimicry functions. Cell124:133-145.
    2.
    Arbeloa, A., M. Blanco, F. C. Moreira, R. Bulgin, C. Lopez, G. Dahbi, J. E. Blanco, A. Mora, M. P. Alonso, R. C. Mamani, T. A. Gomes, J. Blanco, and G. Frankel.2009. Distribution of espM and espT among enteropathogenic and enterohaemorrhagic Escherichia coli. J. Med. Microbiol.58:988-995.
    3.
    Arbeloa, A., R. R. Bulgin, G. MacKenzie, R. K. Shaw, M. J. Pallen, V. F. Crepin, C. N. Berger, and G. Frankel.2008. Subversion of actin dynamics by EspM effectors of attaching and effacing bacterial pathogens. Cell. Microbiol.10:1429-1441.
    4.
    Arbeloa, A., J. Garnett, J. Lillington, R. R. Bulgin, C. Berger, S. M. Lea, S. Matthews, and G. Frankel. 21 December 2009, posting date. EspM2 is a RhoA guanine nucleotide exchange factor. Cell. Microbiol. doi:
    5.
    Bakshi, C. S., V. P. Singh, M. W. Wood, P. W. Jones, T. S. Wallis, and E. E. Galyov.2000. Identification of SopE2, a Salmonella secreted protein which is highly homologous to SopE and involved in bacterial invasion of epithelial cells. J. Bacteriol.182:2341-2344.
    6.
    Bellanger, J. M., C. Astier, C. Sardet, Y. Ohta, T. P. Stossel, and A. Debant.2000. The Rac1- and RhoG-specific GEF domain of Trio targets filamin to remodel cytoskeletal actin. Nat. Cell Biol.2:888-892.
    7.
    Berger, C. N., V. F. Crepin, M. A. Jepson, A. Arbeloa, and G. Frankel.2009. The mechanisms used by enteropathogenic Escherichia coli to control filopodia dynamics. Cell. Microbiol.11:309-322.
    8.
    Beuzon, C. R., S. Meresse, K. E. Unsworth, J. Ruiz-Albert, S. Garvis, S. R. Waterman, T. A. Ryder, E. Boucrot, and D. W. Holden.2000. Salmonella maintains the integrity of its intracellular vacuole through the action of SifA. EMBO J.19:3235-3249.
    9.
    Boucrot, E., C. R. Beuzon, D. W. Holden, J. P. Gorvel, and S. Meresse.2003. Salmonella typhimurium SifA effector protein requires its membrane-anchoring C-terminal hexapeptide for its biological function. J. Biol. Chem.278:14196-14202.
    10.
    Boucrot, E., T. Henry, J. P. Borg, J. P. Gorvel, and S. Meresse.2005. The intracellular fate of Salmonella depends on the recruitment of kinesin. Science308:1174-1188.
    11.
    Boyle, E. C., N. F. Brown, and B. B. Finlay.2006. Salmonella enterica serovar Typhimurium effectors SopB, SopE, SopE2 and SipA disrupt tight junction structure and function. Cell. Microbiol.8:1946-1957.
    12.
    Brumell, J. H., C. M. Rosenberger, G. T. Gotto, S. L. Marcus, and B. B. Finlay.2001. SifA permits survival and replication of Salmonella typhimurium in murine macrophages. Cell. Microbiol.3:75-84.
    13.
    Bruno, V. M., S. Hannemann, M. Lara-Tejero, R. A. Flavell, S. H. Kleinstein, and J. E. Galan.2009. Salmonella Typhimurium type III secretion effectors stimulate innate immune responses in cultured epithelial cells. PLoS Pathog.5:e1000538.
    14.
    Buchwald, G., A. Friebel, J. E. Galan, W. D. Hardt, A. Wittinghofer, and K. Scheffzek.2002. Structural basis for the reversible activation of a Rho protein by the bacterial toxin SopE. EMBO J.21:3286-3295.
    15.
    Bulgin, R., A. Arbeloa, D. Goulding, G. Dougan, F. V. Crepin, B. Raymond, and G. Frankel.2009. The T3SS effector EspT defines a new category of invasive enteropathogenic E. coli (EPEC) which form intracellular actin pedestals. PLoS Pathog.5:e1000683.
    16.
    Bulgin, R. R., A. Arbeloa, J. C. Chung, and G. Frankel.2009. EspT triggers formation of lamellipodia and membrane ruffles through activation of Rac-1 and Cdc42. Cell. Microbiol.11:217-229.
    17.
    Dean, P., and B. Kenny.2004. Intestinal barrier dysfunction by enteropathogenic Escherichia coli is mediated by two effector molecules and a bacterial surface protein. Mol. Microbiol.54:665-675.
    18.
    Dean, P., M. Maresca, S. Schuller, A. D. Phillips, and B. Kenny.2006. Potent diarrheagenic mechanism mediated by the cooperative action of three enteropathogenic Escherichia coli-injected effector proteins. Proc. Natl. Acad. Sci. U. S. A.103:1876-1881.
    19.
    Deng, W., J. L. Puente, S. Gruenheid, Y. Li, B. A. Vallance, A. Vazquez, J. Barba, J. A. Ibarra, P. O'Donnell, P. Metalnikov, K. Ashman, S. Lee, D. Goode, T. Pawson, and B. B. Finlay.2004. Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc. Natl. Acad. Sci. U. S. A.101:3597-3602.
    20.
    Deng, W., C. L. de Hoog, H. B. Yu, Y. Li, M. A. Croxen, N. A. Thomas, J. L. Puente, L. J. Foster, and B. B. Finlay. 24 December 2009, posting date. A comprehensive proteomic analysis of the type III secretome of Citrobacter rodentium. J. Biol. Chem. doi:
    21.
    Donnenberg, M. S., and J. B. Kaper.1992. Enteropathogenic Escherichia coli. Infect. Immun.60:3953-3961.
    22.
    Dvorsky, R., and M. R. Ahmadian.2004. Always look on the bright site of Rho: structural implications for a conserved intermolecular interface. EMBO Rep.5:1130-1136.
    23.
    Finlay, B. B.2005. Bacterial virulence strategies that utilize Rho GTPases. Curr. Top. Microbiol. Immunol.291:1-10.
    24.
    Freeman, J. A., M. E. Ohl, and S. I. Miller.2003. The Salmonella enterica serovar typhimurium translocated effectors SseJ and SifB are targeted to the Salmonella-containing vacuole. Infect. Immun.71:418-427.
    25.
    Fukazawa, A., C. Alonso, K. Kurachi, S. Gupta, C. F. Lesser, B. A. McCormick, and H. C. Reinecker.2008. GEF-H1 mediated control of NOD1 dependent NF-kappaB activation by Shigella effectors. PLoS Pathog.4:e1000228.
    26.
    Galan, J. E., and H. Wolf-Watz.2006. Protein delivery into eukaryotic cells by type III secretion machines. Nature444:567-573.
    27.
    Guttman, J. A., Y. Li, M. E. Wickham, W. Deng, A. W. Vogl, and B. B. Finlay.2006. Attaching and effacing pathogen-induced tight junction disruption in vivo. Cell. Microbiol.8:634-645.
    28.
    Hachani, A., L. Biskri, G. Rossi, A. Marty, R. Menard, P. Sansonetti, C. Parsot, G. T. Van Nhieu, M. L. Bernardini, and A. Allaoui.2008. IpgB1 and IpgB2, two homologous effectors secreted via the Mxi-Spa type III secretion apparatus, cooperate to mediate polarized cell invasion and inflammatory potential of Shigella flexneri. Microbes Infect.10:260-268.
    29.
    Hall, A.1998. Rho GTPases and the actin cytoskeleton. Science279:509-514.
    30.
    Handa, Y., M. Suzuki, K. Ohya, H. Iwai, N. Ishijima, A. J. Koleske, Y. Fukui, and C. Sasakawa.2007. Shigella IpgB1 promotes bacterial entry through the ELMO-Dock180 machinery. Nat. Cell Biol.9:121-128.
    31.
    Hapfelmeier, S., and W. D. Hardt.2005. A mouse model for S. typhimurium-induced enterocolitis. Trends Microbiol.13:497-503.
    32.
    Hardt, W. D., L. M. Chen, K. E. Schuebel, X. R. Bustelo, and J. E. Galan.1998. S. typhimurium encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells. Cell93:815-826.
    33.
    Harrison, R. E., J. H. Brumell, A. Khandani, C. Bucci, C. C. Scott, X. Jiang, B. B. Finlay, and S. Grinstein.2004. Salmonella impairs RILP recruitment to Rab7 during maturation of invasion vacuoles. Mol. Biol. Cell15:3146-3154.
    34.
    Hernandes, R. T., R. M. Silva, S. M. Carneiro, F. A. Salvador, M. C. Fernandes, A. C. Padovan, D. Yamamoto, R. A. Mortara, W. P. Elias, M. R. da Silva Briones, and T. A. Gomes.2008. The localized adherence pattern of an atypical enteropathogenic Escherichia coli is mediated by intimin omicron and unexpectedly promotes HeLa cell invasion. Cell. Microbiol.10:415-425.
    35.
    Hoffman, G. R., N. Nassar, and R. A. Cerione.2000. Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI. Cell100:345-356.
    36.
    Huang, Z., S. E. Sutton, A. J. Wallenfang, R. C. Orchard, X. Wu, Y. Feng, J. Chai, and N. M. Alto.2009. Structural insights into host GTPase isoform selection by a family of bacterial GEF mimics. Nat. Struct. Mol. Biol.16:853-860.
    37.
    Hussain, N. K., S. Jenna, M. Glogauer, C. C. Quinn, S. Wasiak, M. Guipponi, S. E. Antonarakis, B. K. Kay, T. P. Stossel, N. Lamarche-Vane, and P. S. McPherson.2001. Endocytic protein intersectin-l regulates actin assembly via Cdc42 and N-WASP. Nat. Cell Biol.3:927-932.
    38.
    Jaffe, A. B., and A. Hall.2005. Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol.21:247-269.
    39.
    Joseph, R. E., and F. A. Norris.2005. Substrate specificity and recognition is conferred by the pleckstrin homology domain of the Dbl family guanine nucleotide exchange factor P-Rex2. J. Biol. Chem.280:27508-27512.
    40.
    Karasova, D., A. Sebkova, V. Vrbas, H. Havlickova, F. Sisak, and I. Rychlik.2009. Comparative analysis of Salmonella enterica serovar Enteritidis mutants with a vaccine potential. Vaccine27:5265-5670.
    41.
    Kenny, B., S. Ellis, A. D. Leard, J. Warawa, H. Mellor, and M. A. Jepson.2002. Co-ordinate regulation of distinct host cell signalling pathways by multifunctional enteropathogenic Escherichia coli effector molecules. Mol. Microbiol.44:1095-1107.
    42.
    Kubori, T., and J. E. Galan.2003. Temporal regulation of salmonella virulence effector function by proteasome-dependent protein degradation. Cell115:333-342.
    43.
    Ma, C., M. E. Wickham, J. A. Guttman, W. Deng, J. Walker, K. L. Madsen, K. Jacobson, W. A. Vogl, B. B. Finlay, and B. A. Vallance.2006. Citrobacter rodentium infection causes both mitochondrial dysfunction and intestinal epithelial barrier disruption in vivo: role of mitochondrial associated protein (Map). Cell. Microbiol.8:1669-1686.
    44.
    Mallett, C. P., L. VanDeVerg, H. H. Collins, and T. L. Hale.1993. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine11:190-196.
    45.
    Mukherjee, K., S. Parashuraman, M. Raje, and A. Mukhopadhyay.2001. SopE acts as an Rab5-specific nucleotide exchange factor and recruits non-prenylated Rab5 on Salmonella-containing phagosomes to promote fusion with early endosomes. J. Biol. Chem.276:23607-23615.
    46.
    Muller, A. J., C. Hoffmann, M. Galle, A. Van Den Broeke, M. Heikenwalder, L. Falter, B. Misselwitz, M. Kremer, R. Beyaert, and W. D. Hardt.2009. The S. Typhimurium effector SopE induces caspase-1 activation in stomal cells to inititate gut inflammation. Cell Host Microbe6:125-136.
    47.
    Mundy, R., T. T. MacDonald, G. Dougan, G. Frankel, and S. Wiles.2005. Citrobacter rodentium of mice and man. Cell. Microbiol.7:1697-1706.
    48.
    Mundy, R., L. Petrovska, K. Smollett, N. Simpson, R. K. Wilson, J. Yu, X. Tu, I. Rosenshine, S. Clare, G. Dougan, and G. Frankel.2004. Identification of a novel Citrobacter rodentium type III secreted protein, EspI, and roles of this and other secreted proteins in infection. Infect. Immun.72:2288-2302.
    49.
    Niebuhr, K., S. Giuriato, T. Pedron, D. J. Philpott, F. Gaits, J. Sable, M. P. Sheetz, C. Parsot, P. J. Sansonetti, and B. Payrastre.2002. Conversion of PtdIns(4, 5)P(2) into PtdIns(5)P by the S. flexneri effector IpgD reorganizes host cell morphology. EMBO J.21:5069-5078.
    50.
    Norris, F. A., M. P. Wilson, T. S. Wallis, E. E. Galyov, and P. W. Majerus.1998. SopB, a protein required for virulence of Salmonella dublin, is an inositol phosphate phosphatase. Proc. Natl. Acad. Sci. U. S. A.95:14057-14069.
    51.
    Ohlson, M. B., Z. Huang, N. M. Alto, M. P. Blanc, J. E. Dixon, J. Chai, and S. I. Miller.2008. Structure and function of Salmonella SifA indicate that its interactions with SKIP, SseJ, and RhoA family GTPases induce endosomal tubulation. Cell Host Microbe4:434-446.
    52.
    Ohya, K., Y. Handa, M. Ogawa, M. Suzuki, and C. Sasakawa.2005. IpgB1 is a novel Shigella effector protein involved in bacterial invasion of host cells. Its activity to promote membrane ruffling via Rac1 and Cdc42 activation. J. Biol. Chem.280:24022-24034.
    53.
    Reinicke, A. T., J. L. Hutchinson, A. I. Magee, P. Mastroeni, J. Trowsdale, and A. P. Kelly.2005. A Salmonella typhimurium effector protein SifA is modified by host cell prenylation and S-acylation machinery. J. Biol. Chem.280:14620-14627.
    54.
    Ridley, A. J.2006. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol.16:522-529.
    55.
    Roberts, P. J., N. Mitin, P. J. Keller, E. J. Chenette, J. P. Madigan, R. O. Currin, A. D. Cox, O. Wilson, P. Kirschmeier, and C. J. Der.2008. Rho family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. J. Biol. Chem.283:25150-25163.
    56.
    Rudolph, M. G., C. Weise, S. Mirold, B. Hillenbrand, B. Bader, A. Wittinghofer, and W. D. Hardt.1999. Biochemical analysis of SopE from Salmonella typhimurium, a highly efficient guanosine nucleotide exchange factor for RhoGTPases. J. Biol. Chem.274:30501-30509.
    57.
    Ruiz-Albert, J., X. J. Yu, C. R. Beuzon, A. N. Blakey, E. E. Galyov, and D. W. Holden.2002. Complementary activities of SseJ and SifA regulate dynamics of the Salmonella typhimurium vacuolar membrane. Mol. Microbiol.44:645-661.
    58.
    Salcedo, S. P., M. Noursadeghi, J. Cohen, and D. W. Holden.2001. Intracellular replication of Salmonella typhimurium strains in specific subsets of splenic macrophages in vivo. Cell. Microbiol.3:587-597.
    59.
    Scheffzek, K., I. Stephan, O. N. Jensen, D. Illenberger, and P. Gierschik.2000. The Rac-RhoGDI complex and the structural basis for the regulation of Rho proteins by RhoGDI. Nat. Struct. Biol.7:122-126.
    60.
    Seipel, K., S. P. O'Brien, E. Iannotti, Q. G. Medley, and M. Streuli.2001. Tara, a novel F-actin binding protein, associates with the Trio guanine nucleotide exchange factor and regulates actin cytoskeletal organization. J. Cell Sci.114:389-399.
    61.
    Serény, B., C. Tenner, and P. Rácz.1971. Immunogenicity of living attenuated shigellae. Acta Microbiol. Acad. Sci. Hung.18:239-245.
    62.
    Simovitch, M., H. Sason, S. Cohen, E. E. Zahavi, N. Melamed-Book, A. Weiss, B. Aroeti, and I. Rosenshine.2009. EspM inhibits pedestal formation by EHEC and EPEC and disrupts the architecture of a polarized epithelial monolayer. Cell. Microbiol. doi:
    63.
    Simpson, N., R. Shaw, V. F. Crepin, R. Mundy, A. J. FitzGerald, N. Cummings, A. Straatman-Iwanowska, I. Connerton, S. Knutton, and G. Frankel.2006. The enteropathogenic Escherichia coli type III secretion system effector Map binds EBP50/NHERF1: implication for cell signalling and diarrhoea. Mol. Microbiol.60:349-363.
    64.
    Stein, M. A., K. Y. Leung, M. Zwick, F. Garcia-del Portillo, and B. B. Finlay.1996. Identification of a Salmonella virulence gene required for formation of filamentous structures containing lysosomal membrane glycoproteins within epithelial cells. Mol. Microbiol.20:151-164.
    65.
    Stender, S., A. Friebel, S. Linder, M. Rohde, S. Mirold, and W. D. Hardt.2000. Identification of SopE2 from Salmonella typhimurium, a conserved guanine nucleotide exchange factor for Cdc42 of the host cell. Mol. Microbiol.36:1206-1221.
    66.
    Stevens, M. P., A. Friebel, L. A. Taylor, M. W. Wood, P. J. Brown, W. D. Hardt, and E. E. Galyov.2003. A Burkholderia pseudomallei type III secreted protein, BopE, facilitates bacterial invasion of epithelial cells and exhibits guanine nucleotide exchange factor activity. J. Bacteriol.185:4992-4996.
    67.
    Stevens, M. P., A. Haque, T. Atkins, J. Hill, M. W. Wood, A. Easton, M. Nelson, C. Underwood-Fowler, R. W. Titball, G. J. Bancroft, and E. E. Galyov.2004. Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology150:2669-2676.
    68.
    Tran Van Nhieu, G., A. Ben-Ze'ev, and P. J. Sansonetti.1997. Modulation of bacterial entry into epithelial cells by association between vinculin and the Shigella IpaA invasin. EMBO J.16:2717-2729.
    69.
    Tran Van Nhieu, G., E. Caron, A. Hall, and P. J. Sansonetti.1999. IpaC induces actin polymerization and filopodia formation during Shigella entry into epithelial cells. EMBO J.18:3249-3262.
    70.
    Upadhyay, A., H. L. Wu, C. Williams, T. Field, E. E. Galyov, J. M. van den Elsen, and S. Bagby.2008. The guanine-nucleotide-exchange factor BopE from Burkholderia pseudomallei adopts a compact version of the Salmonella SopE/SopE2 fold and undergoes a closed-to-open conformational change upon interaction with Cdc42. Biochem. J.411:485-493.
    71.
    Vanni, C., A. Parodi, P. Mancini, V. Visco, C. Ottaviano, M. R. Torrisi, and A. Eva.2004. Phosphorylation-independent membrane relocalization of ezrin following association with Dbl in vivo. Oncogene23:4098-4106.
    72.
    Vetter, I. R., and A. Wittinghofer.2001. The guanine nucleotide-binding switch in three dimensions. Science294:1299-1304.
    73.
    Yoshida, S., E. Katayama, A. Kuwae, H. Mimuro, T. Suzuki, and C. Sasakawa.2002. Shigella deliver an effector protein to trigger host microtubule destabilization, which promotes Rac1 activity and efficient bacterial internalization. EMBO J.21:2923-2935.
    74.
    Zhang, S., R. L. Santos, R. M. Tsolis, S. Stender, W. D. Hardt, A. J. Baumler, and L. G. Adams.2002. The Salmonella enterica serotype typhimurium effector proteins SipA, SopA, SopB, SopD, and SopE2 act in concert to induce diarrhea in calves. Infect. Immun.70:3843-3855.

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 78Number 4April 2010
    Pages: 1417 - 1425

    History

    Published online: 1 February 2010

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Richard Bulgin
    Centre for Molecular Microbiology and Infection, Division of Cell and Molecular Biology
    Benoit Raymond
    Centre for Molecular Microbiology and Infection, Division of Cell and Molecular Biology
    James A. Garnett
    Division of Molecular Biosciences, Imperial College, London, United Kingdom
    Gad Frankel [email protected]
    Centre for Molecular Microbiology and Infection, Division of Cell and Molecular Biology
    Valerie F. Crepin
    Centre for Molecular Microbiology and Infection, Division of Cell and Molecular Biology
    Cedric N. Berger
    Centre for Molecular Microbiology and Infection, Division of Cell and Molecular Biology
    Ana Arbeloa
    Centre for Molecular Microbiology and Infection, Division of Cell and Molecular Biology

    Notes

    Editor: A. T. Maurelli

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    Pretreatment of Mice with Streptomycin Provides a Salmonella enterica Serovar Typhimurium Colitis Model That Allows Analysis of Both Pathogen and Host

    Pretreatment of Mice with Streptomycin Provides a Salmonella enterica Serovar Typhimurium Colitis Model That Allows Analysis of Both Pathogen and Host

    ABSTRACT

    Salmonella enterica subspecies 1 serovar Typhimurium is a principal cause of human enterocolitis. For unknown reasons, in mice serovar Typhimurium does not provoke intestinal inflammation but rather targets the gut-associated lymphatic tissues and causes a systemic typhoid-like infection. The lack of a suitable murine model has limited the analysis of the pathogenetic mechanisms of intestinal salmonellosis. We describe here how streptomycin-pretreated mice provide a mouse model for serovar Typhimurium colitis. Serovar Typhimurium colitis in streptomycin-pretreated mice resembles many aspects of the human infection, including epithelial ulceration, edema, induction of intercellular adhesion molecule 1, and massive infiltration of PMN/CD18+ cells. This pathology is strongly dependent on protein translocation via the serovar Typhimurium SPI1 type III secretion system. Using a lymphotoxin β-receptor knockout mouse strain that lacks all lymph nodes and organized gut-associated lymphatic tissues, we demonstrate that Peyer's patches and mesenteric lymph nodes are dispensable for the initiation of murine serovar Typhimurium colitis. Our results demonstrate that streptomycin-pretreated mice offer a unique infection model that allows for the first time to use mutants of both the pathogen and the host to study the molecular mechanisms of enteric salmonellosis.

    REFERENCES

    1.
    Baumler, A. J., R. M. Tsolis, and F. Heffron.1996. The lpf fimbrial operon mediates adhesion of Salmonella typhimurium to murine Peyer's patches. Proc. Natl. Acad. Sci. USA93:279-283.
    2.
    Bohnhoff, M., B. L. Drake, and C. P. Miller.1954. Effect of streptomycin on susceptibility of intestinal tract to experimental Salmonella infection. Proc. Soc. Exp. Biol.86:132-137.
    3.
    Bohnhoff, M., and C. P. Miller.1962. Enhanced susceptibility to Salmonella infection in streptomycin-treated mice. J. Infect. Dis.111:117-127.
    4.
    Bohnhoff, M., C. P. Miller, and W. R. Martin.1964. Resistance of the mouse intestinal tract to experimental Salmonella infection. (I) Factors which interfere with the initiation of infection by oral inoculation. J. Exp. Med.120:805-816.
    5.
    Bohnhoff, M., C. P. Miller, and W. R. Martin.1964. Resistance of the mouse intestinal tract to experimental Salmonella infection. II. Factors responsible for its loss following streptomycin treatment. J. Exp. Med.120:817-828.
    6.
    Borghesi, C., M. Regoli, E. Bertelli, and C. Nicoletti.1996. Modifications of the follicle-associated epithelium by short-term exposure to a non-intestinal bacterium. J. Pathol.180:326-332.
    7.
    Borghesi, C., M. J. Taussig, and C. Nicoletti.1999. Rapid appearance of M cells after microbial challenge is restricted at the periphery of the follicle-associated epithelium of Peyer's patch. Lab. Investig.79:1393-1401.
    8.
    Boyd, J. F.1985. Pathology of the alimentary tract in Salmonella typhimurium food poisoning. Gut26:935-944.
    9.
    Brown, K. J., G. W. Tannock, R. A. Eyres, R. B. Elliott, and D. R. Lines.1979. Colonization by Salmonella typhimurium and Shigella flexneri III of the gastrointestinal tract of mice treated with β-2-thienylalanine and streptomycin. Antonie Leeuwenhoek45:531-546.
    10.
    Carter, P. B., and F. M. Collins.1974. The route of enteric infection in normal mice. J. Exp. Med.139:1189-1203.
    11.
    Clark, M. A., B. H. Hirst, and M. A. Jepson.1998. Inoculum composition and Salmonella pathogenicity island 1 regulate M-cell invasion and epithelial destruction by Salmonella typhimurium. Infect. Immun.66:724-731.
    12.
    Clark, M. A., M. A. Jepson, N. L. Simmons, and B. H. Hirst.1994. Preferential interaction of Salmonella typhimurium with mouse Peyer's patch M cells. Res. Microbiol.145:543-552.
    13.
    Collazo, C. M., and J. E. Galan.1997. The invasion-associated type III system of Salmonella typhimurium directs the translocation of Sip proteins into the host cell. Mol. Microbiol.24:747-756.
    14.
    Collazo, C. M., and J. E. Galan.1996. Requirement for exported proteins in secretion through the invasion-associated type III system of Salmonella typhimurium. Infect. Immun.64:3524-3531.
    15.
    Collazo, C. M., M. K. Zierler, and J. E. Galan.1995. Functional analysis of the Salmonella typhimurium invasion genes invI and invJ and identification of a target of the protein secretion apparatus encoded in the inv locus. Mol. Microbiol.15:25-38.
    16.
    Collins, F. M., and P. B. Carter.1978. Growth of salmonellae in orally infected germfree mice. Infect. Immun.21:41-47.
    17.
    Day, D. W., B. K. Mandal, and B. C. Morson.1978. The rectal biopsy appearances in Salmonella colitis. Histopathology2:117-131.
    18.
    Debard, N., F. Sierro, J. Browning, and J. P. Kraehenbuhl.2001. Effect of mature lymphocytes and lymphotoxin on the development of the follicle-associated epithelium and M cells in mouse Peyer's patches. Gastroenterology120:1173-1182.
    19.
    Eckmann, L., M. F. Kagnoff, and J. Fierer.1993. Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry. Infect. Immun.61:4569-4574.
    20.
    Everest, P., J. Ketley, S. Hardy, G. Douce, S. Khan, J. Shea, D. Holden, D. Maskell, and G. Dougan.1999. Evaluation of Salmonella typhimurium mutants in a model of experimental gastroenteritis. Infect. Immun.67:2815-2821.
    21.
    Fierer, J., and D. G. Guiney.2001. Diverse virulence traits underlying different clinical outcomes of Salmonella infection. J. Clin. Investig.107:775-780.
    22.
    Filho-Lima, J. V., E. C. Vieira, and J. R. Nicoli.2000. Antagonistic effect of Lactobacillus acidophilus, Saccharomyces boulardii, and Escherichia coli combinations against experimental infections with Shigella flexneri and Salmonella enteritidis subsp. typhimurium in gnotobiotic mice. J. Appl. Microbiol.88:365-370.
    23.
    Finlay, B. B., and J. H. Brumell.2000. Salmonella interactions with host cells: in vitro to in vivo. Philos. Trans. R. Soc. Lond. B355:623-631.
    24.
    Fu, Y. X., and D. D. Chaplin.1999. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol.17:399-433.
    25.
    Futterer, A., K. Mink, A. Luz, M. H. Kosco-Vilbois, and K. Pfeffer.1998. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity9:59-70.
    26.
    Galan, J. E.2001. Salmonella interactions with host cells: type III secretion at work. Annu. Rev. Cell Dev. Biol.17:53-86.
    27.
    Galan, J. E., and R. Curtiss III.1989. Cloning and molecular characterization of genes whose products allow Salmonella typhimurium to penetrate tissue culture cells. Proc. Natl. Acad. Sci. USA86:6383-6387.
    28.
    Galyov, E. E., M. W. Wood, R. Rosqvist, P. B. Mullan, P. R. Watson, S. Hedges, and T. S. Wallis.1997. A secreted effector protein of Salmonella dublin is translocated into eukaryotic cells and mediates inflammation and fluid secretion in infected ileal mucosa. Mol. Microbiol.25:903-912.
    29.
    Gewirtz, A. T., T. A. Navas, S. Lyons, P. J. Godowski, and J. L. Madara.2001. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol.167:1882-1885.
    30.
    Govoni, G., and P. Gros.1998. Macrophage NRAMP1 and its role in resistance to microbial infections. Inflamm. Res.47:277-284.
    31.
    Hayashi, F., K. D. Smith, A. Ozinsky, T. R. Hawn, E. C. Yi, D. R. Goodlett, J. K. Eng, S. Akira, D. M. Underhill, and A. Aderem.2001. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature410:1099-1103.
    32.
    Hayday, A., and J. L. Viney.2000. The ins and outs of body surface immunology. Science290:97-100.
    33.
    Hensel, M.2000. Salmonella pathogenicity island 2. Mol. Microbiol.36:1015-1023.
    34.
    Hobbie, S., L. M. Chen, R. J. Davis, and J. E. Galan.1997. Involvement of mitogen-activated protein kinase pathways in the nuclear responses and cytokine production induced by Salmonella typhimurium in cultured intestinal epithelial cells. J. Immunol.159:5550-5559.
    35.
    Hohmann, A. W., G. Schmidt, and D. Rowley.1978. Intestinal colonization and virulence of Salmonella in mice. Infect. Immun.22:763-770.
    36.
    Hoiseth, S. K., and B. A. Stocker.1981. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature291:238-239.
    37.
    Huang, G. T., L. Eckmann, T. C. Savidge, and M. F. Kagnoff.1996. Infection of human intestinal epithelial cells with invasive bacteria upregulates apical intercellular adhesion molecule-1 (ICAM-1) expression and neutrophil adhesion. J. Clin. Investig.98:572-583.
    38.
    Hudault, S., H. Bewa, C. Bridonneau, and P. Raibaud.1985. Efficiency of various bacterial suspensions derived from cecal floras of conventional chickens in reducing the population level of Salmonella typhimurium in gnotobiotic mice and chicken intestines. Can. J. Microbiol.31:832-838.
    39.
    Hueck, C. J., M. J. Hantman, V. Bajaj, C. Johnston, C. A. Lee, and S. I. Miller.1995. Salmonella typhimurium secreted invasion determinants are homologous to Shigella Ipa proteins. Mol. Microbiol.18:479-490.
    40.
    Janeway, C. A., Jr.2001. How the immune system works to protect the host from infection: a personal view. Proc. Natl. Acad. Sci. USA98:7461-7468.
    41.
    Jones, B. D., N. Ghori, and S. Falkow.1994. Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. J. Exp. Med.180:15-23.
    42.
    Jones, P. W., G. Dougan, C. Hayward, N. Mackensie, P. Collins, and S. N. Chatfield.1991. Oral vaccination of calves against experimental salmonellosis using a double aro mutant of Salmonella typhimurium. Vaccine9:29-34.
    43.
    Kaniga, K., J. C. Bossio, and J. E. Galan.1994. The Salmonella typhimurium invasion genes invF and invG encode homologues of the AraC and PulD family of proteins. Mol. Microbiol.13:555-568.
    44.
    Kaniga, K., D. Trollinger, and J. E. Galan.1995. Identification of two targets of the type III protein secretion system encoded by the inv and spa loci of Salmonella typhimurium that have homology to the Shigella IpaD and IpaA proteins. J. Bacteriol.177:7078-7085.
    45.
    Kaniga, K., S. Tucker, D. Trollinger, and J. E. Galan.1995. Homologs of the Shigella IpaB and IpaC invasins are required for Salmonella typhimurium entry into cultured epithelial cells. J. Bacteriol.177:3965-3971.
    46.
    Kraehenbuhl, J. P., and M. R. Neutra.2000. Epithelial M cells: differentiation and function. Annu. Rev. Cell Dev. Biol.16:301-332.
    47.
    Lee, C. A., M. Silva, A. M. Siber, A. J. Kelly, E. Galyov, and B. A. McCormick.2000. A secreted Salmonella protein induces a proinflammatory response in epithelial cells, which promotes neutrophil migration. Proc. Natl. Acad. Sci. USA97:12283-12288.
    48.
    Lehrer, R. I., and T. Ganz.2002. Defensins of vertebrate animals. Curr. Opin. Immunol.14:96-102.
    49.
    Madsen, K., A. Cornish, P. Soper, C. McKaigney, H. Jijon, C. Yachimec, J. Doyle, L. Jewell, and C. De Simone.2001. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology121:580-591.
    50.
    McCormick, B. A., S. P. Colgan, C. Delp-Archer, S. I. Miller, and J. L. Madara.1993. Salmonella typhimurium attachment to human intestinal epithelial monolayers: transcellular signalling to subepithelial neutrophils. J. Cell Biol.123:895-907.
    51.
    McCormick, B. A., P. M. Hofman, J. Kim, D. K. Carnes, S. I. Miller, and J. L. Madara.1995. Surface attachment of Salmonella typhimurium to intestinal epithelia imprints the subepithelial matrix with gradients chemotactic for neutrophils. J. Cell Biol.131:1599-1608.
    52.
    McGovern, V. J., and L. J. Slavutin.1979. Pathology of salmonella colitis. Am. J. Surg Pathol.3:483-490.
    53.
    Meynell, G. G.1955. Some factors affecting the resistance of mice to oral infection by Salmonella typhimurium. Proc. R. Soc. Med.48:916-918.
    54.
    Meynell, G. G., and T. V. Subbaiah.1963. Antibacterial mechanisms of the mouse gut. I. Kinetics of infection by Salmonella typhimurium in normal and streptomycin-treated mice studied with abortive transductants. Br. J. Exp. Pathol.44:197-208.
    55.
    Miller, C. P., and M. Bohnhoff.1963. Changes in the mouse's enteric microflora associated with enhanced susceptibility to Salmonella infection following streptomycin treatment. J. Infect. Dis.113:59-66.
    56.
    Mowat, A. M., and J. L. Viney.1997. The anatomical basis of intestinal immunity. Immunol. Rev.156:145-166.
    57.
    Murray, R. A., and C. A. Lee.2000. Invasion genes are not required for Salmonella enterica serovar Typhimurium to breach the intestinal epithelium: evidence that Salmonella pathogenicity island 1 has alternative functions during infection. Infect. Immun.68:5050-5055.
    58.
    Nagler-Anderson, C.2001. Man the barrier! Strategic defences in the intestinal mucosa. Nat. Rev. Immunol.1:59-67.
    59.
    Nardi, R. M., M. E. Silva, E. C. Vieira, E. A. Bambirra, and J. R. Nicoli.1989. Intragastric infection of germfree and conventional mice with Salmonella typhimurium. Braz. J. Med. Biol. Res.22:1389-1392.
    60.
    Neutra, M. R., N. J. Mantis, and J. P. Kraehenbuhl.2001. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat. Immunol.2:1004-1009.
    61.
    Norris, F. A., M. P. Wilson, T. S. Wallis, E. E. Galyov, and P. W. Majerus.1998. SopB, a protein required for virulence of Salmonella dublin, is an inositol phosphate phosphatase. Proc. Natl. Acad. Sci. USA95:14057-14059.
    62.
    Ohl, M. E., and S. I. Miller.2001. Salmonella: a model for bacterial pathogenesis. Annu. Rev. Med.52:259-274.
    63.
    Pascopella, L., B. Raupach, N. Ghori, D. Monack, S. Falkow, and P. L. Small.1995. Host restriction phenotypes of Salmonella typhi and Salmonella gallinarum. Infect. Immun.63:4329-4335.
    64.
    Penheiter, K. L., N. Mathur, D. Giles, T. Fahlen, and B. D. Jones.1997. Non-invasive Salmonella typhimurium mutants are avirulent because of an inability to enter and destroy M cells of ileal Peyer's patches. Mol. Microbiol.24:697-709.
    65.
    Que, J. U., S. W. Casey, and D. J. Hentges.1986. Factors responsible for increased susceptibility of mice to intestinal colonization after treatment with streptomycin. Infect. Immun.53:116-123.
    66.
    Que, J. U., and D. J. Hentges.1985. Effect of streptomycin administration on colonization resistance to Salmonella typhimurium in mice. Infect. Immun.48:169-174.
    67.
    Rescigno, M., M. Urbano, B. Valzasina, M. Francolini, G. Rotta, R. Bonasio, F. Granucci, J. P. Kraehenbuhl, and P. Ricciardi-Castagnoli.2001. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol.2:361-367.
    68.
    Santos, R. L., S. Zhang, R. M. Tsolis, R. A. Kingsley, L. G. Adams, and A. J. Baumler.2001. Animal models of Salmonella infections: enteritis versus typhoid fever. Microbes Infect.3:1335-1344.
    69.
    Savage, D. C., and R. Dubos.1968. Alterations in the mouse cecum and its flora produced by antibacterial drugs. J. Exp. Med.128:97-110.
    70.
    Savidge, T. C., M. W. Smith, P. S. James, and P. Aldred.1991. Salmonella-induced M-cell formation in germ-free mouse Peyer's patch tissue. Am. J. Pathol.139:177-184.
    71.
    Schmitt, C. K., J. S. Ikeda, S. C. Darnell, P. R. Watson, J. Bispham, T. S. Wallis, D. L. Weinstein, E. S. Metcalf, and A. D. O'Brien.2001. Absence of all components of the flagellar export and synthesis machinery differentially alters virulence of Salmonella enterica serovar Typhimurium in models of typhoid fever, survival in macrophages, tissue culture invasiveness, and calf enterocolitis. Infect. Immun.69:5619-5625.
    72.
    Takeuchi, A.1967. Electron microscope studies of experimental Salmonella infection. I. Penetration into the intestinal epithelium by Salmonella typhimurium. Am. J. Pathol.50:109-136.
    73.
    Tsolis, R. M., L. G. Adams, T. A. Ficht, and A. J. Baumler.1999. Contribution of Salmonella typhimurium virulence factors to diarrheal disease in calves. Infect. Immun.67:4879-4885.
    74.
    Tsolis, R. M., L. G. Adams, M. J. Hantman, C. A. Scherer, T. Kimbrough, R. A. Kingsley, T. A. Ficht, S. I. Miller, and A. J. Baumler.2000. SspA is required for lethal Salmonella enterica serovar Typhimurium infections in calves but is not essential for diarrhea. Infect. Immun.68:3158-3163.
    75.
    Tsolis, R. M., R. A. Kingsley, S. M. Townsend, T. A. Ficht, L. G. Adams, and A. J. Baumler.1999. Of mice, calves, and men: comparison of the mouse typhoid model with other Salmonella infections. Adv. Exp. Med. Biol.473:261-274.
    76.
    Tsolis, R. M., S. M. Townsend, E. A. Miao, S. I. Miller, T. A. Ficht, L. G. Adams, and A. J. Baumler.1999. Identification of a putative Salmonella enterica serotype Typhimurium host range factor with homology to IpaH and YopM by signature-tagged mutagenesis. Infect. Immun.67:6385-6393.
    77.
    Underhill, D. M., and A. Ozinsky.2002. Toll-like receptors: key mediators of microbe detection. Curr. Opin. Immunol.14:103-110.
    78.
    Uzzau, S., D. J. Brown, T. Wallis, S. Rubino, G. Leori, S. Bernard, J. Casadesus, D. J. Platt, and J. E. Olsen.2000. Host adapted serotypes of Salmonella enterica. Epidemiol. Infect.125:229-255.
    79.
    Vazquez-Torres, A., and F. C. Fang.2000. Cellular routes of invasion by enteropathogens. Curr. Opin. Microbiol.3:54-59.
    80.
    Vazquez-Torres, A., J. Jones-Carson, A. J. Baumler, S. Falkow, R. Valdivia, W. Brown, M. Le, R. Berggren, W. T. Parks, and F. C. Fang.1999. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. Nature401:804-808.
    81.
    Wallis, T. S., and E. E. Galyov.2000. Molecular basis of Salmonella-induced enteritis. Mol. Microbiol.36:997-1005.
    82.
    Watson, P. R., E. E. Galyov, S. M. Paulin, P. W. Jones, and T. S. Wallis.1998. Mutation of invH, but not stn, reduces Salmonella-induced enteritis in cattle. Infect. Immun.66:1432-1438.
    83.
    Wood, M. W., R. Rosqvist, P. B. Mullan, M. H. Edwards, and E. E. Galyov.1996. SopE, a secreted protein of Salmonella dublin, is translocated into the target eukaryotic cell via a sip-dependent mechanism and promotes bacterial entry. Mol. Microbiol.22:327-338.
    84.
    Wray, C., and W. J. Sojka.1978. Experimental Salmonella typhimurium infection in calves. Res. Vet. Sci.25:139-143.
    85.
    Yang, R. B., M. R. Mark, A. Gray, A. Huang, M. H. Xie, M. Zhang, A. Goddard, W. I. Wood, A. L. Gurney, and P. J. Godowski.1998. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature395:284-288.
    86.
    Zhang, S., R. L. Santos, R. M. Tsolis, S. Stender, W. D. Hardt, A. J. Baumler, and L. G. Adams.2002. The Salmonella enterica serotype Typhimurium effector proteins SipA, SopA, SopB, SopD, and SopE2 act in concert to induce diarrhea in calves. Infect. Immun.70:3843-3855.

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 71Number 5May 2003
    Pages: 2839 - 2858

    History

    Received: 25 November 2002
    Revision received: 16 January 2003
    Accepted: 6 February 2003

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Manja Barthel
    Institute of Microbiology, ETH Zürich, 8092 Zürich, Switzerland
    Max von Pettenkofer-Institut, Ludwig Maximilians Universität, 80336 Munich
    Siegfried Hapfelmeier
    Institute of Microbiology, ETH Zürich, 8092 Zürich, Switzerland
    Max von Pettenkofer-Institut, Ludwig Maximilians Universität, 80336 Munich
    Leticia Quintanilla-Martínez
    GSF-Research Center for Environment and Health, 85764 Neuherberg
    Marcus Kremer
    Institute of Medical Microbiology, Immunology, and Hygiene
    GSF-Research Center for Environment and Health, 85764 Neuherberg
    Manfred Rohde
    GBF, 38124 Braunschweig, Germany
    Michael Hogardt
    Max von Pettenkofer-Institut, Ludwig Maximilians Universität, 80336 Munich
    Klaus Pfeffer
    Institute of Pathology, Technical University of Munich, 81675 Munich
    Holger Rüssmann
    Max von Pettenkofer-Institut, Ludwig Maximilians Universität, 80336 Munich
    Wolf-Dietrich Hardt [email protected]
    Institute of Microbiology, ETH Zürich, 8092 Zürich, Switzerland

    Notes

    Editor: D. L. Burns

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    Salmonella enterica Serovars Dublin and Enteritidis Comparative Proteomics Reveals Differential Expression of Proteins Involved in Stress Resistance, Virulence, and Anaerobic Metabolism

    Salmonella enterica Serovars Dublin and Enteritidis Comparative Proteomics Reveals Differential Expression of Proteins Involved in Stress Resistance, Virulence, and Anaerobic Metabolism

    ABSTRACT

    The Enteritidis and Dublin serovars of Salmonella enterica are phylogenetically closely related yet differ significantly in host range and virulence. S. Enteritidis is a broad-host-range serovar that commonly causes self-limited gastroenteritis in humans, whereas S. Dublin is a cattle-adapted serovar that can infect humans, often resulting in invasive extraintestinal disease. The mechanism underlying the higher invasiveness of S. Dublin remains undetermined. In this work, we quantitatively compared the proteomes of clinical isolates of each serovar grown under gut-mimicking conditions. Compared to S. Enteritidis, the S. Dublin proteome was enriched in proteins linked to response to several stress conditions, such as those encountered during host infection, as well as to virulence. The S. Enteritidis proteome contained several proteins related to central anaerobic metabolism pathways that were undetected in S. Dublin. In contrast to what has been observed in other extraintestinal serovars, most of the coding genes for these pathways are not degraded in S. Dublin. Thus, we provide evidence that S. Dublin metabolic functions may be much more affected than previously reported based on genomic studies. Single and double null mutants in stress response proteins Dps, YciF, and YgaU demonstrate their relevance to S. Dublin invasiveness in a murine model of invasive salmonellosis. All in all, this work provides a basis for understanding interserovar differences in invasiveness and niche adaptation, underscoring the relevance of using proteomic approaches to complement genomic studies.

    REFERENCES

    1.
    Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleesschauwer B, Dopfer D, Fazil A, Fischer-Walker CL, Hald T, Hall AJ, Keddy KH, Lake RJ, Lanata CF, Torgerson PR, Havelaar AH, Angulo FJ. 2015. World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: a data synthesis. PLoS Med 12:e1001921.
    2.
    Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. 2015. Global burden of invasive nontyphoidal Salmonella disease, 2010. Emerg Infect Dis 21:941–949.
    3.
    Issenhuth-Jeanjean S, Roggentin P, Mikoleit M, Guibourdenche M, de Pinna E, Nair S, Fields PI, Weill FX. 2014. Supplement 2008–2010 (no. 48) to the White-Kauffmann-Le Minor scheme. Res Microbiol 165:526–530.
    4.
    Harvey RR, Friedman CR, Crim SM, Judd M, Barrett KA, Tolar B, Folster JP, Griffin PM, Brown AC. 2017. Epidemiology of Salmonella enterica serotype Dublin infections among humans, United States, 1968–2013. Emerg Infect Dis 23:1493–1501.
    5.
    Hendriksen RS, Vieira AR, Karlsmose S, Lo Fo Wong DM, Jensen AB, Wegener HC, Aarestrup FM. 2011. Global monitoring of Salmonella serovar distribution from the World Health Organization Global Foodborne Infections Network Country Data Bank: results of quality assured laboratories from 2001 to 2007. Foodborne Pathog Dis 8:887–900.
    6.
    Langridge GC, Wain J, Nair S. 2012. Invasive salmonellosis in humans. EcoSal Plus 2015.
    7.
    Langridge GC, Fookes M, Connor TR, Feltwell T, Feasey N, Parsons BN, Seth-Smith HM, Barquist L, Stedman A, Humphrey T, Wigley P, Peters SE, Maskell DJ, Corander J, Chabalgoity JA, Barrow P, Parkhill J, Dougan G, Thomson NR. 2015. Patterns of genome evolution that have accompanied host adaptation in Salmonella. Proc Natl Acad Sci U S A 112:863–868.
    8.
    Betancor L, Yim L, Martinez A, Fookes M, Sasias S, Schelotto F, Thomson N, Maskell D, Chabalgoity JA. 2012. Genomic comparison of the closely related Salmonella enterica serovars Enteritidis and Dublin. Open Microbiol J 6:5–13.
    9.
    Matthews TD, Schmieder R, Silva GG, Busch J, Cassman N, Dutilh BE, Green D, Matlock B, Heffernan B, Olsen GJ, Farris Hanna L, Schifferli DM, Maloy S, Dinsdale EA, Edwards RA. 2015. Genomic comparison of the closely-related Salmonella enterica serovars Enteritidis, Dublin and Gallinarum. PLoS One 10:e0126883.
    10.
    Fenske GJ, Thachil A, McDonough PL, Glaser A, Scaria J. 2019. Geography Shapes the Population Genomics of Salmonella enterica Dublin. Genome Biol Evol 11:2220–2231.
    11.
    Mohammed M, Cormican M. 2016. Whole genome sequencing provides insights into the genetic determinants of invasiveness in Salmonella Dublin. Epidemiol Infect 144:2430–2439.
    12.
    Parkhill J, Dougan G, James KD, Thomson NR, Pickard D, Wain J, Churcher C, Mungall KL, Bentley SD, Holden MT, Sebaihia M, Baker S, Basham D, Brooks K, Chillingworth T, Connerton P, Cronin A, Davis P, Davies RM, Dowd L, White N, Farrar J, Feltwell T, Hamlin N, Haque A, Hien TT, Holroyd S, Jagels K, Krogh A, Larsen TS, Leather S, Moule S, O'Gaora P, Parry C, Quail M, Rutherford K, Simmonds M, Skelton J, Stevens K, Whitehead S, Barrell BG. 2001. Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature 413:848–852.
    13.
    McClelland M, Sanderson KE, Clifton SW, Latreille P, Porwollik S, Sabo A, Meyer R, Bieri T, Ozersky P, McLellan M, Harkins CR, Wang C, Nguyen C, Berghoff A, Elliott G, Kohlberg S, Strong C, Du F, Carter J, Kremizki C, Layman D, Leonard S, Sun H, Fulton L, Nash W, Miner T, Minx P, Delehaunty K, Fronick C, Magrini V, Nhan M, Warren W, Florea L, Spieth J, Wilson RK. 2004. Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of Salmonella enterica that cause typhoid. Nat Genet 36:1268–1274.
    14.
    Thomson NR, Clayton DJ, Windhorst D, Vernikos G, Davidson S, Churcher C, Quail MA, Stevens M, Jones MA, Watson M, Barron A, Layton A, Pickard D, Kingsley RA, Bignell A, Clark L, Harris B, Ormond D, Abdellah Z, Brooks K, Cherevach I, Chillingworth T, Woodward J, Norberczak H, Lord A, Arrowsmith C, Jagels K, Moule S, Mungall K, Sanders M, Whitehead S, Chabalgoity JA, Maskell D, Humphrey T, Roberts M, Barrow PA, Dougan G, Parkhill J. 2008. Comparative genome analysis of Salmonella Enteritidis PT4 and Salmonella Gallinarum 287/91 provides insights into evolutionary and host adaptation pathways. Genome Res 18:1624–1637.
    15.
    Nuccio SP, Baumler AJ. 2014. Comparative analysis of Salmonella genomes identifies a metabolic network for escalating growth in the inflamed gut. mBio 5:e00929-14.
    16.
    Okoro CK, Barquist L, Connor TR, Harris SR, Clare S, Stevens MP, Arends MJ, Hale C, Kane L, Pickard DJ, Hill J, Harcourt K, Parkhill J, Dougan G, Kingsley RA. 2015. Signatures of adaptation in human invasive Salmonella Typhimurium ST313 populations from sub-Saharan Africa. PLoS Negl Trop Dis 9:e0003611.
    17.
    Feasey NA, Hadfield J, Keddy KH, Dallman TJ, Jacobs J, Deng X, Wigley P, Barquist Barquist L, Langridge GC, Feltwell T, Harris SR, Mather AE, Fookes M, Aslett M, Msefula C, Kariuki S, Maclennan CA, Onsare RS, Weill FX, Le Hello S, Smith AM, McClelland M, Desai P, Parry CM, Cheesbrough J, French N, Campos J, Chabalgoity JA, Betancor L, Hopkins KL, Nair S, Humphrey TJ, Lunguya O, Cogan TA, Tapia MD, Sow SO, Tennant SM, Bornstein K, Levine MM, Lacharme-Lora L, Everett DB, Kingsley RA, Parkhill J, Heyderman RS, Dougan G, Gordon MA, Thomson NR. 2016. Distinct Salmonella Enteritidis lineages associated with enterocolitis in high-income settings and invasive disease in low-income settings. Nat Genet 48:1211–1217.
    18.
    Winter SE, Winter MG, Godinez I, Yang HJ, Russmann H, Andrews-Polymenis HL, Baumler AJ. 2010. A rapid change in virulence gene expression during the transition from the intestinal lumen into tissue promotes systemic dissemination of Salmonella. PLoS Pathog 6:e1001060.
    19.
    Sonck KA, Kint G, Schoofs G, Vander Wauven C, Vanderleyden J, De Keersmaecker SC. 2009. The proteome of Salmonella Typhimurium grown under in vivo-mimicking conditions. Proteomics 9:565–579.
    20.
    Levi-Meyrueis C, Monteil V, Sismeiro O, Dillies MA, Monot M, Jagla B, Coppee JY, Dupuy B, Norel F. 2014. Expanding the RpoS/sigmaS-network by RNA sequencing and identification of SigmaS-controlled small RNAs in Salmonella. PLoS One 9:e96918.
    21.
    Battesti A, Majdalani N, Gottesman S. 2011. The RpoS-mediated general stress response in Escherichia coli. Annu Rev Microbiol 65:189–213.
    22.
    Huang KY, Wang YH, Chien KY, Janapatla RP, Chiu CH. 2016. Hyperinvasiveness of Salmonella enterica serovar Choleraesuis linked to hyperexpression of type III secretion systems in vitro. Sci Rep 6:37642.
    23.
    Apel D, Surette MG. 2008. Bringing order to a complex molecular machine: the assembly of the bacterial flagella. Biochim Biophys Acta 1778:1851–1858.
    24.
    Sasias S, Martinez-Sanguine A, Betancor L, Martinez A, D'Alessandro B, Iriarte A, Chabalgoity JA, Yim L. 2017. A naturally occurring deletion in FliE from Salmonella enterica serovar Dublin results in an aflagellate phenotype and defective proinflammatory properties. Infect Immun 86:e00517-17.
    25.
    Stecher B, Barthel M, Schlumberger MC, Haberli L, Rabsch W, Kremer M, Hardt WD. 2008. Motility allows S. Typhimurium to benefit from the mucosal defence. Cell Microbiol 10:1166–1180.
    26.
    Rivera-Chavez F, Winter SE, Lopez CA, Xavier MN, Winter MG, Nuccio SP, Russell JM, Laughlin RC, Lawhon SD, Sterzenbach T, Bevins CL, Tsolis RM, Harshey R, Adams LG, Bäumler AJ. 2013. Salmonella uses energy taxis to benefit from intestinal inflammation. PLoS Pathog 9:e1003267.
    27.
    Lockman HA, Curtiss R, III. 1990. Salmonella typhimurium mutants lacking flagella or motility remain virulent in BALB/c mice. Infect Immun 58:137–143.
    28.
    Yim L, Sasias S, Martinez A, Betancor L, Estevez V, Scavone P, Bielli A, Sirok A, Chabalgoity JA. 2014. Repression of flagella is a common trait in field isolates of Salmonella enterica serovar Dublin and is associated with invasive human infections. Infect Immun 82:1465–1476.
    29.
    Winter SE, Thiennimitr P, Winter MG, Butler BP, Huseby DL, Crawford RW, Russell JM, Bevins CL, Adams LG, Tsolis RM, Roth JR, Bäumler AJ. 2010. Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature 467:426–429.
    30.
    Price-Carter M, Tingey J, Bobik TA, Roth JR. 2001. The alternative electron acceptor tetrathionate supports B12-dependent anaerobic growth of Salmonella enterica serovar typhimurium on ethanolamine or 1,2-propanediol. J Bacteriol 183:2463–2475.
    31.
    Faber F, Thiennimitr P, Spiga L, Byndloss MX, Litvak Y, Lawhon S, Andrews-Polymenis HL, Winter SE, Baumler AJ. 2017. Respiration of microbiota-derived 1,2-propanediol drives Salmonella expansion during colitis. PLoS Pathog 13:e1006129.
    32.
    Halsey TA, Vazquez-Torres A, Gravdahl DJ, Fang FC, Libby SJ. 2004. The ferritin-like Dps protein is required for Salmonella enterica serovar Typhimurium oxidative stress resistance and virulence. Infect Immun 72:1155–1158.
    33.
    Brown RN, Sanford JA, Park JH, Deatherage BL, Champion BL, Smith RD, Heffron F, Adkins JN. 2012. A comprehensive subcellular proteomic survey of Salmonella grown under phagosome-mimicking versus standard laboratory conditions. Int J Proteomics 2012:123076.
    34.
    Prouty AM, Brodsky IE, Manos J, Belas R, Falkow S, Gunn JS. 2004. Transcriptional regulation of Salmonella enterica serovar Typhimurium genes by bile. FEMS Immunol Med Microbiol 41:177–185.
    35.
    Ray S, Da Costa R, Das M, Nandi D. 2019. Interplay of cold shock protein E with an uncharacterized protein, YciF, lowers porin expression and enhances bile resistance in Salmonella Typhimurium. J Biol Chem 294:9084–9099.
    36.
    Ashraf KU, Josts I, Mosbahi K, Kelly SM, Byron O, Smith BO, Walker D. 2016. The potassium binding protein Kbp is a cytoplasmic potassium sensor. Structure 24:741–749.
    37.
    Bernal-Cabas M, Ayala JA, Raivio TL. 2015. The Cpx envelope stress response modifies peptidoglycan cross-linking via the L,D-transpeptidase LdtD and the novel protein YgaU. J Bacteriol 197:603–614.
    38.
    Weber A, Kogl SA, Jung K. 2006. Time-dependent proteome alterations under osmotic stress during aerobic and anaerobic growth in Escherichia coli. J Bacteriol 188:7165–7175.
    39.
    Fang FC, Frawley ER, Tapscott T, Vazquez-Torres A. 2016. Discrimination and integration of stress signals by pathogenic bacteria. Cell Host Microbe 20:144–153.
    40.
    Pradhan D, Devi Negi V. 2019. Stress-induced adaptations in Salmonella: a ground for shaping its pathogenesis. Microbiol Res 229:126311.
    41.
    Suez J, Porwollik S, Dagan A, Marzel A, Schorr YI, Desai PT, Agmon V, McClelland M, Rahav G, Gal-Mor O. 2013. Virulence gene profiling and pathogenicity characterization of non-typhoidal Salmonella accounted for invasive disease in humans. PLoS One 8:e58449.
    42.
    Wright JA, Totemeyer SS, Hautefort I, Appia-Ayme C, Alston M, Danino V, Paterson GK, Mastroeni P, Menager N, Rolfe M, Thompson A, Ugrinovic S, Sait L, Humphrey T, Northen H, Peters SE, Maskell DJ, Hinton JCD, Bryant CE. 2009. Multiple redundant stress resistance mechanisms are induced in Salmonella enterica serovar Typhimurium in response to alteration of the intracellular environment via TLR4 signalling. Microbiology (Reading) 155:2919–2929.
    43.
    Rosenkrantz JT, Aarts H, Abee T, Rolfe MD, Knudsen GM, Nielsen MB, Thomsen LE, Zwietering MH, Olsen JE, Pin C. 2013. Non-essential genes form the hubs of genome scale protein function and environmental gene expression networks in Salmonella enterica serovar Typhimurium. BMC Microbiol 13:294.
    44.
    Chaudhuri RR, Peters SE, Pleasance SJ, Northen H, Willers C, Paterson GK, Cone DB, Allen AG, Owen PJ, Shalom G, Stekel DJ, Charles IG, Maskell DJ. 2009. Comprehensive identification of Salmonella enterica serovar typhimurium genes required for infection of BALB/c mice. PLoS Pathog 5:e1000529.
    45.
    Lawhon SD, Maurer R, Suyemoto M, Altier C. 2002. Intestinal short-chain fatty acids alter Salmonella typhimurium invasion gene expression and virulence through BarA/SirA. Mol Microbiol 46:1451–1464.
    46.
    Betancor L, Yim L, Fookes M, Martinez A, Thomson NR, Ivens A, Peters S, Bryant C, Algorta G, Kariuki S, Schelotto F, Maskell D, Dougan G, Chabalgoity JA. 2009. Genomic and phenotypic variation in epidemic-spanning Salmonella enterica serovar Enteritidis isolates. BMC Microbiol 9:237.
    47.
    Yim L, Betancor L, Martinez A, Giossa G, Bryant C, Maskell D, Chabalgoity JA. 2010. Differential phenotypic diversity among epidemic-spanning Salmonella enterica serovar enteritidis isolates from humans or animals. Appl Environ Microbiol 76:6812–6820.
    48.
    D'Alessandro B, Perez Escanda V, Balestrazzi L, Iriarte A, Pickard D, Yim L, Chabalgoity JA, Betancor L. 2018. A novel prophage identified in strains from Salmonella enterica serovar Enteritidis is a phylogenetic signature of the lineage ST-1974. Microb Genom 4:e000161.
    49.
    D'Alessandro B, Perez Escanda V, Balestrazzi L, Grattarola F, Iriarte A, Pickard D, Yim L, Chabalgoity JA, Betancor L. 2020. Comparative genomics of Salmonella enterica serovar Enteritidis ST-11 isolated in Uruguay reveals lineages associated with particular epidemiological traits. Sci Rep 10:3638.
    50.
    Brettin T, Davis JJ, Disz T, Edwards RA, Gerdes S, Olsen GJ, Olson R, Overbeek R, Parrello B, Pusch GD, Shukla M, Thomason JA, III, Stevens R, Vonstein V, Wattam AR, Xia F. 2015. RASTtk: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. Sci Rep 5:8365.
    51.
    Contreras-Moreira B, Vinuesa P. 2013. GET_HOMOLOGUES, a versatile software package for scalable and robust microbial pangenome analysis. Appl Environ Microbiol 79:7696–7701.
    52.
    Li L, Stoeckert CJ, Jr, Roos DS. 2003. OrthoMCL: identification of ortholog groups for eukaryotic genomes. Genome Res 13:2178–2189.
    53.
    Carvalho PC, Fischer JS, Perales J, Yates JR, Barbosa VC, Bareinboim E. 2011. Analyzing marginal cases in differential shotgun proteomics. Bioinformatics 27:275–276.
    54.
    Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. J Mol Biol 215:403–410.
    55.
    Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009. BLAST+: architecture and applications. BMC Bioinformatics 10:421.
    56.
    Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. 2000. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25:25–29.
    57.
    The Gene Ontology Consortium. 2018. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res 47:D330–D338.
    58.
    Huerta-Cepas J, Forslund K, Coelho LP, Szklarczyk D, Jensen LJ, von Mering C, Bork P. 2017. Fast genome-wide functional annotation through orthology assignment by eggNOG-Mapper. Mol Biol Evol 34:2115–2122.
    59.
    Buchfink B, Xie C, Huson DH. 2015. Fast and sensitive protein alignment using DIAMOND. Nat Methods 12:59–60.
    60.
    Huerta-Cepas J, Szklarczyk D, Forslund K, Cook H, Heller D, Walter MC, Rattei T, Mende DR, Sunagawa S, Kuhn M, Jensen LJ, von Mering C, Bork P. 2016. eggNOG 4.5: a hierarchical orthology framework with improved functional annotations for eukaryotic, prokaryotic and viral sequences. Nucleic Acids Res 44:D286–D293.
    61.
    Alexa A, Rahnenfuhrer J, Lengauer T. 2006. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 22:1600–1607.
    62.
    Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408.
    63.
    Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640–6645.
    64.
    Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, Inuganti A, Griss J, Mayer G, Eisenacher M, Pérez E, Uszkoreit J, Pfeuffer J, Sachsenberg T, Yilmaz S, Tiwary S, Cox J, Audain E, Walzer M, Jarnuczak AF, Ternent T, Brazma A, Vizcaíno JA. 2019. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res 47:D442–D450.

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 89Number 316 February 2021
    eLocator: e00606-20
    Editor: Manuela Raffatellu
    University of California San Diego School of Medicine

    History

    Received: 27 September 2020
    28 October 2020
    Accepted: 10 December 2020
    Published online: 23 December 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. comparative proteomics
    2. Salmonella Dublin
    3. Salmonella Enteritidis
    4. stress resistance
    5. virulence
    6. anaerobic metabolism

    Contributors

    Authors

    A. Y. Martinez-Sanguiné
    Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
    B. D’Alessandro
    Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
    M. Langleib
    Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
    G. M. Traglia
    Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
    A. Mónaco
    Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
    R. Durán
    Instituto Pasteur de Montevideo, Montevideo, Uruguay
    Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay
    J. A. Chabalgoity
    Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
    L. Betancor
    Departamento de Bacteriología y Virología, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
    Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay

    Editor

    Manuela Raffatellu
    Editor
    University of California San Diego School of Medicine

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    Random Transposon Mutagenesis ofCampylobacter jejuni

    Random Transposon Mutagenesis ofCampylobacter jejuni

    ABSTRACT

    Genetic studies of Campylobacter jejuni have been limited due to the lack of a transposon mutagenesis method. Here, we describe a novel technique for random transposon mutagenesis using amariner-based transposon into C. jejuni strain 480. Insertions were random, as demonstrated by Southern blot analysis and insertional junction sequencing. We have demonstrated, for the first time, random in vivo transposon mutagenesis of C. jejuni.

    REFERENCES

    1.
    Akerley B. J., Rubin E. J., Camilli A., Lampe D. J., Robertson H. M., and Mekalanos J. J.Systematic identification of essential genes by in vitro mariner mutagenesis.Proc. Natl. Acad. Sci. USA9519988927-8932
    2.
    Bleumink-Pluym N. M., Verschoor F., Gaastra W., van der Zeijst B. A., and Fry B. N.A novel approach for the construction of a Campylobacter mutant library.Microbiology14519992145-2151
    3.
    King V., Wassenaar T., van der Zeijst B. A. M., and Newell D. G.Variations in Campylobacter jejuni flagellin, and flagellin genes, during in vivo and in vitro passage.Microb. Ecol. Health Dis.41991135-140
    4.
    Labigne A., Courcoux P., and Tompkins L.Cloning of Campylobacter jejuni genes required for leucine biosynthesis, and construction of leu-negative mutant of C. jejuni by shuttle transposon mutagenesis.Res. Microbiol.143199215-26
    5.
    Labigne-Roussel A., Courcoux P., and Tompkins L.Gene disruption and replacement as a feasible approach for mutagenesis of Campylobacter jejuni.J. Bacteriol.17019881704-1708
    6.
    Lampe D. J., Akerley B. J., Rubin E. J., Mekalanos J. J., and Robertson H. M.Hyperactive transposase mutants of the Himar1 mariner transposon.Proc. Natl. Acad. Sci. USA96199911428-11433
    7.
    Lampe D. J., Churchill M. E., and Robertson H. M.A purified mariner transposase is sufficient to mediate transposition in vitro.EMBO J.1519965470-5479
    8.
    Nuijten P. J., Bleumink-Pluym N. M., Gaastra W., and van der Zeijst B. A.Flagellin expression in Campylobacter jejuni is regulated at the transcriptional level.Infect. Immun.5719891084-1088
    9.
    Parkhill J., Wren B. W., Mungall K., Ketley J. M., Churcher C., Basham D., Chillingworth T., Davies R. M., Feltwell T., Holroyd S., Jagels K., Karlyshev A. V., Moule S., Pallen M. J., Penn C. W., Quail M. A., Rajandream M. A., Rutherford K. M., van Vliet A. H., Whitehead S., and Barrell B. G.The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences.Nature4032000665-668
    10.
    Rubin E. J., Akerley B. J., Novik V. N., Lampe D. J., Husson R. N., and Mekalanos J. J.In vivo transposition of mariner-based elements in enteric bacteria and mycobacteria.Proc. Natl. Acad. Sci. USA9619991645-1650
    11.
    Tauxe R. V.Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nationsCampylobacter jejuni: current status and future trends.Nachamkin I., Blaser M. J., and Tompkins L. S.1992919American Society for MicrobiologyWashington, D.C.
    12.
    Tompkins L. S.Genetic and molecular approach to Campylobacter pathogenesisCampylobacter jejuni: current status and future trends.Nachamkin I., Blaser M. J., and Tompkins L. S.1992241254American Society for MicrobiologyWashington, D.C.
    13.
    Wassenaar T. M., Fry B. N., and van der Zeijst B. A.Genetic manipulation of Campylobacter: evaluation of natural transformation and electro-transformation.Gene1321993131-135
    14.
    Wosten M. M., Boeve M., Koot M. G., van Nuene A. C., and van der Zeijst B. A.Identification of Campylobacter jejuni promoter sequences.J. Bacteriol.1801998594-599
    15.
    Yao R., Alm R. A., Trust T. J., and Guerry P.Construction of new Campylobacter cloning vectors and a new mutational cat cassette.Gene1301993127-130
    16.
    Yao R., Burr D. H., Doig P., Trust T. J., Niu H., and Guerry P.Isolation of motile and non-motile insertional mutants of Campylobacter jejuni: the role of motility in adherence and invasion of eukaryotic cells.Mol. Microbiol.141994883-893

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 68Number 91 September 2000
    Pages: 5450 - 5453
    Editor: A. D. O'Brien

    History

    Received: 3 February 2000
    22 March 2000
    Accepted: 14 June 2000

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Neal J. Golden
    Departments of Immunology and Pathology1 and
    Andrew Camilli
    Molecular Microbiology,2 Tufts University, Boston, Massachusetts 02111
    David W. K. Acheson
    Division of Geographic Medicine and Infectious Diseases, New England Medical Center,3 and
    Departments of Immunology and Pathology1 and

    Editor

    A. D. O'Brien

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    Model for In Vivo Assessment of Humoral Protection against Malaria Sporozoite Challenge by Passive Transfer of Monoclonal Antibodies and Immune Serum

    Model for In Vivo Assessment of Humoral Protection against Malaria Sporozoite Challenge by Passive Transfer of Monoclonal Antibodies and Immune Serum

    ABSTRACT

    Evidence from clinical trials of malaria vaccine candidates suggests that both cell-mediated and humoral immunity to pre-erythrocytic parasite stages can provide protection against infection. Novel pre-erythrocytic antibody (Ab) targets could be key to improving vaccine formulations, which are currently based on targeting antigens such as the circumsporozoite protein (CSP). However, methods to assess the effects of sporozoite-specific Abs on pre-erythrocytic infection in vivo remain underdeveloped. Here, we combined passive transfer of monoclonal Abs (MAbs) or immune serum with a luciferase-expressing Plasmodium yoelii sporozoite challenge to assess Ab-mediated inhibition of liver infection in mice. Passive transfer of a P. yoelii CSP MAb showed inhibition of liver infection when mice were challenged with sporozoites either intravenously or by infectious mosquito bite. However, inhibition was most potent for the mosquito bite challenge, leading to a more significant reduction of liver-stage burden and even a lack of progression to blood-stage parasitemia. This suggests that Abs provide effective protection against a natural infection. Inhibition of liver infection was also achieved by passive transfer of immune serum from whole-parasite-immunized mice. Furthermore, we demonstrated that passive transfer of a MAb against P. falciparum CSP inhibited liver-stage infection in a humanized mouse/P. falciparum challenge model. Together, these models constitute unique and sensitive in vivo methods to assess serum-transferable protection against Plasmodium sporozoite challenge.

    REFERENCES

    1.
    Casares S, Brumeanu TD, and Richie TL. 2010. The RTS,S malaria vaccine. Vaccine 28:4880–4894.
    2.
    Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kabore B, Sombie O, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, et al. 2012. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367:2284–2295.
    3.
    Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, Lievens M, Leboulleux D, Njuguna P, Peshu N, Marsh K, and Bejon P. 2013. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 368:1111–1120.
    4.
    Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, and Heppner DG Jr. 2009. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200:337–346.
    5.
    Clyde DF, McCarthy VC, Miller RM, and Hornick RB. 1973. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 266:398–403.
    6.
    Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL, and VRC 312 Study Team. 8 August 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science doi:
    7.
    Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, Renia L, van der Ven A, Hermsen CC, and Sauerwein R. 2009. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361:468–477.
    8.
    Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, Arens T, Beckers P, van Gemert G, van de Vegte-Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, and Sauerwein RW. 2011. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377:1770–1776.
    9.
    Luke TC and Hoffman SL. 2003. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206:3803–3808.
    10.
    Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, and Harty JT. 2011. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9:451–462.
    11.
    Khan SM, Janse CJ, Kappe SH, and Mikolajczak SA. 2012. Genetic engineering of attenuated malaria parasites for vaccination. Curr. Opin. Biotechnol. 23:908–916.
    12.
    Chen DH, Tigelaar RE, and Weinbaum FI. 1977. Immunity to sporozoite-induced malaria infeciton in mice. I. The effect of immunization of T and B cell-deficient mice. J. Immunol. 118:1322–1327.
    13.
    Weiss WR, Sedegah M, Beaudoin RL, Miller LH, and Good MF. 1988. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl. Acad. Sci. U. S. A. 85:573–576.
    14.
    Egan JE, Weber JL, Ballou WR, Hollingdale MR, Majarian WR, Gordon DM, Maloy WL, Hoffman SL, Wirtz RA, and Schneider I. 1987. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science 236:453–456.
    15.
    Rodrigues M, Nussenzweig RS, and Zavala F. 1993. The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria. Immunology 80:1–5.
    16.
    Vanderberg J, Mueller AK, Heiss K, Goetz K, Matuschewski K, Deckert M, and Schluter D. 2007. Assessment of antibody protection against malaria sporozoites must be done by mosquito injection of sporozoites. Am. J. Pathol. 171:1405–1406; author reply, 1406.
    17.
    Sinnis P and Zavala F. 2008. The skin stage of malaria infection: biology and relevance to the malaria vaccine effort. Future Microbiol. 3:275–278.
    18.
    Coppi A, Tewari R, Bishop JR, Bennett BL, Lawrence R, Esko JD, Billker O, and Sinnis P. 2007. Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe 2:316–327.
    19.
    Amino R, Giovannini D, Thiberge S, Gueirard P, Boisson B, Dubremetz JF, Prevost MC, Ishino T, Yuda M, and Menard R. 2008. Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. Cell Host Microbe 3:88–96.
    20.
    Vanderberg JP and Frevert U. 2004. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int. J. Parasitol. 34:991–996.
    21.
    Kebaier C, Voza T, and Vanderberg J. 2009. Kinetics of mosquito-injected Plasmodium sporozoites in mice: fewer sporozoites are injected into sporozoite-immunized mice. PLoS Pathog. 5:e1000399.
    22.
    Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA, and Hoffman SL. 2011. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334:475–480.
    23.
    Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, Ewer KJ, Havelock T, Mahungu T, Bliss CM, Miura K, Poulton ID, Lillie PJ, Antrobus RD, Berrie E, Moyle S, Gantlett K, Colloca S, Cortese R, Long CA, Sinden RE, Gilbert SC, Lawrie AM, Doherty T, Faust SN, Nicosia A, Hill AV, and Draper SJ. 2012. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20:2355–2368.
    24.
    Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, and Richie TL. 2013. DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 8:e55571.
    25.
    White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, Ockenhouse CF, and Ghani AC. 2013. The relationship between RTS,S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. PLoS One 8:e61395.
    26.
    Crompton PD, Pierce SK, and Miller LH. 2010. Advances and challenges in malaria vaccine development. J. Clin. Invest. 120:4168–4178.
    27.
    Lindner SE, Swearingen KE, Harupa A, Vaughan AM, Sinnis P, Moritz RL, and Kappe SH. 2013. Total and putative surface proteomics of malaria parasite salivary gland sporozoites. Mol. Cell. Proteomics 12:1127–1143.
    28.
    Wang R, Smith JD, and Kappe SH. 2009. Advances and challenges in malaria vaccine development. Expert Rev. Mol. Med. 11:e39.
    29.
    Charoenvit Y, Mellouk S, Cole C, Bechara R, Leef MF, Sedegah M, Yuan LF, Robey FA, Beaudoin RL, and Hoffman SL. 1991. Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J. Immunol. 146:1020–1025.
    30.
    Ak M, Bower JH, Hoffman SL, Sedegah M, Lees A, Carter M, Beaudoin RL, and Charoenvit Y. 1993. Monoclonal antibodies of three different immunoglobulin G isotypes produced by immunization with a synthetic peptide or native protein protect mice against challenge with Plasmodium yoelii sporozoites. Infect. Immun. 61:2493–2497.
    31.
    Brahimi K, Badell E, Sauzet JP, BenMohamed L, Daubersies P, Guerin-Marchand C, Snounou G, and Druilhe P. 2001. Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo. Infect. Immun. 69:3845–3852.
    32.
    Vaughan AM, O'Neill MT, Tarun AS, Camargo N, Phuong TM, Aly AS, Cowman AF, and Kappe SH. 2009. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell. Microbiol. 11:506–520.
    33.
    Aly AS, Lindner SE, MacKellar DC, Peng X, and Kappe SH. 2011. SAP1 is a critical post-transcriptional regulator of infectivity in malaria parasite sporozoite stages. Mol. Microbiol. 79:929–939.
    34.
    Vaughan AM, Mikolajczak SA, Camargo N, Lakshmanan V, Kennedy M, Lindner SE, Miller JL, Hume JC, and Kappe SH. 2012. A transgenic Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle. Mol. Biochem. Parasitol. 186:143–147.
    35.
    Vaughan AM, Mikolajczak SA, Wilson EM, Grompe M, Kaushansky A, Camargo N, Bial J, Ploss A, and Kappe SH. 2012. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J. Clin. Invest. 122:3618–3628.
    36.
    Miller JL, Murray S, Vaughan AM, Harupa A, Sack B, Baldwin M, Crispe IN, and Kappe SH. 2013. Quantitative bioluminescent imaging of pre-erythrocytic malaria parasite infection using luciferase-expressing Plasmodium yoelii. PLoS One 8:e60820.
    37.
    Ploemen I, Behet M, Nganou-Makamdop K, van Gemert GJ, Bijker E, Hermsen C, and Sauerwein R. 2011. Evaluation of immunity against malaria using luciferase-expressing Plasmodium berghei parasites. Malaria J. 10:350.
    38.
    Portugal S, Carret C, Recker M, Armitage AE, Goncalves LA, Epiphanio S, Sullivan D, Roy C, Newbold CI, Drakesmith H, and Mota MM. 2011. Host-mediated regulation of superinfection in malaria. Nat. Med. 17:732–737.
    39.
    Medica DL and Sinnis P. 2005. Quantitative dynamics of Plasmodium yoelii sporozoite transmission by infected anopheline mosquitoes. Infect. Immun. 73:4363–4369.
    40.
    Kaushansky A, Rezakhani N, Mann H, and Kappe SH. 2012. Development of a quantitative flow cytometry-based assay to assess infection by Plasmodium falciparum sporozoites. Mol. Biochem. Parasitol. 183:100–103.
    41.
    Shin SC, Vanderberg JP, and Terzakis JA. 1982. Direct infection of hepatocytes by sporozoites of Plasmodium berghei. J. Protozool. 29:448–454.
    42.
    Yamauchi LM, Coppi A, Snounou G, and Sinnis P. 2007. Plasmodium sporozoites trickle out of the injection site. Cell. Microbiol. 9:1215–1222.
    43.
    World Health Organization. 2012. World malaria report 2012. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/publications/world_malaria_report_2012/report/en/index.html.
    44.
    Harlow E and Lane D. 1988. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 82Number 2February 2014
    Pages: 808 - 817
    Editor: J. H. Adams

    History

    Received: 2 October 2013
    30 October 2013
    Accepted: 30 November 2013
    Published online: 9 December 2013

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Brandon K. Sack
    Seattle Biomedical Research Institute, Seattle, Washington, USA
    Jessica L. Miller
    Seattle Biomedical Research Institute, Seattle, Washington, USA
    Ashley M. Vaughan
    Seattle Biomedical Research Institute, Seattle, Washington, USA
    Alyse Douglass
    Seattle Biomedical Research Institute, Seattle, Washington, USA
    Alexis Kaushansky
    Seattle Biomedical Research Institute, Seattle, Washington, USA
    Sebastian Mikolajczak
    Seattle Biomedical Research Institute, Seattle, Washington, USA
    Alida Coppi
    Regeneron Pharmaceuticals, Tarrytown, New York, USA
    Gloria Gonzalez-Aseguinolaza
    Centro de Investigacion Medica Aplicada, Division of Hepatology and Gene Therapy, University of Navarra, Pamplona, Spain
    Moriya Tsuji
    HIV and Malaria Vaccine Program, Aaron Diamond AIDS Research Center, Affiliate of Rockefeller University, New York, New York, USA
    Fidel Zavala
    Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Photini Sinnis
    Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Stefan H. I. Kappe
    Seattle Biomedical Research Institute, Seattle, Washington, USA
    Department of Global Health, University of Washington, Seattle, Washington, USA

    Editor

    J. H. Adams
    Editor

    Notes

    Address correspondence to Stefan H. I. Kappe, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    The Adaptor CARD9 Is Required for Adaptive but Not Innate Immunity to Oral Mucosal Candida albicans Infections

    The Adaptor CARD9 Is Required for Adaptive but Not Innate Immunity to Oral Mucosal Candida albicans Infections

    ABSTRACT

    Oropharyngeal candidiasis (OPC [thrush]) is an opportunistic infection caused by the commensal fungus Candida albicans. OPC is common in individuals with HIV/AIDS, infants, patients on chemotherapy, and individuals with congenital immune defects. Immunity to OPC is strongly dependent on the interleukin-23 (IL-23)/IL-17R axis, as mice and humans with defects in IL-17R signaling (IL17F, ACT1, IL-17RA) or in genes that direct Th17 differentiation (STAT3, STAT1, CARD9) are prone to mucocutaneous candidiasis. Conventional Th17 cells are induced in response to C. albicans infection via signals from C-type lectin receptors, which signal through the adaptor CARD9, leading to production of Th17-inducing cytokines such as IL-6, IL-1β, and IL-23. Recent data indicate that IL-17 can also be made by numerous innate cell subsets. These innate “type 17” cells resemble conventional Th17 cells, but they can be activated without need for prior antigen exposure. Because C. albicans is not a commensal organism in rodents and mice are thus naive to this fungus, we had the opportunity to assess the role of CARD9 in innate versus adaptive responses using an OPC infection model. As expected, CARD9−/− mice failed to mount an adaptive Th17 response following oral Candida infection. Surprisingly, however, CARD9−/− mice had preserved innate IL-17-dependent responses to Candida and were almost fully resistant to OPC. Thus, CARD9 is important primarily for adaptive immunity to C. albicans, whereas alternate recognition systems appear to be needed for effective innate responses.

    REFERENCES

    1.
    Fidel PL Jr. 2011. Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis. Adv. Dent. Res. 23:45–49.
    2.
    Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, and Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503–535.
    3.
    Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, and Napolitani G. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8:639–646.
    4.
    Huppler AR, Bishu S, and Gaffen SL. 2012. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res. Ther. 14:217.
    5.
    Puel A, Picard C, Cypowyj S, Lilic D, Abel L, and Casanova JL. 2010. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines? Curr. Opin. Immunol. 22:467–474.
    6.
    Boisson B, Wang C, Pedergnana V, Wu L, Cypowyj S, Rybojad M, Belkadi A, Picard C, Abel L, Fieschi C, Puel A, Li X, and Casanova J-L. 2013. A biallelic ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 39:676–686.
    7.
    Hernández-Santos N and Gaffen SL. 2012. Th17 cells in immunity to Candida albicans. Cell Host Microbe 11:425–435.
    8.
    Reid DM, Gow NA, and Brown GD. 2009. Pattern recognition: recent insights from Dectin-1. Curr. Opin. Immunol. 21:30–37.
    9.
    Gross O, Gewies A, Finger K, Schafer M, Sparwasser T, Peschel C, Forster I, and Ruland J. 2006. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442:651–656.
    10.
    LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V, Brown GD, Ruland J, and Reis ESC. 2007. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol. 8:630–638.
    11.
    Saijo S, Ikeda S, Yamabe K, Kakuta S, Ishigame H, Akitsu A, Fujikado N, Kusaka T, Kubo S, Chung SH, Komatsu R, Miura N, Adachi Y, Ohno N, Shibuya K, Yamamoto N, Kawakami K, Yamasaki S, Saito T, Akira S, and Iwakura Y. 2010. Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 32:681–691.
    12.
    Zhu LL, Zhao XQ, Jiang C, You Y, Chen XP, Jiang YY, Jia XM, and Lin X. 2013. C-type lectin receptors dectin-3 and dectin-2 form a heterodimeric pattern-recognition receptor for host defense against fungal infection. Immunity 39:324–334.
    13.
    Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, Findon H, Haynes K, Steele C, Botto M, Gordon S, and Brown GD. 2007. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat. Immunol. 8:31–38.
    14.
    Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, Salzer U, Pfeifer D, Veelken H, Warnatz K, Tahami F, Jamal S, Manguiat A, Rezaei N, Amirzargar AA, Plebani A, Hannesschlager N, Gross O, Ruland J, and Grimbacher B. 2009. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 361:1727–1735.
    15.
    Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H, Elbers CC, Johnson MD, Cambi A, Huysamen C, Jacobs L, Jansen T, Verheijen K, Masthoff L, Morre SA, Vriend G, Williams DL, Perfect JR, Joosten LA, Wijmenga C, van der Meer JW, Adema GJ, Kullberg BJ, Brown GD, and Netea MG. 2009. Human dectin-1 deficiency and mucocutaneous fungal infections. N. Engl. J. Med. 361:1760–1767.
    16.
    Plantinga TS, van der Velden WJ, Ferwerda B, van Spriel AB, Adema G, Feuth T, Donnelly JP, Brown GD, Kullberg BJ, Blijlevens NM, and Netea MG. 2009. Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 49:724–732.
    17.
    Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, Brown J, Becker CA, Fleshner PR, Dubinsky M, Rotter JI, Wang HL, McGovern DP, Brown GD, and Underhill DM. 2012. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 336:1314–1317.
    18.
    Hernández-Santos N, Huppler AR, Peterson AC, Khader SA, McKenna KC, and Gaffen SL. 2013. Th17 cells confer long term adaptive immunity to oral mucosal Candida albicans infections. Mucosal Immunol. 6:900–910.
    19.
    Bär E, Gladiator A, Bastidas S, Roschitzki B, Acha-Orbea H, Oxenius A, and LeibundGut-Landmann S. 2012. A novel Th cell epitope of Candida albicans mediates protection from fungal infection. J. Immunol. 188:5636–5643.
    20.
    Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, Ho AW, Hai JH, Yu JJ, Jung JW, Filler SG, Masso-Welch P, Edgerton M, and Gaffen SL. 2009. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 206:299–311.
    21.
    Ho A, Shen F, Conti H, Patel N, Childs E, Peterson A, Hernandez-Santos N, Kolls J, Kane L, Ouyang W, and Gaffen S. 2010. IL-17RC is required for immune signaling via an extended SEFIR domain in the cytoplasmic tail. J. Immunol. 185:1063–1070.
    22.
    Hsu YM, Zhang Y, You Y, Wang D, Li H, Duramad O, Qin XF, Dong C, and Lin X. 2007. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat. Immunol. 8:198–205.
    23.
    Hise AG, Tomalka J, Ganesan S, Patel K, Hall BA, Brown GD, and Fitzgerald KA. 2009. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 5:487–497.
    24.
    Carvalho A, Giovannini G, De Luca A, D'Angelo C, Casagrande A, Iannitti RG, Ricci G, Cunha C, and Romani L. 2012. Dectin-1 isoforms contribute to distinct Th1/Th17 cell activation in mucosal candidiasis. Cell Mol. Immunol. 9:276–286.
    25.
    Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, and Daly MJ. 2008. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40:955–962.
    26.
    Romani L. 2011. Immunity to fungal infections. Nat. Rev. Immunol. 11:275–288.
    27.
    Vautier S, Sousa Mda G, and Brown GD. 2010. C-type lectins, fungi and Th17 responses. Cytokine Growth Factor Rev. 21:405–412.
    28.
    Cua DJ and Tato CM. 2010. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 10:479–489.
    29.
    Gaffen SL. 2009. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9:556–567.
    30.
    Puel A, Cypowji S, Bustamante J, Wright J, Liu L, Lim H, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman N, Al-Muhsen S, Galicchio M, Abel L, Picard C, and Casanova J-L. 2011. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332:65–68.
    31.
    Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, Ersvaer E, Perheentupa J, Erichsen MM, Bratanic N, Meloni A, Cetani F, Perniola R, Ergun-Longmire B, Maclaren N, Krohn KJ, Pura M, Schalke B, Strobel P, Leite MI, Battelino T, Husebye ES, Peterson P, Willcox N, and Meager A. 2010. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207:299–308.
    32.
    Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, Cobat A, Ouachee-Chardin M, Toulon A, Bustamante J, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McConnell V, Cant AJ, Abinun M, Polak M, Bougneres PF, Kumararatne D, Marodi L, Nahum A, Roifman C, Blanche S, Fischer A, Bodemer C, Abel L, Lilic D, and Casanova JL. 2010. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207:291–297.
    33.
    Browne SK and Holland SM. 2010. Immunodeficiency secondary to anticytokine autoantibodies. Curr. Opin. Allergy Clin. Immunol. 10:534–541.
    34.
    Tangye SG, Cook MC, and Fulcher DA. 2009. Insights into the role of STAT3 in human lymphocyte differentiation as revealed by the hyper-IgE syndrome. J. Immunol. 182:21–28.
    35.
    Kamai Y, Kubota M, Kamai Y, Hosokawa T, Fukuoka T, and Filler S. 2001. New model of oropharyngeal candidiasis in mice. Antimicrob. Agents Chemother. 45:3195–3197.
    36.
    Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A, and Sallusto F. 2012. Pathogen-induced human T(H)17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 484:514–518.
    37.
    von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, Chrabieh M, Mustapha IB, Ghandil P, Camcioglu Y, Vasconcelos J, Sirvent N, Guedes M, Vitor AB, Herrero-Mata MJ, Arostegui JI, Rodrigo C, Alsina L, Ruiz-Ortiz E, Juan M, Fortuny C, Yague J, Anton J, Pascal M, Chang HH, Janniere L, Rose Y, Garty BZ, Chapel H, Issekutz A, Marodi L, Rodriguez-Gallego C, Banchereau J, Abel L, Li X, Chaussabel D, Puel A, and Casanova JL. 2008. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321:691–696.
    38.
    Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C, Hitchcock R, Lammas D, Davies G, Al-Ghonaium A, Al-Rayes H, Al-Jumaah S, Al-Hajjar S, Al-Mohsen IZ, Frayha HH, Rucker R, Hawn TR, Aderem A, Tufenkeji H, Haraguchi S, Day NK, Good RA, Gougerot-Pocidalo MA, Ozinsky A, and Casanova JL. 2003. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299:2076–2079.
    39.
    Ku CL, Picard C, Erdos M, Jeurissen A, Bustamante J, Puel A, von Bernuth H, Filipe-Santos O, Chang HH, Lawrence T, Raes M, Marodi L, Bossuyt X, and Casanova JL. 2007. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J. Med. Genet. 44:16–23.
    40.
    Wells CA, Salvage-Jones JA, Li X, Hitchens K, Butcher S, Murray RZ, Beckhouse AG, Lo YL, Manzanero S, Cobbold C, Schroder K, Ma B, Orr S, Stewart L, Lebus D, Sobieszczuk P, Hume DA, Stow J, Blanchard H, and Ashman RB. 2008. The macrophage-inducible C-type lectin, mincle, is an essential component of the innate immune response to Candida albicans. J. Immunol. 180:7404–7413.
    41.
    Tomalka J, Ganesan S, Azodi E, Patel K, Majmudar P, Hall BA, Fitzgerald KA, and Hise AG. 2011. A novel role for the NLRC4 inflammasome in mucosal defenses against the fungal pathogen Candida albicans. PLoS Pathog. 7:e1002379.
    42.
    Glocker E and Grimbacher B. 2010. Chronic mucocutaneous candidiasis and congenital susceptibility to Candida. Curr. Opin. Allergy Clin. Immunol. 10:542–550.
    43.
    Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, and White TC. 2012. Hidden killers: human fungal infections. Sci. Transl. Med. 4:165rv113.

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 82Number 3March 2014
    Pages: 1173 - 1180
    Editor: G. S. Deepe Jr.

    History

    Received: 17 October 2013
    11 November 2013
    Accepted: 18 December 2013
    Published online: 30 December 2013

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Shrinivas Bishu
    Division of Gastroenterology, Hepatology & Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Nydiaris Hernández-Santos
    Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Michelle R. Simpson-Abelson
    Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Anna R. Huppler
    Children's Hospital of the University of Pittsburgh Medical Center, Division of Pediatric Infectious Diseases, Pittsburgh, Pennsylvania, USA
    Heather R. Conti
    Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Nico Ghilardi
    Genentech Inc., Dept. of Immunology, South San Francisco, California, USA
    Anna J. Mamo
    Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Sarah L. Gaffen
    Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    Editor

    G. S. Deepe Jr.
    Editor

    Notes

    Address correspondence to Sarah L. Gaffen, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    A Novel Urease-Negative HelicobacterSpecies Associated with Colitis and Typhlitis in IL-10-Deficient Mice

    A Novel Urease-Negative HelicobacterSpecies Associated with Colitis and Typhlitis in IL-10-Deficient Mice

    ABSTRACT

    A spiral-shaped bacterium with bipolar, single-sheathed flagella was isolated from the intestines of IL-10 (interleukin-10)-deficient (IL-10−/−) mice with inflammatory bowel disease. The organism was microaerobic, grew at 37 and 42°C, and was oxidase and catalase positive but urease negative. On the basis of 16S rRNA gene sequence analysis and biochemical and phenotypic criteria, the organism is classified as a novel helicobacter. Cesarean section-rederived IL-10−/− mice without helicobacter infection did not have histological evidence of intestinal inflammation. However, helicobacter-free IL-10−/−, SCID/NCr, and A/JNCr mice experimentally inoculated with the novel urease-negativeHelicobacter sp. developed variable degrees of inflammation in the lower intestine, and in immunocompetent mice, the experimental infection was accompanied by a corresponding elevated immunoglobulin G antibody response to the novel Helicobacter sp. antigen. These data support other recent studies which demonstrate that multipleHelicobacter spp. in both naturally and experimentally infected mice can induce inflammatory bowel disease. The mouse model of helicobacter-associated intestinal inflammation should prove valuable in understanding how specific microbial antigens influence a complex disease process.

    REFERENCES

    1.
    Berg O. J., Davidson N., Kuhn R., Muller W., Menon S., Holland G., and Thompson-Snipes L.Enterocolitis and colon cancer in interleukin 10 deficient mice are associated with aberrant cytokine production and CD4 + Th1-like response.J. Clin. Investig.9819961010-1020
    2.
    Cahill R. J., Foltz C. J., Fox J. G., Dangler C. A., Powrie F., and Schauer D. B.Inflammatory bowel disease: an immune-mediated condition triggered by bacterial infection with Helicobacter hepaticus.Infect. Immun.6519973126-3131
    3.
    Chin E. Y., Jha J., Dangler C. A., and Schauer D. B.Infectious colitis in T cell receptor knockout mice, abstr. B436.Abstracts of the 98th General Meeting of the American Society for Microbiology 1998.1998American Society for MicrobiologyWashington, D.C
    4.
    Foltz C. J., Fox J. G., Cahill R. J., Murphy R. C., Yan L., Shames B., and Schauer D. B.Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus.Helicobacter3199869-78
    5.
    Fox J. G., Dewhirst F. E., Tully J. G., Paster B. J., Yan L., Taylor N. S., Collins M. J., Gorelick P. L., and Ward J. M.Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice.J. Clin. Microbiol.3219941238-1245
    6.
    Fox J. G., Yan L., Dewhirst F. E., Paster B. J., Shames B., Murphy J. C., Hayward A., Belcher J. C., and Mendes E. N.Helicobacter bilis sp. nov., a novel Helicobacter species isolated from bile, livers, and intestines of aged, inbred mouse strains.J. Clin. Microbiol.331995445-454
    7.
    Fox J. G., Yan L., Shames B., Campbell J., Murphy J. C., and Li X.Persistent hepatitis and enterocolitis in germfree mice infected with Helicobacter hepaticus.Infect. Immun.6419963673-3681
    8.
    Graham D. Y.Campylobacter pylori and peptic ulcer disease.Gastroenterology961989615-623
    9.
    Jukes T. H. and Cantor C. R.Evolution of protein moleculesMammalian protein metabolism.Munro H. N.196921132Academic PressNew York, N.Y
    10.
    Kühn R., Lohler J., Rennick D., Rajewsky K., and Müller W.Interleukin-10-deficient mice develop chronic enterocolitis.Cell751993263-274
    10a.
    Kullberg, M. Unpublished observations.
    11.
    Kullberg M. C., Ward J. M., Gorelick P. L., Caspar P., Hieny S., Cheever A., Jankovic D., and Sher A.Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism.Infect. Immun.6619985157-5166
    12.
    Li X., Fox J. G., Whary M., Yan L., Shames B., and Zhao Z.Scid/NCr mice naturally infected with Helicobacter hepaticus develop progressive hepatitis, proliferative typhlitis, and colitis.Infect. Immun.6619985477-5484
    13.
    Marshall B. J.Treatment strategies for Helicobacter pylori infection.Gastroenterol. Clin. North Am.221993183-198
    14.
    Mombaerts P., Mizoguchi E., Grusby M. J., Glimcher L. H., Bhan A. K., and Tonegawa S.Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice.Cell751993274-282
    15.
    Parsonnet J.Bacterial infection as a cause of cancer.Environ. Health Perspect.1031995263-268
    16.
    Paster B. J. and Dewhirst F. E.Phylogeny of Campylobacter, wolinellas, Bacteroides gracilis, and Bacteroides ureolyticus by 16S ribosomal ribonucleic acid sequencing.Int. J. Syst. Bacteriol.38198856-62
    17.
    Sadlack B., Merz H., Schorle H., Schimpl A., Feller A. C., and Horak I.Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.Cell751993253-261
    18.
    Saitou N. and Nei M.The neighbor-joining method: a new method for reconstructing phylogenetic trees.Mol. Biol. Evol.41987406-425
    19.
    Shames B., Fox J. G., Dewhirst F. E., Yan L., Shen Z., and Taylor N. S.Identification of widespread Helicobacter hepaticus infection in feces in commercial mouse colonies by culture and PCR assay.J. Clin. Microbiol.3319952968-2972
    20.
    Shen Z., Fox J. G., Dewhirst F. E., Paster B. J., Foltz C. J., Yan L., Shames B., and Perry L.Helicobacter rodentium sp. nov., a urease-negative Helicobacter species isolated from laboratory mice.Int. J. Syst. Bacteriol.471997627-634
    21.
    Shomer N. H., Dangler C. A., and Fox J. G.Helicobacter bilis-induced inflammatory bowel disease in defined flora scid mice.Infect. Immun.6519974858-4864
    22.
    Shomer N. H., Dangler C. A., Marini R., and Fox J. G.Helicobacter bilis/Helicobacter rodentium co-infection associated with diarrhea in a colony of scid mice.Lab. Anim. Sci.481998455-459
    23.
    Stanley J., Linton D., Burens A. P., Dewhirst F. E., On S. L., Porter A., Owen R. J., and Costas M.Helicobacter pullorum sp. nov.—genotype and phenotype of a new species isolated from poultry and from human patients with gastroenteritis.Microbiology14019943441-3449
    24.
    Stanley J., Linton D., Burens A. P., Dewhirst F. E., and Owen R. J.Helicobacter canis sp. nov., a new species from dogs: an integrated study of phenotype and genotype.J. Gen. Microbiol.13919932495-2504
    25.
    Totten P. A., Fennel C. L., and Tenover F. C.Campylobacter cinaedi (sp. nov.) and Campylobacter fennelliae (sp. nov.): two new Campylobacter species associated with enteric disease in homosexual men.J. Infect. Dis.1511985131-139
    26.
    Ward J. M., Anver M. R., Haines D. C., Melhorn J. M., Gorelick P., Yan L., and Fox J. G.Inflammatory large bowel disease in immunodeficient mice naturally infected with Helicobacter hepaticus.Lab. Anim. Sci.46199615-20
    27.
    Ward J. M., Fox J. G., Anver M. R., Haines D. C., George C. V., Collins M. J., Gorelick P. L., Nagashima K., Gonda M. A., Gilden R. V., Tully J. G., Russell R. J., Benveniste R. E., Paster B. J., Dewhirst F. E., Donovan J. C., Anderson L. M., and Rice J. M.Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species.J. Natl. Cancer Inst.8619941222-1227
    28.
    Whary M. T., Morgan T. J., Dangler C. A., Gaudes K. J., Taylor N. S., and Fox J. G.Chronic active hepatitis induced by Helicobacter hepaticus in the A/JCr mouse is associated with a Th1 cell-mediated immune response.Infect. Immun.6619983142-3148

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 67Number 41 April 1999
    Pages: 1757 - 1762
    Editor: D. L. Burns

    History

    Received: 8 October 1998
    11 December 1998
    Accepted: 23 December 1998

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    James G. Fox
    Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts 021391;
    Peter L. Gorelick
    Animal Health Diagnostic Laboratory, Laboratory Animal Sciences Program, NCI-FCRDC, Science Applications International Corporation,2 and
    Marika C. Kullberg
    Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-042513; and
    Zhongming Ge
    Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts 021391;
    Floyd E. Dewhirst
    Forsyth Dental Center, Boston, Massachusetts 021154
    Jerrold M. Ward
    Veterinary and Tumor Pathology Section, Animal Sciences Branch, Office of Laboratory Animal Resources, Division of Basic Sciences, National Cancer Institute,5 Frederick, Maryland 21702;

    Editor

    D. L. Burns

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    Intestinal Intraepithelial Lymphocytes Sustain the Epithelial Barrier Function against Eimeria vermiformis Infection

    Intestinal Intraepithelial Lymphocytes Sustain the Epithelial Barrier Function against Eimeria vermiformis Infection

    ABSTRACT

    Eimeria spp. are intracellular protozoa that infect intestinal epithelia of most vertebrates, causing coccidiosis. Intestinal intraepithelial lymphocytes (IEL) that reside at the basolateral site of epithelial cells (EC) have immunoregulatory and immunoprotective roles against Eimeria spp. infection. However, it remains unknown how IEL are involved in the regulation of epithelial barrier during Eimeria sp. infection. Here, we demonstrated two distinct roles of IEL against infection with Eimeria vermiformis, a murine pathogen: production of cytokines to induce protective immunity and expression of junctional molecules to preserve epithelial barrier. The number of IEL markedly increased when oocyst production reached a peak. During infection, IEL increased production of gamma interferon (IFN-γ) and tumor necrosis factor alpha (TNF-α) and decreased transforming growth factor β (TGF-β) production. Addition of IFN-γ and TNF-α or supernatants obtained from cultured IEL from E. vermiformis-infected mice reduced transepithelial electrical resistance (TER) in a confluent CMT93 cell monolayer, a murine intestine-derived epithelial line, but antibodies against these cytokines suppressed the decline of TER. Moreover, TGF-β attenuated the damage of epithelial monolayer and changes in TER caused by IFN-γ and TNF-α. The expression of junctional molecules by EC was decreased when IEL produced a high level of IFN-γ and TNF-α and a low level of TGF-β in E. vermiformis-infected mice. Interestingly, IEL constantly expressed junctional molecules and a coculture of EC with IEL increased TER. These results suggest that IEL play important multifunctional roles not only in protection of the epithelium against E. vermiformis-induced change by cytokine production but also in direct interaction with the epithelial barrier when intra-EC junctions are down-regulated.

    REFERENCES

    1.
    Baumgart, D. C., W. A. Olivier, T. Reya, D. Peritt, J. L. Rombeau, and S. R. Carding.1998. Mechanisms of intestinal epithelial cell injury and colitis in interleukin 2 (IL2)-deficient mice. Cell. Immunol.187:52-66.
    2.
    Berkes, J., V. K. Viswanathan, S. D. Savkovic, and G. Hecht.2003. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut52:439-451.
    3.
    Blagburn, B. L., and K. S. Todd, Jr.1984. Pathological changes and immunity associated with experimental Eimeria vermiformis infections in Mus musculus. J. Protozool.31:556-561.
    4.
    Chapman, H. D.2001. Use of anticoccidial drugs in broiler chickens in the USA: analysis for the years 1995 to 1999. Poult. Sci.80:572-580.
    5.
    Chobotar, B., H. D. Danforth, and R. Entzeroth.1993. Ultrastructural observations of host-cell invasion by sporozoites of Eimeria papillata in vivo. Parasitol. Res.79:15-23.
    6.
    Dignass, A. U., and D. K. Podolsky.1993. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology105:1323-1332.
    7.
    Ehrhardt, R. O., W. Strober, and G. R. Harriman.1992. Effect of transforming growth factor (TGF)-beta 1 on IgA isotype expression. TGF-beta 1 induces a small increase in sIgA+ B cells regardless of the method of B cell activation. J. Immunol.148:3830-3836.
    8.
    Findly, R. C., S. J. Roberts, and A. C. Hayday.1993. Dynamic response of murine gut intraepithelial T cells after infection by the coccidian parasite Eimeria. Eur. J. Immunol.23:2557-2564.
    9.
    Fujita, K., J. Katahira, Y. Horiguchi, N. Sonoda, M. Furuse, and S. Tsukita.2000. Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett.476:258-261.
    10.
    Guy-Grand, D., N. Cerf-Bensussan, B. Malissen, M. Malassis-Seris, C. Briottet, and P. Vassalli.1991. Two gut intraepithelial CD8+ lymphocyte populations with different T cell receptors: a role for the gut epithelium in T cell differentiation. J. Exp. Med.173:471-481.
    11.
    Guy-Grand, D., M. Malassis-Seris, C. Briottet, and P. Vassalli.1991. Cytotoxic differentiation of mouse gut thymodependent and independent intraepithelial T lymphocytes is induced locally. Correlation between functional assays, presence of perforin and granzyme transcripts, and cytoplasmic granules. J. Exp. Med.173:1549-1552.
    12.
    Inagaki-Ohara, K., T. Chinen, G. Matsuzaki, A. Sasaki, Y. Sakamoto, K. Hiromatsu, F. Nakamura-Uchiyama, Y. Nawa, and A. Yoshimura.2004. Mucosal T cells bearing TCRγδ play a protective role in intestinal inflammation. J. Immunol.173:1390-1398.
    13.
    Inagaki-Ohara, K., H. Nishimura, A. Mitani, and Y. Yoshikai.1997. Interleukin-15 preferentially promotes the growth of intestinal intraepithelial lymphocytes bearing gamma delta T cell receptor in mice. Eur. J. Immunol.27:2885-2891.
    14.
    Inagaki-Ohara, K., H. Nishimura, T. Sakai, D. H. Lynch, and Y. Yoshikai.1997. Potential for involvement of Fas antigen/Fas ligand interaction in apoptosis of epithelial cells by intraepithelial lymphocytes in murine small intestine. Lab. Investig.77:421-429.
    15.
    Inagaki-Ohara, K., A. Sawaguchi, T. Suganuma, G. Matsuzaki, and Y. Nawa.2005. Intraepithelial lymphocytes express junctional molecules in murine small intestine. Biochem. Biophys. Res. Commun.331:977-983.
    16.
    Jenkins, M. C.2001. Advances and prospects for subunit vaccines against protozoa of veterinary importance. Vet. Parasitol.101:291-310.
    17.
    Kitani, A., I. J. Fuss, K. Nakamura, O. M. Schwartz, T. Usui, and W. Strober.2000. Treatment of experimental (trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J. Exp. Med.192:41-52.
    18.
    Komano, H., Y. Fujiura, M. Kawaguchi, S. Matsumoto, Y. Hashimoto, S. Obana, P. Mombaerts, S. Tonegawa, H. Yamamoto, S. Itohara, et al.1995. Homeostatic regulation of intestinal epithelia by intraepithelial gamma delta T cells. Proc. Natl. Acad. Sci. USA92:6147-6151.
    19.
    Lecuit, M., S. Dramsi, C. Gottardi, M. Fedor-Chaiken, B. Gumbiner, and P. Cossart.1999. A single amino acid in E-cadherin responsible for host specificity towards the human pathogen Listeria monocytogenes. EMBO J.18:3956-3963.
    20.
    Li, E., W. F. Stenson, C. Kunz-Jenkins, P. E. Swanson, R. Duncan, and S. L. Stanley, Jr.1994. Entamoeba histolytica interactions with polarized human intestinal Caco-2 epithelial cells. Infect. Immun.62:5112-5119.
    21.
    Li, Y., K. Ishii, H. Hisaeda, S. Hamano, M. Zhang, K. Nakanishi, T. Yoshimoto, H. Hemmi, K. Takeda, S. Akira, Y. Iwakura, and K. Himeno.2004. IL-18 gene therapy develops Th1-type immune responses in Leishmania major-infected BALB/c mice: is the effect mediated by the CpG signaling TLR9? Gene Ther.11:941-948.
    22.
    Loetscher, H., Y. C. Pan, H. W. Lahm, R. Gentz, M. Brockhaus, H. Tabuchi, and W. Lesslauer.1990. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell61:351-359.
    23.
    Madara, J. L.1998. Regulation of the movement of solutes across tight junctions. Annu. Rev. Physiol.60:143-159.
    24.
    Mankertz, J., S. Tavalali, H. Schmitz, A. Mankertz, E. O. Riecken, M. Fromm, and J. D. Schulzke.2000. Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. J. Cell Sci.113:2085-2090.
    25.
    Mengaud, J., H. Ohayon, P. Gounon, R. M. Mege, and P. Cossart.1996. E-cadherin is the receptor for internalin, a surface protein required for entry of L. monocytogenes into epithelial cells. Cell84:923-932.
    26.
    Oshima, T., F. S. Laroux, L. L. Coe, Z. Morise, S. Kawachi, P. Bauer, M. B. Grisham, R. D. Specian, P. Carter, S. Jennings, D. N. Granger, T. Joh, and J. S. Alexander.2001. Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvasc. Res.61:130-143.
    27.
    Ovington, K. S., L. M. Alleva, and E. A. Kerr.1995. Cytokines and immunological control of Eimeria spp. Int. J. Parasitol.25:1331-1351.
    28.
    Planchon, S. M., C. A. Martins, R. L. Guerrant, and J. K. Roche.1994. Regulation of intestinal epithelial barrier function by TGF-beta 1. Evidence for its role in abrogating the effect of a T cell cytokine. J. Immunol.153:5730-5739.
    29.
    Powrie, F., J. Carlino, M. W. Leach, S. Mauze, and R. L. Coffman.1996. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J. Exp. Med.183:2669-2674.
    30.
    Ramsburg, E., R. Tigelaar, J. Craft, and A. Hayday.2003. Age-dependent requirement for γδ T cells in the primary but not secondary protective immune response against an intestinal parasite. J. Exp. Med.198:1403-1414.
    31.
    Roberts, S. J., A. L. Smith, A. B. West, L. Wen, R. C. Findly, M. J. Owen, and A. C. Hayday.1996. T-cell alpha beta + and gamma delta + deficient mice display abnormal but distinct phenotypes toward a natural, widespread infection of the intestinal epithelium. Proc. Natl. Acad. Sci. USA93:11774-11779.
    32.
    Rose, M. E., P. Hesketh, R. K. Grencis, and A. J. Bancroft.2000. Vaccination against coccidiosis: host strain-dependent evocation of protective and suppressive subsets of murine lymphocytes. Parasite Immunol.22:161-172.
    33.
    Rose, M. E., D. G. Owen, and P. Hesketh.1984. Susceptibility to coccidiosis: effect of strain of mouse on reproduction of Eimeria vermiformis. Parasitology88:45-54.
    34.
    Rose, M. E., A. L. Smith, and D. Wakelin.1991. Gamma interferon-mediated inhibition of Eimeria vermiformis growth in cultured fibroblasts and epithelial cells. Infect. Immun.59:580-586.
    35.
    Rose, M. E., D. Wakelin, and P. Hesketh.1989. Gamma interferon controls Eimeria vermiformis primary infection in BALB/c mice. Infect. Immun.57:1599-1603.
    36.
    Schneeberger, E. E., and R. D. Lynch.2004. The tight junction: a multifunctional complex. Am. J. Physiol. Cell Physiol.286:C1213-C1228.
    37.
    Schubert, W. D., C. Urbanke, T. Ziehm, V. Beier, M. P. Machner, E. Domann, J. Wehland, T. Chakraborty, and D. W. Heinz.2002. Structure of internalin, a major invasion protein of Listeria monocytogenes, in complex with its human receptor E-cadherin. Cell111:825-836.
    38.
    Shields, J. M., and B. H. Olson.2003. Cyclospora cayetanensis: a review of an emerging parasitic coccidian. Int. J. Parasitol.33:371-391.
    39.
    Shirley, M. W.1992. Research on avian coccidia: an update. Br. Vet. J.148:479-499.
    40.
    Smith, A. L., and A. C. Hayday.2000. An alphabeta T-cell-independent immunoprotective response towards gut coccidia is supported by gammadelta cells. Immunology101:325-332.
    41.
    Smith, A. L., and A. C. Hayday.2000. Genetic dissection of primary and secondary responses to a widespread natural pathogen of the gut, Eimeria vermiformis. Infect. Immun.68:6273-6280.
    42.
    Smith, C. A., T. Davis, D. Anderson, L. Solam, M. P. Beckmann, R. Jerzy, S. K. Dower, D. Cosman, and R. G. Goodwin.1990. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science248:1019-1023.
    43.
    Sonoda, N., M. Furuse, H. Sasaki, S. Yonemura, J. Katahira, Y. Horiguchi, and S. Tsukita.1999. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J. Cell Biol.147:195-204.
    44.
    Taguchi, T., W. K. Aicher, K. Fujihashi, M. Yamamoto, J. R. McGhee, J. A. Bluestone, and H. Kiyono.1991. Novel function for intestinal intraepithelial lymphocytes. Murine CD3+, gamma/delta TCR+ T cells produce IFN-gamma and IL-5. J. Immunol.147:3736-3744.
    45.
    Tartaglia, L. A., and D. V. Goeddel.1992. Two TNF receptors. Immunol. Today13:151-153.
    46.
    Todd, K. S., Jr., and D. L. Lepp.1971. The life cycle of Eimeria vermiformis Ernst, Chobotar and Hammond, 1971 in the mouse Mus musculus. J. Protozool.18:332-337.
    47.
    Wachtel, M., M. F. Bolliger, H. Ishihara, K. Frei, H. Bluethmann, and S. M. Gloor.2001. Down-regulation of occludin expression in astrocytes by tumour necrosis factor (TNF) is mediated via TNF type-1 receptor and nuclear factor-κB activation. J. Neurochem.78:155-162.
    48.
    Yamamoto, M., K. Fujihashi, M. Amano, J. R. McGhee, K. W. Beagley, and H. Kiyono.1994. Cytokine synthesis and apoptosis by intestinal intraepithelial lymphocytes: signaling of high density alpha beta T cell receptor+ and gamma delta T cell receptor+ T cells via T cell receptor-CD3 complex results in interferon-gamma and interleukin-5 production, while low density T cells undergo DNA fragmentation. Eur. J. Immunol.24:1301-1306.
    49.
    Yamamoto, M., K. Fujihashi, K. Kawabata, J. R. McGhee, and H. Kiyono.1998. A mucosal intranet: intestinal epithelial cells down-regulate intraepithelial, but not peripheral, T lymphocytes. J. Immunol.160:2188-2196.

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 74Number 9September 2006
    Pages: 5292 - 5301

    History

    Received: 16 December 2005
    Revision received: 1 March 2006
    Accepted: 30 June 2006

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Kyoko Inagaki-Ohara [email protected]
    Parasitic Diseases Unit, Department of Infectious Diseases, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan
    Fitriya Nurannisa Dewi
    Department of Veterinary Teaching Hospital and Internal Medicine, Faculty of Agriculture, University of Miyazaki, Gakuen Kibanadai Nishi, Miyazaki 889-2192, Japan
    Faculty of Veterinary Medicine, Bogor Agricultural University, Jalan Agatis Campus IPB Darmaga Bogor 16680, Jawa Barat, Indonesia
    Hajime Hisaeda
    Department of Parasitology, Graduate School of Medical Science, Kyushu University, 3-1-1 Higashi-ku, Maidashi, Fukuoka 812-8582, Japan
    Adrian L. Smith
    Division of Immunology, Institute for Animal Health, Compton, Nr. Newbury, Berkshire RG20 7NN, United Kingdom
    Fumiko Jimi
    Department of Veterinary Teaching Hospital and Internal Medicine, Faculty of Agriculture, University of Miyazaki, Gakuen Kibanadai Nishi, Miyazaki 889-2192, Japan
    Maki Miyahira
    Department of Veterinary Teaching Hospital and Internal Medicine, Faculty of Agriculture, University of Miyazaki, Gakuen Kibanadai Nishi, Miyazaki 889-2192, Japan
    Ayman Samir Farid Abdel-Aleem
    Department of Veterinary Teaching Hospital and Internal Medicine, Faculty of Agriculture, University of Miyazaki, Gakuen Kibanadai Nishi, Miyazaki 889-2192, Japan
    Yoichiro Horii
    Department of Veterinary Teaching Hospital and Internal Medicine, Faculty of Agriculture, University of Miyazaki, Gakuen Kibanadai Nishi, Miyazaki 889-2192, Japan
    Yukifumi Nawa
    Parasitic Diseases Unit, Department of Infectious Diseases, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan

    Notes

    Editor: J. L. Flynn

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    Unraveling the Role of MicroRNAs in Mycobacterium tuberculosis Infection and Disease: Advances and Pitfalls

    Unraveling the Role of MicroRNAs in Mycobacterium tuberculosis Infection and Disease: Advances and Pitfalls

    ABSTRACT

    Tuberculosis (TB) is an infectious disease of extremely high epidemiological burden worldwide that is easily acquired through the inhalation of infected respiratory droplets. The complex pathogenesis of this infection spans from subjects never developing this disease despite intense exposure, to others in which immune containment fails catastrophically and severe or disseminated forms of disease ensue. In recent decades, microRNAs (miRNAs) have gained increasing attention due to their role as gene silencers and because of their altered expression in diverse human diseases, including some infections. Recent research regarding miRNAs and TB has revealed that the expression profile for particular miRNAs clearly changes upon Mycobacterium tuberculosis infection and also varies in the different stages of this disease. However, despite the growing number of studies—some of which have even proposed some miRNAs as potential biomarkers—methodological variations and key differences in relevant factors, such as sex and age, cell type analyzed, M. tuberculosis strain, and antimicrobial therapy status, strongly hinder the comparison of data. In this review, we summarize and discuss the literature and highlight the role of selected miRNAs that have specifically and more consistently been associated with M. tuberculosis infection, together with a discussion of the possible gene and immune regulation pathways involved.

    REFERENCES

    1.
    World Health Organization. 2019. Global tuberculosis report 2019. World Health Organization, Geneva, Switzerland.
    2.
    Narasimhan P, Wood J, Macintyre CR, Mathai D. 2013. Risk factors for tuberculosis. Pulm Med 2013:828939.
    3.
    Bhatt K, Salgame P. 2007. Host innate immune response to Mycobacterium tuberculosis. J Clin Immunol 27:347–362.
    4.
    Liu PT, Modlin RL. 2008. Human macrophage host defense against Mycobacterium tuberculosis. Curr Opin Immunol 20:371–376.
    5.
    Pieters J. 2008. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 3:399–407.
    6.
    Frahm M, Goswami ND, Owzar K, Hecker E, Mosher A, Cadogan E, Nahid P, Ferrari G, Stout JE. 2011. Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis (Edinb) 91:250–256.
    7.
    Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297.
    8.
    Xu P, Vernooy SY, Guo M, Hay BA. 2003. The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol 13:790–795.
    9.
    Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW, Ruohola-Baker H. 2005. Stem cell division is regulated by the microRNA pathway. Nature 435:974–978.
    10.
    Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ. 2007. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67:7713–7722.
    11.
    Thatcher EJ, Flynt AS, Li N, Patton JR, Patton JG. 2007. miRNA expression analysis during normal zebrafish development and following inhibition of the Hedgehog and Notch signaling pathways. Dev Dyn 236:2172–2180.
    12.
    Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, Golub TR, Pieske B, Pu WT. 2007. Altered microRNA expression in human heart disease. Physiol Genomics 31:367–373.
    13.
    Agirre X, Jiménez-Velasco A, San José-Enériz E, Garate L, Bandrés E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, Pérez-Roger I, García-Foncillas J, Torres A, Heiniger A, Calasanz MJ, Fortes P, Román-Gómez J, Prósper F. 2008. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res 6:1830–1840.
    14.
    Johnson R, Zuccato C, Belyaev ND, Guest DJ, Cattaneo E, Buckley NJ. 2008. A microRNA-based gene dysregulation pathway in Huntington’s disease. Neurobiol Dis 29:438–445.
    15.
    Sun R, Fu X, Li Y, Xie Y, Mao Y. 2009. Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours. BMC Genomics 10:93.
    16.
    Almeida MI, Reis RM, Calin GA. 2011. MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res 717:1–8.
    17.
    Skalsky RL, Cullen BR. 2010. Viruses, microRNAs, and host interactions. Annu Rev Microbiol 64:123–141.
    18.
    Staedel C, Darfeuille F. 2013. MicroRNAs and bacterial infection. Cell Microbiol 15:1496–1507.
    19.
    Vance V, Vaucheret H. 2001. RNA silencing in plants–defense and counterdefense. Science 292:2277–2280.
    20.
    Watanabe Y, Kishi A, Yachie N, Kanai A, Tomita M. 2007. Computational analysis of microRNA-mediated antiviral defense in humans. FEBS Lett 581:4603–4610.
    21.
    Gottwein E, Mukherjee N, Sachse C, Frenzel C, Majoros WH, Chi JTA, Braich R, Manoharan M, Soutschek J, Ohler U, Cullen BR. 2007. A viral microRNA functions as an orthologue of cellular miR-155. Nature 450:1096–1099.
    22.
    Lindsay MA. 2008. microRNAs and the immune response. Trends Immunol 29:343–351.
    23.
    Pedersen I, David M. 2008. MicroRNAs in the immune response. Cytokine 43:391–394.
    24.
    Tsitsiou E, Lindsay MA. 2009. microRNAs and the immune response. Curr Opin Pharmacol 9:514–520.
    25.
    Li QJ, Chau J, Ebert PJR, Sylvester G, Min H, Liu G, Braich R, Manoharan M, Soutschek J, Skare P, Klein LO, Davis MM, Chen CZ. 2007. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129:147–161.
    26.
    Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, Van Dongen S, Grocock RJ, Das PP, Miska EA, Vetrie D, Okkenhaug K, Enright AJ, Dougan G, Turner M, Bradley A. 2007. Requirement of bic/microRNA-155 for normal immune function. Science 316:608–611.
    27.
    Thai T, Calado D, Casola S, Ansel K, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok J, Schmidt-Supprian M, Rajewsky N, Yancopoulos G, Rao A, Rajewsky K. 2007. Regulation of the germinal center response by microRNA-155. Science 316:604–609.
    28.
    Lu L, Boldin MP, Chaudhry A, Lin L, Konstantin D, Hanada T, Yoshimura A, Baltimore D, Rudensky AY. 2010. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142:914–929.
    29.
    O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. 2010. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 10:111–122.
    30.
    Lee RC, Feinbaum RL, Ambros V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854.
    31.
    Wightman B, Ha I, Ruvkun G. 1993. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75:855–862.
    32.
    Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. 2000. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403:901–906.
    33.
    Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E, Ruvkun G. 2000. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408:86–89.
    34.
    Treiber T, Treiber N, Meister G. 2019. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol 20:5–20.
    35.
    Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. 2019. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol 234:5451–5465.
    36.
    O’Brien J, Hayder H, Zayed Y, Peng C. 2018. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 9:402.
    37.
    Michlewski G, Cáceres JF. 2019. Post-transcriptional control of miRNA biogenesis. RNA 25:1–16.
    38.
    Pu M, Chen J, Tao Z, Miao L, Qi X, Wang Y, Ren J. 2019. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci 76:441–451.
    39.
    Zhang B, Wang Q, Pan X. 2007. MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol 210:279–289.
    40.
    Morin RD, Bainbridge M, Fejes A, Hirst M, Krzywinski M, Pugh TJ, McDonald H, Varhol R, Jones SJM, Marra MA. 2008. Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. Biotechniques 45:81–94.
    41.
    Thomson JM, Parker J, Perou CM, Hammond SM. 2004. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 1:47–53.
    42.
    Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ. 2005. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33:e179.
    43.
    Lao K, Xu NL, Yeung V, Chen C, Livak KJ, Straus NA. 2006. Multiplexing RT-PCR for the detection of multiple miRNA species in small samples. Biochem Biophys Res Commun 343:85–89.
    44.
    Raabe CA, Tang TH, Brosius J, Rozhdestvensky TS. 2014. Biases in small RNA deep sequencing data. Nucleic Acids Res 42:1414–1426.
    45.
    Griffiths-Jones S. 2004. The microRNA registry. Nucleic Acids Res 32:D109–D111.
    46.
    Kozomara A, Griffiths-Jones S. 2014. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42:D68–D73.
    47.
    Kozomara A, Birgaoanu M, Griffiths-Jones S. 2019. miRBase: from microRNA sequences to function. Nucleic Acids Res 47:D155–D162.
    48.
    Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, Chiew MY, Tai CS, Wei TY, Tsai TR, Huang HT, Wang CY, Wu HY, Ho SY, Chen PR, Chuang CH, Hsieh PJ, Wu YS, Chen WL, Li MJ, Wu YC, Huang XY, Ng FL, Buddhakosai W, Huang PC, Lan KC, Huang CY, Weng SL, Cheng YN, Liang C, Hsu WL, Huang HD. 2018. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res 46:D296–D302.
    49.
    Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, Ma S, Meermeier E, Lewinsohn DM, Sherman DR. 2018. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev 31:e00021-18.
    50.
    Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G, Urbanowski M, Chaturvedi N, Srinivasan S, Johnson DH, Bishai WR. 2018. Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. Lancet Infect Dis 18:e64–e75.
    51.
    Guo W, Li JT, Pan X, Wei L, Wu JY. 2010. Candidate Mycobacterium tuberculosis genes targeted by human microRNAs. Protein Cell 1:419–421.
    52.
    Maudet C, Mano M, Eulalio A. 2014. MicroRNAs in the interaction between host and bacterial pathogens. FEBS Lett 588:4140–4147.
    53.
    Zheng L, Leung E, Lee N, Lui G, To KF, Chan RCY, Ip M. 2015. Differential microRNA expression in human macrophages with Mycobacterium tuberculosis infection of Beijing/W and non-Beijing/W strain types. PLoS One 10:e0126018.
    54.
    Ren N, Gao G, Sun Y, Zhang L, Wang H, Hua W, Wan K, Li X. 2015. MicroRNA signatures from multidrug-resistant Mycobacterium tuberculosis. Mol Med Rep 12:6561–6567.
    55.
    Wang C, Yang S, Liu CM, Jiang TT, Chen ZL, Tu HH, Mao LG, Li ZJ, Li JC. 2018. Screening and identification of four serum miRNAs as novel potential biomarkers for cured pulmonary tuberculosis. Tuberculosis (Edinb) 108:26–34.
    56.
    Wagh V, Urhekar A, Modi D. 2017. Levels of microRNA miR-16 and miR-155 are altered in serum of patients with tuberculosis and associate with responses to therapy. Tuberculosis (Edinb) 102:24–30.
    57.
    Fu Y, Yi Z, Wu X, Li J, Xu F. 2011. Circulating microRNAs in patients with active pulmonary tuberculosis. J Clin Microbiol 49:4246–4251.
    58.
    Xu Z, Zhou A, Ni J, Zhang Q, Wang Y, Lu J, Wu W, Karakousis PC, Lu S, Yao Y. 2015. Differential expression of miRNAs and their relation to active tuberculosis. Tuberculosis (Edinb) 95:395–403.
    59.
    Qi Y, Cui L, Ge Y, Shi Z, Zhao K, Guo X, Yang D, Yu H, Cui L, Shan Y, Zhou M, Wang H, Lu Z. 2012. Altered serum microRNAs as biomarkers for the early diagnosis of pulmonary tuberculosis infection. BMC Infect Dis 12:384.
    60.
    Zhang H, Sun Z, Wei W, Liu Z, Fleming J, Zhang S, Lin N, Wang M, Chen M, Xu Y, Zhou J, Li C, Bi L, Zhou G. 2014. Identification of serum microRNA biomarkers for tuberculosis using RNA-seq. PLoS One 9:e88909.
    61.
    Yi Z, Fu Y, Ji R, Li R, Guan Z. 2012. Altered microRNA signatures in sputum of patients with active pulmonary tuberculosis. PLoS One 7:e43184.
    62.
    Wu LSH, Lee SW, Huang KY, Lee TY, Hsu PWC, Weng J. 2014. Systematic expression profiling analysis identifies specific microRNA-gene interactions that may differentiate between active and latent tuberculosis infection. Biomed Res Int 2014:895179.
    63.
    Zhang X, Guo J, Fan S, Li Y, Wei L, Yang X, Jiang T, Chen Z, Wang C, Liu J, Ping Z, Xu D, Wang J, Li Z, Qiu Y, Li JC. 2013. Screening and identification of six serum microRNAs as novel potential combination biomarkers for pulmonary tuberculosis diagnosis. PLoS One 8:e81076.
    64.
    Corral-Fernández NE, Cortes-García JD, Bruno RS, Romano-Moreno S, Medellín-Garibay SE, Magaña-Aquino M, Salazar-González RA, González-Amaro R, Portales-Pérez DP. 2017. Analysis of transcription factors, microRNAs and cytokines involved in T lymphocyte differentiation in patients with tuberculosis after directly observed treatment short-course. Tuberculosis (Edinb) 105:1–8.
    65.
    Sato F, Tsuchiya S, Terasawa K, Tsujimoto G. 2009. Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS One 4:e5540.
    66.
    Schwarzenbach H, da Silva AM, Calin G, Pantel K. 2015. Data normalization strategies for microRNA quantification. Clin Chem 61:1333–1342.
    67.
    Faraldi M, Gomarasca M, Sansoni V, Perego S, Banfi G, Lombardi G. 2019. Normalization strategies differently affect circulating miRNA profile associated with the training status. Sci Rep 9:1584.
    68.
    Benz F, Roderburg C, Cardenas DV, Vucur M, Gautheron J, Koch A, Zimmermann H, Janssen J, Nieuwenhuijsen L, Luedde M, Frey N, Tacke F, Trautwein C, Luedde T. 2013. U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis. Exp Mol Med 45:e42.
    69.
    Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, Patil M, Sheldon H, Betts G, Homer J, West C, Ragoussis J, Harris AL. 2011. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer 104:1168–1177.
    70.
    Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034.
    71.
    Shen Y, Tian F, Chen Z, Li R, Ge Q, Lu Z. 2015. Amplification-based method for microRNA detection. Biosens Bioelectron 71:322–331.
    72.
    Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, Vandesompele J. 2009. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10:R64.
    73.
    Chugh P, Dittmer DP. 2012. Potential pitfalls in microRNA profiling. Wiley Interdiscip Rev RNA 3:601–616.
    74.
    Lv Y, Guo S, Li XG, Chi JY, Qu YQ, Zhong HL. 2016. Sputum and serum microRNA-144 levels in patients with tuberculosis before and after treatment. Int J Infect Dis 43:68–73.
    75.
    Krakauer T. 2019. Inflammasomes, autophagy, and cell death: the trinity of innate host defense against intracellular bacteria. Mediators Inflamm 2019:2471215.
    76.
    Siqueira MDS, Ribeiro RM, Travassos LH. 2018. Autophagy and its interaction with intracellular bacterial pathogens. Front Immunol 9:935.
    77.
    Guo L, Zhou L, Gao Q, Zhang A, Wei J, Hong D, Chu Y, Duan X, Zhang Y, Xu G. 2017. MicroRNA-144-3p inhibits autophagy activation and enhances Bacillus Calmette-Guérin infection by targeting ATG4a in RAW264.7 macrophage cells. PLoS One 12:e0179772.
    78.
    Liu Y, Wang X, Jiang J, Cao Z, Yang B, Cheng X. 2011. Modulation of T cell cytokine production by miR-144* with elevated expression in patients with pulmonary tuberculosis. Mol Immunol 48:1084–1090.
    79.
    Kim JK, Lee HM, Park KS, Shin DM, Kim TS, Kim YS, Suh HW, Kim SY, Kim IS, Kim JM, Son JW, Sohn KM, Jung SS, Chung C, Han SB, Yang CS, Jo EK. 2017. MIR144* inhibits antimicrobial responses against Mycobacterium tuberculosis in human monocytes and macrophages by targeting the autophagy protein DRAM2. Autophagy 13:423–441.
    80.
    Spinelli SV, Diaz A, D'Attilio L, Marchesini MM, Bogue C, Bay ML, Bottasso OA. 2013. Altered microRNA expression levels in mononuclear cells of patients with pulmonary and pleural tuberculosis and their relation with components of the immune response. Mol Immunol 53:265–269.
    81.
    Liu Z, Zhou G, Deng X, Yu Q, Hu Y, Sun H, Wang Z, Chen H, Jia C, Wang D. 2014. Analysis of miRNA expression profiling in human macrophages responding to Mycobacterium infection: induction of the immune regulator miR-146a. J Infect 68:553–561.
    82.
    Li M, Wang J, Fang Y, Gong S, Li M, Wu M, Lai X, Zeng G, Wang Y, Yang K, Huang X. 2016. MicroRNA-146a promotes mycobacterial survival in macrophages through suppressing nitric oxide production. Sci Rep 6:24555.
    83.
    Malardo T, Gardinassi LG, Moreira BP, Padilha É, Lorenzi JCC, Soares LS, Gembre AF, Fontoura IC, de Almeida LP, de Miranda Santos IKF, Silva CL, Coelho-Castelo A. 2016. MicroRNA expression signatures in lungs of mice infected with Mycobacterium tuberculosis. Tuberculosis (Edinb) 101:151–159.
    84.
    Furci L, Schena E, Miotto P, Cirillo DM. 2013. Alteration of human macrophages microRNA expression profile upon infection with Mycobacterium tuberculosis. Int J Mycobacteriol 2:128–134.
    85.
    Etna MP, Sinigaglia A, Grassi A, Giacomini E, Romagnoli A, Pardini M, Severa M, Cruciani M, Rizzo F, Anastasiadou E, Di Camillo B, Barzon L, Fimia GM, Manganelli R, Coccia EM. 2018. Mycobacterium tuberculosis-induced miR-155 subverts autophagy by targeting ATG3 in human dendritic cells. PLoS Pathog 14:e1006790.
    86.
    Zhou M, Yu G, Yang X, Zhu C, Zhang Z, Zhan X. 2016. Circulating microRNAs as biomarkers for the early diagnosis of childhood tuberculosis infection. Mol Med Rep 13:4620–4626.
    87.
    Barry SE, Ellis M, Yang YR, Guan G, Wang X, Britton WJ, Saunders BM. 2018. Identification of a plasma microRNA profile in untreated pulmonary tuberculosis patients that is modulated by anti-mycobacterial therapy. J Infect 77:341–348.
    88.
    Li S, Yue Y, Xu W, Xiong S. 2013. MicroRNA-146a represses mycobacteria-induced inflammatory response and facilitates bacterial replication via targeting IRAK-1 and TRAF-6. PLoS One 8:e81438.
    89.
    Reference deleted.
    90.
    Li D, Wang T, Song X, Qucuo M, Yang B, Zhang J, Wang J, Ying B, Tao C, Wang L. 2011. Genetic study of two single nucleotide polymorphisms within corresponding microRNAs and susceptibility to tuberculosis in a Chinese Tibetan and Han population. Hum Immunol 72:598–602.
    91.
    Zhang X, Li Y, Li X, Zhang W, Pan Z, Wu F, Wang C, Chen Z, Jiang T, Xu D, Ping Z, Liu J, Liu C, Li Z, Li JC. 2015. Association of the miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms with susceptibility to pulmonary tuberculosis in the Chinese Uygur, Kazak and Southern Han populations. BMC Infect Dis 15:41.
    92.
    Zhang C, Xi X, Wang Q, Jiao J, Zhang L, Zhao H, Lai Z. 2015. The association between serum miR-155 and natural killer cells from tuberculosis patients. Int J Clin Exp Med 8:9168–9172.
    93.
    Rajaram MVS, Ni B, Morris JD, Brooks MN, Carlson TK, Bakthavachalu B, Schoenberg DR, Torrelles JB, Schlesinger LS. 2011. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. Proc Natl Acad Sci U S A 108:17408–17413.
    94.
    Das K, Saikolappan S, Dhandayuthapani S. 2013. Differential expression of miRNAs by macrophages infected with virulent and avirulent Mycobacterium tuberculosis. Tuberculosis 93:S47–S50.
    95.
    Kumar R, Halder P, Sahu SK, Kumar M, Kumari M, Jana K, Ghosh Z, Sharma P, Kundu M, Basu J. 2012. Identification of a novel role of ESAT-6-dependent miR-155 induction during infection of macrophages with Mycobacterium tuberculosis. Cell Microbiol 14:1620–1631.
    96.
    Wang J, Yang K, Zhou L, Minhao W, Wu Y, Zhu M, Lai X, Chen T, Feng L, Li M, Huang C, Zhong Q, Huang X. 2013. MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS Pathog 9:e1003697.
    97.
    Elizabeth MC, Hernández de la Cruz ON, Mauricio CA. 2016. Infection of J774A.1 with different Mycobacterium species induces differential immune and miRNA-related responses. Microbiol Immunol 60:356–363.
    98.
    Wu J, Lu C, Diao N, Zhang S, Wang S, Wang F, Gao Y, Chen J, Shao L, Lu J, Zhang X, Weng X, Wang H, Zhang W, Huang Y. 2012. Analysis of microRNA expression profiling identifies miR-155 and miR-155* as potential diagnostic markers for active tuberculosis: a preliminary study. Hum Immunol 73:31–37.
    99.
    Huang J, Jiao J, Xu W, Zhao H. 2015. miR-155 is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO3. Mol Med Rep 12:7102–7108.
    100.
    Yang S, Li F, Jia S, Zhang K, Jiang W, Shang Y, Chang K, Deng S, Chen M. 2015. Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes apoptosis of macrophages via targeting the microRNA155-SOCS1 interaction. Cell Physiol Biochem 35:1276–1288.
    101.
    Iwai H, Funatogawa K, Matsumura K, Kato-Miyazawa M, Kirikae F, Kiga K, Sasakawa C, Miyoshi-Akiyama T, Kirikae T. 2015. MicroRNA-155 knockout mice are susceptible to Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 95:246–250.
    102.
    Bonilla-Muro MG, Hernández de la Cruz ON, Gonzalez-Barrios JA, Alcaráz-Estrada SL, Castañón-Arreola M. 13 September 2019. EsxA mainly contributes to the miR-155 overexpression in human monocyte-derived macrophages and potentially affect the immune mechanism of macrophages through miRNA dysregulation. J Microbiol Immunol Infect doi:
    103.
    Yao J, Du X, Chen S, Shao Y, Deng K, Jiang M, Liu J, Shen Z, Chen X, Feng G. 2018. Rv2346c enhances mycobacterial survival within macrophages by inhibiting TNF-α and IL-6 production via the p38/miRNA/NF-κB pathway. Emerg Microbes Infect 7:1–16.
    104.
    Zhou Z-Q, Wang Z-K, Zhang L, Ren Y-Q, Ma Z-W, Zhao N, Sun F-Y. 2017. Role of ESAT-6 in renal injury by regulating microRNA-155 expression via TLR4/MyD88 signaling pathway in mice with Mycobacterium tuberculosis infection. Biosci Rep 37:BSR20170021.
    105.
    Zheng M, Zhou N, Luo C. 2016. MiRNA-155 and miRNA-132 as potential diagnostic biomarkers for pulmonary tuberculosis: a preliminary study. Microb Pathog 100:78–83.
    106.
    Kleinsteuber K, Heesch K, Schattling S, Kohns M, Sander-Jülch C, Walzl G, Hesseling A, Mayatepek E, Fleischer B, Marx FM, Jacobsen M. 2013. Decreased expression of miR-21, miR-26a, miR-29a, and miR-142-3p in CD4+ T cells and peripheral blood from tuberculosis patients. PLoS One 8:e61609.
    107.
    Zhao Z, Hao J, Li X, Chen Y, Qi X. 2019. MiR-21-5p regulates mycobacterial survival and inflammatory responses by targeting Bcl-2 and TLR4 in Mycobacterium tuberculosis-infected macrophages. FEBS Lett 593:1326–1335.
    108.
    Wang Q, Liu S, Tang Y, Liu Q, Yao Y. 2014. MPT64 protein from Mycobacterium tuberculosis inhibits apoptosis of macrophages through NF-kB-miRNA21-Bcl-2 pathway. PLoS One 9:e100949.
    109.
    Afum-Adjei Awuah A, Ueberberg B, Owusu-Dabo E, Frempong M, Jacobsen M. 2014. Dynamics of T-cell IFN-γ and miR-29a expression during active pulmonary tuberculosis. Int Immunol 26:579–582.
    110.
    Pan D, Pan M, Xu YM. 2017. Mir-29a expressions in peripheral blood mononuclear cell and cerebrospinal fluid: diagnostic value in patients with pediatric tuberculous meningitis. Brain Res Bull 130:231–235.
    111.
    Yi Z, Gao K, Li R, Fu Y. 2018. Dysregulated circRNAs in plasma from active tuberculosis patients. J Cell Mol Med 22:4076–4084.
    112.
    Sharbati J, Lewin A, Kutz-Lohroff B, Kamal E, Einspanier R, Sharbati S. 2011. Integrated microRNA-mRNA-analysis of human monocyte derived macrophages upon Mycobacterium avium subsp. hominissuis infection. PLoS One 6:e20258.
    113.
    Ma F, Xu S, Liu X, Zhang Q, Xu X, Liu M, Hua M, Li N, Yao H, Cao X. 2011. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol 12:861–869.
    114.
    Ebert MS, Neilson JR, Sharp PA. 2007. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4:721–726.
    115.
    Kluiver J, Gibcus JH, Hettinga C, Adema A, Richter MKS, Halsema N, Slezak-Prochazka I, Ding Y, Kroesen BJ, van den Berg A. 2012. Rapid generation of microRNA sponges for microRNA inhibition. PLoS One 7:e29275.
    116.
    Siddle KJ, Deschamps M, Tailleux L, Nédélec Y, Pothlichet J, Lugo-Villarino G, Libri V, Gicquel B, Neyrolles O, Laval G, Patin E, Barreiro LB, Quintana-Murci L. 2014. A genomic portrait of the genetic architecture and regulatory impact of microRNA expression in response to infection. Genome Res 24:850–859.
    117.
    Fu Y, Yi Z, Li J, Li R. 2014. Deregulated microRNAs in CD4+ T cells from individuals with latent tuberculosis versus active tuberculosis. J Cell Mol Med 18:503–513.

    Information & Contributors

    Information

    Published In

    Infection and Immunity
    Volume 88Number 320 February 2020
    eLocator: e00649-19
    Editor: Karen M. Ottemann
    University of California, Santa Cruz

    History

    Published online: 23 December 2019

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. tuberculosis
    2. miRNA
    3. biomarker
    4. Mycobacterium tuberculosis
    5. infection
    6. disease

    Contributors

    Authors

    Departamento de Enfermedades Infecciosas del Adulto, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
    Rodrigo Naves
    Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
    Departamento de Enfermedades Infecciosas del Adulto, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

    Editor

    Karen M. Ottemann
    Editor
    University of California, Santa Cruz

    Notes

    Address correspondence to Cinthya Ruiz-Tagle, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Infection and ImmunityArticle
    Editorial Board

      Information & Contributors

      Information

      Published In

      Infection and Immunity
      Volume 88Number 423 March 2020
      eLocator: masthead-88-4

      History

      Published online: 23 March 2020

      Permissions

      Request permissions for this article.

      Contributors

      Metrics & Citations

      Metrics

      Citations

      View Options

      Media

      Figures

      Other

      Tables

      Share

    • Infection and ImmunityArticle
      NHR-49 Transcription Factor Regulates Immunometabolic Response and Survival of Caenorhabditis elegans during Enterococcus faecalis Infection

      NHR-49 Transcription Factor Regulates Immunometabolic Response and Survival of Caenorhabditis elegans during Enterococcus faecalis Infection

      ABSTRACT

      Immune response to pathogens is energetically expensive to the host; however, the cellular source of energy to fuel immune response remains unknown. In this study, we show that Caenorhabditis elegans exposed to pathogenic Gram-positive and Gram-negative bacteria or yeast rapidly utilizes lipid droplets, the major energy reserve. The nematode’s response to the pathogenic bacterium Enterococcus faecalis entails metabolic rewiring for the upregulation of several genes involved in lipid utilization and downregulation of lipid synthesis genes. Genes encoding acyl-CoA synthetase ACS-2, involved in lipid metabolism, and flavin monooxygenase FMO-2, involved in detoxification, are two highly upregulated genes during E. faecalis infection. We find that both ACS-2 and FMO-2 are necessary for survival and rely on NHR-49, a peroxisome proliferator-activated receptor alpha (PPARα) ortholog, for upregulation during E. faecalis infection. Thus, NHR-49 regulates an immunometabolic axis of survival in C. elegans by modulating breakdown of lipids as well as immune effector production upon E. faecalis exposure.

      REFERENCES

      1.
      Rauw WM. 2012. Immune response from a resource allocation perspective. Front Genet 3:267–214.
      2.
      Vale PF, Fenton A, Brown SP. 2014. Limiting damage during infection: lessons from infection tolerance for novel therapeutics. PLoS Biol 12:e1001769.
      3.
      Hart BL. 1988. Biological basis of the behaviour of sick animals. Neurosci Biobehav Rev 12:123–137.
      4.
      Lee KA. 2006. Linking immune defenses and life history at the levels of the individual and the species. Integr Comp Biol 46:1000–1015.
      5.
      Tang RJ, Breger J, Idnurm A, Gerik KJ, Lodge JK, Heitman J, Calderwood SB, Mylonakis E. 2005. Cryptococcus neoformans gene involved in mammalian pathogenesis identified by a Caenorhabditis elegans progeny-based approach. Infect Immun 73:8219–8225.
      6.
      Engelmann I, Griffon A, Tichit L, Montañana-Sanchis F, Wang G, Reinke V, Waterston RH, Hillier LDW, Ewbank JJ. 2011. A comprehensive analysis of gene expression changes provoked by bacterial and fungal infection in C. elegans. PLoS One 6:e19055.
      7.
      Irazoqui JE, Troemel ER, Feinbaum RL, Luhachack LG, Cezairliyan BO, Ausubel FM. 2010. Distinct pathogenesis and host responses during infection of C. elegans by P aeruginosa and S. aureus. PLoS Pathog 6:e1000982.
      8.
      Troemel ER, Chu SW, Reinke V, Lee SS, Ausubel FM, Kim DH. 2006. p38 MAPK regulates expression of immune response genes and contributes to longevity in C. elegans. PLoS Genet 2:e183.
      9.
      Nomura T, Horikawa M, Shimamura S, Hashimoto T, Sakamoto K. 2010. Fat accumulation in Caenorhabditis elegans is mediated by SREBP homolog SBP-1. Genes Nutr 5:17–27.
      10.
      Taubert S, Van Gilst MR, Hansen M, Yamamoto KR. 2006. A mediator subunit, MDT-15, integrates regulation of fatty acid metabolism by NHR-49-dependent and -independent pathways in C. elegans. Genes Dev 20:1137–1149.
      11.
      Van Gilst MR, Hadjivassiliou H, Jolly A, Yamamoto KR. 2005. Nuclear hormone receptor NHR-49 controls fat consumption and fatty acid composition in C. elegans. PLoS Biol 3:e53.
      12.
      Van Gilst MR, Hadjivassiliou H, Yamamoto KR. 2005. A Caenorhabditis elegans nutrient response system partially dependent on nuclear receptor NHR-49. Proc Natl Acad Sci U S A 102:13496–13501.
      13.
      Liu F, Xiao Y, Ji XL, Zhang KQ, Zou CG. 2017. The cAMP-PKA pathway-mediated fat mobilization is required for cold tolerance in C. elegans. Sci Rep 7:638.
      14.
      Lynn DA, Dalton HM, Sowa JN, Wang MC, Soukas AA, Curran SP. 2015. Omega-3 and -6 fatty acids allocate somatic and germline lipids to ensure fitness during nutrient and oxidative stress in Caenorhabditis elegans. Proc Natl Acad Sci U S A 112:15378–15383.
      15.
      O'Rourke EJ, Soukas AA, Carr CE, Ruvkun G. 2009. C. elegans major fats are stored in vesicles distinct from lysosome-related organelles. Cell Metab 10:430–435.
      16.
      O'Rourke EJ, Ruvkun G. 2013. MXL-3 and HLH-30 transcriptionally link lipolysis and autophagy to nutrient availability. Nat Cell Biol 15:668–676.
      17.
      Nandakumar M, Tan MW. 2008. Gamma-linolenic and stearidonic acids are required for basal immunity in Caenorhabditis elegans through their effects on p38 MAP kinase activity. PLoS Genet 4:e1000273.
      18.
      Anderson SM, Cheesman HK, Peterson ND, Salisbury JE, Soukas AA, Pukkila-Worley R. 2019. The fatty acid oleate is required for innate immune activation and pathogen defense in Caenorhabditis elegans. PLoS Pathog 15:e1007893.
      19.
      Ratnappan R, Amrit FRG, Chen SW, Gill H, Holden K, Ward J, Yamamoto KR, Olsen CP, Ghazi A. 2014. Germline signals deploy NHR-49 to modulate fatty-acid β-oxidation and desaturation in somatic tissues of C. elegans. PLoS Genet 10:e1004829.
      20.
      Sim S, Hibberd ML. 2016. Caenorhabditis elegans susceptibility to gut Enterococcus faecalis infection is associated with fat metabolism and epithelial junction integrity. BMC Microbiol 16:6–10.
      21.
      Hyun M, Davis K, Lee I, Kim J, Dumur C, You YJ. 2016. Fat metabolism regulates satiety behaviour in C. elegans. Sci Rep 6:24841.
      22.
      Han S, Schroeder EA, Silva-García CG, Hebestreit K, Mair WB, Brunet A. 2017. Mono-unsaturated fatty acids link H3K4me3 modifiers to C. elegans lifespan. Nature 544:185–190.
      23.
      Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J, Ruvkun G. 2003. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421:268–272.
      24.
      Lee S, Murphy CT, Kenyon C. 2009. Glucose shortens the lifespan of Caenorhabditis elegans by down-regulating aquaporin gene expression. Cell Metab 10:379–391.
      25.
      Garsin DA, Villanueva JM, Begun J, Kim DH, Sifri CD, Calderwood SB, Ruvkun G, Ausubel FM. 2003. Long-lived C. elegans daf-2 mutants are resistant to bacterial pathogens. Science 300:1921.
      26.
      Singh V, Aballay A. 2006. Heat-shock transcription factor (HSF)-1 pathway required for Caenorhabditis elegans immunity. Proc Natl Acad Sci U S A 103:13092–13097.
      27.
      Kiontke K, Fitch DHA. 2005. The phylogenetic relationships of Caenorhabditis and other rhabditids. WormBook 2005:1–11.
      28.
      Yuen GJ, Ausubel FM. 2018. Both live and dead enterococci activate Caenorhabditis elegans host defense via immune and stress pathways. Virulence 9:683–699.
      29.
      Hébert L, Courtin P, Torelli R, Sanguinetti M, Chapot-Chartier MP, Auffray Y, Benachour A. 2007. Enterococcus faecalis constitutes an unusual bacterial model in lysozyme resistance. Infect Immun 75:5390–5398.
      30.
      Herbert S, Bera A, Nerz C, Kraus D, Peschel A, Goerke C, Meehl M, Cheung A, Go F. 2007. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog 3:e102.
      31.
      Warren GH, Gray J, Bartell P. 1955. The lysis of Pseudomonas aeruginosa by lysozyme. J Bacteriol 70:614–619.
      32.
      Larance M, Pourkarimi E, Wang B, Brenes-Murillo A, Kent R, Lamond AI, Gartner A. 2015. Global proteomics analysis of the response to starvation in C. elegans. Mol Cell Proteomics 14:1989–2001.
      33.
      Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, Ahringer J, Li H, Kenyon C. 2003. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 424:277–283.
      34.
      Chavez V, Mohri-Shiomi A, Garsin DA. 2009. Ce-Duox1/BLI-3 generates reactive oxygen species as a protective innate immune mechanism in Caenorhabditis elegans. Infect Immun 77:4983–4989.
      35.
      Hu Q, D'Amora DR, MacNeil LT, Walhout AJM, Kubiseski TJ. 2018. The Caenorhabditis elegans oxidative stress response requires the NHR-49 transcription factor. G3 (Bethesda) 8:3857–3863.
      36.
      Qi W, Gutierrez GE, Gao X, Dixon H, McDonough JA, Marini AM, Fisher AL. 2017. The ω-3 fatty acid α-linolenic acid extends Caenorhabditis elegans lifespan via NHR-49/PPARα and oxidation to oxylipins. Aging Cell 16:1125–1135.
      37.
      Goh GYS, Winter JJ, Bhanshali F, Doering KRS, Lai R, Lee K, Veal EA, Taubert S. 2018. NHR-49/HNF4 integrates regulation of fatty acid metabolism with a protective transcriptional response to oxidative stress and fasting. Aging Cell 17:e12743.
      38.
      Burkewitz K, Morantte I, Weir HJM, Yeo R, Zhang Y, Huynh FK, Ilkayeva OR, Hirschey MD, Grant AR, Mair WB. 2015. Neuronal CRTC-1 governs systemic mitochondrial metabolism and lifespan via a catecholamine signal. Cell 160:842–855.
      39.
      Nhan JD, Turner CD, Anderson SM, Yen CA, Dalton HM, Cheesman HK, Ruter DL, Uma Naresh N, Haynes CM, Soukas AA, Pukkila-Worley R, Curran SP. 2019. Redirection of SKN-1 abates the negative metabolic outcomes of a perceived pathogen infection. Proc Natl Acad Sci U S A 116:22322–22330.
      40.
      Daniel J, Maamar H, Deb C, Sirakova TD, Kolattukudy PE. 2011. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog 7:e1002093.
      41.
      Kumar Y, Cocchiaro J, Valdivia RH. 2006. The obligate intracellular pathogen Chlamydia trachomatis targets host lipid droplets. Curr Biol 16:1646–1651.
      42.
      Boulant S, Targett-Adams P, McLauchlan J. 2007. Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J Gen Virol 88:2204–2213.
      43.
      Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. 2007. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9:1089–1097.
      44.
      Anand P, Cermelli S, Li Z, Kassan A, Bosch M, Sigua R, Huang L, Ouellette AJ, Pol A, Welte MA, Gross SP. 2012. A novel role for lipid droplets in the organismal antibacterial response. Elife 1:e00003.
      45.
      Hood MI, Skaar EP. 2012. Nutritional immunity: transition metals at the pathogen-host interface. Nat Rev Microbiol 10:525–537.
      46.
      Brenner S. 1974. The genetics of Caenorhabditis elegans. Genetics 77:71–94.
      47.
      Klapper M, Ehmke M, Palgunow D, Bohme M, Matthaus C, Bergner G, Dietzek B, Popp J, Doring F. 2011. Fluorescence-based fixative and vital staining of lipid droplets in Caenorhabditis elegans reveal fat stores using microscopy and flow cytometry approaches. J Lipid Res 52:1281–1293.
      48.
      Morris DL. 1948. Quantitative determination of carbohydrates with Dreywood’s Anthrone reagent. Science 107:254–255.
      49.
      Bradford MM. 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254.
      50.
      Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2-(delta delta C(T)) method. Methods 25:402–408.
      51.
      Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. 2016. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc 11:1650–1667.

      Information & Contributors

      Information

      Published In

      Infection and Immunity
      Volume 88Number 821 July 2020
      eLocator: e00130-20
      Editor: Marvin Whiteley
      Georgia Institute of Technology School of Biological Sciences

      History

      Received: 5 March 2020
      26 March 2020
      Accepted: 12 May 2020
      Published online: 1 June 2020

      Permissions

      Request permissions for this article.

      KEYWORDS

      1. Caenorhabditis elegans
      2. Cryptococcus neoformans
      3. Enterococcus faecalis
      4. Pseudomonas aeruginosa
      5. fatty acids
      6. immune response
      7. metabolism
      8. nuclear hormone receptor
      9. nutritional immunity

      Contributors

      Authors

      Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, Karnataka, India
      Meghana Shashikanth
      Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, Karnataka, India
      Anjali Gupta
      Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, Karnataka, India
      Anjali Sandhu
      Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, Karnataka, India
      Atreyee De
      Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, Karnataka, India
      Salil Javed
      Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, Karnataka, India
      Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, Karnataka, India
      Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, Karnataka, India

      Editor

      Marvin Whiteley
      Editor
      Georgia Institute of Technology School of Biological Sciences

      Notes

      Address correspondence to Varsha Singh, [email protected].

      Metrics & Citations

      Metrics

      Citations

      View Options

      Media

      Figures

      Other

      Tables

      Share

    • Infection and ImmunityArticle
      Inflammatory Monocytes but Not Neutrophils Are Necessary To Control Infection with Toxoplasma gondii in Mice

      Inflammatory Monocytes but Not Neutrophils Are Necessary To Control Infection with Toxoplasma gondii in Mice

      ABSTRACT

      Previous studies have suggested that both inflammatory monocytes and neutrophils are important for controlling acute toxoplasmosis in the mouse model. To test the role of these cell types, we used monoclonal antibody (MAb) RB6-8C5 to deplete both subsets of cells or MAb 1A8 to selectively remove neutrophils. RB6-8C5 MAb-treated mice succumbed to oral infection with Toxoplasma gondii, similar to Ccr2−/− mice, which are deficient in monocyte recruitment but have normal neutrophils. In contrast, mice treated with MAb 1A8 controlled parasite replication and survived acute infection. Ccr2−/− mice suffered from acute ileitis and inflammation in the spleen that was associated with a lack of inflammatory monocytes and elevated numbers of neutrophils. RB6-8C5 MAb-treated C57BL/6 mice also suffered from intestinal pathology and splenic damage, although this was less extensive due to the reduced numbers of neutrophils. Neutrophil-depleted infected wild-type mice displayed no pathological changes, compared to untreated infected controls. Collectively, these observations demonstrate the critical role of inflammatory monocytes during the acute infection with the parasite T. gondii and reveal that neutrophils are not protective but rather contribute to the pathology.

      REFERENCES

      1.
      Adams, L. B., J. B. Hibbs, R. R. Taintor, and J. L. Krahenbuhl.1990. Microbiostatic effect of murine-activated macrophages for Toxoplasma gondii: role for synthesis of inorganic nitrogen oxides from L-arginine. J. Immunol.144:2725-2729.
      2.
      Auffray, C., D. Fogg, M. Garfa, G. Elain, O. Join-Lambert, S. Kayal, S. Sarnacki, A. Cumano, G. Lauvau, and F. Geissmann.2007. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science317:666-670.
      3.
      Barragan, A., and L. D. Sibley.2003. Migration of Toxoplasma gondii across biological barriers. Trends Microbiol.11:426-430.
      4.
      Bliss, S. K., B. A. Butcher, and E. Y. Denkers.2000. Rapid recruitment of neutrophils containing prestored IL-12 during microbial infection. J. Immunol.165:4515-4521.
      5.
      Bliss, S. K., L. C. Gavrilescu, A. Alcaraz, and E. Y. Denkers.2001. Neutrophil depletion during Toxoplasma gondii infection leads to impaired immunity and lethal systemic pathology. Infect. Immun.69:4898-4905.
      6.
      Bliss, S. K., A. J. Marshall, Y. Zhang, and E. Y. Denkers.1999. Human polymorphonuclear leukocytes produce IL-12, TNF-α, and the chemokines macrophage-inflammatory protein-1α and -1β in response to Toxoplasma gondii antigens. J. Immunol.162:7369-7375.
      7.
      Bliss, S. K., Y. Zhang, and E. Y. Denkers.1999. Murine neutrophil stimulation by Toxoplasma gondii antigen drives high level production of IFN-γ-independent IL-12. J. Immunol.163:2081-2088.
      8.
      Chen, L., Z. Zhang, and F. Sendo.2000. Neutrophils play a critical role in the pathogenesis of experimental cerebral malaria. Clin. Exp. Immunol.120:125-133.
      9.
      Chen, L., Z. H. Zhang, T. Watanabe, T. Yamashita, T. Kobayakawa, A. Kaneko, H. Fujiwara, and F. Sendo.2005. The involvement of neutrophils in the resistance to Leishmania major infection in susceptible but not in resistant mice. Parasitol. Int.54:109-118.
      10.
      Chen, L. A., T. Watanabe, H. Watanabe, and F. Sendo.2001. Neutrophil depletion exacerbates experimental Chagas' disease in BALB/c but protects C57BL/6 mice through modulating the Th1/Th2 dichotomy in different directions. Eur. J. Immunol.31:265-275.
      11.
      Courret, N., S. Darche, P. Songio, G. Milon, D. Buzoni-Gatel, and I. Tardieux.2005. CD11c and CD11b expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to the brain. Blood107:309-316.
      12.
      Daley, J. M., A. A. Thomay, M. D. Connolly, J. S. Reichner, and J. E. Albina.2007. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol.83:64-70.
      13.
      Del Rio, L., S. Bennouna, J. Salinas, and E. Y. Denkers.2001. CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during Toxoplasma gondii infection. J. Immunol.167:6503-6509.
      14.
      Dunay, I. R., R. A. DaMatta, B. Fux, R. Presti, A. Greco, M. Colonna, and L. D. Sibley.2008. Gr1+ inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunity29:306-317.
      15.
      Fleming, T. J., M. L. Fleming, and T. R. Malek.1993. Selective expression of Ly-6G on myeloid lineage cells n mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J. Immunol.151:2399-2408.
      16.
      Furze, R. C., and S. M. Rankin.2008. Neutrophil mobilization and clearance in the bone marrow. Immunology125:281-288.
      17.
      Geissmann, F., C. Auffrey, R. Palframan, C. Wirrig, A. Ciocca, L. Campisis, E. Narni-Manichelli, and G. Lauvau.2008. Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol. Cell Biol.86:398-408.
      18.
      Geissmann, F., S. Jung, and D. R. Littman.2003. Blood monocytes consist of two principle subsets with distinct migratory properties. Immunity19:71-82.
      19.
      Joynson, D. H., and T. J. Wreghitt (ed.).2001. Toxoplasmosis: a comprehensive clinical guide. Cambridge University Press, Cambridge, United Kingdom.
      20.
      Kelly, M. N., J. K. Kolls, K. Happel, J. D. Schwartzman, P. Schwarzenberger, C. Combe, M. M. Moretto, and I. A. Khan.2005. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect. Immun.73:617-621.
      21.
      Mayer-Scholl, A., P. Averhoff, and A. Zychlinsky.2004. How do neutrophils and pathogens interact. Curr. Opin. Microbiol.7:62-66.
      22.
      Mordue, D. G., F. Monroy, M. La Regina, C. A. Dinarello, and L. D. Sibley.2001. Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. J. Immunol.167:4574-4584.
      23.
      Mordue, D. G., and L. D. Sibley.2003. A novel population of Gr-1+ activated macrophages induced during acute toxoplasmosis. J. Leukoc. Biol.74:1015-1025.
      24.
      Robben, P. R., M. Laregina, W. A. Kuziel, and L. D. Sibley.2005. Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis. J. Exp. Med.201:1761-1769.
      25.
      Rousseau, D., S. Demartino, B. Ferrua, J. F. Michiels, F. Anjuère, K. Fragaki, Y. Le Fichoux, and J. Kubar.2001. In vivo involvement of polymorphonuclear neutrophils in Leishmania infantum infection. BMC Microbiol.1:17.
      26.
      Sayles, P. C., and L. L. Johnson.1996. Exacerbation of toxoplasmosis in neutrophil-depleted mice. Nat. Immun.15:249-258.
      27.
      Scapini, P., J. A. Lapinet-Vera, S. Gasperini, F. Calzetti, and M. A. Cassatella.2000. The neutrophil as a cellular source of chemokines. Immunol. Rev.177:195-203.
      28.
      Serbina, N. V., and E. G. Pamer.2006. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol.7:311-317.
      29.
      Sibley, L. D., L. B. Adams, Y. Fukutomi, and J. L. Krahenbuhl.1991. Tumor necrosis factor-α triggers antitoxoplasmal activity of IFN-γ primed macrophages. J. Immunol.147:2340-2345.
      30.
      Soehnlein, O., A. Zernecke, E. E. Eriksson, S. G. Rothfuchs, C. T. Pham, H. Herwald, K. Bidzhekov, M. E. Rottenberg, C. Weber, and L. Linbom.2008. Neutrophil secretion products pave the way for inflammatory monocytes. Blood112:1461-1471.
      31.
      Tateda, K., T. A. Moore, M. W. Newstead, W. C. Tsai, X. Zeng, J. C. Deng, G. Chen, R. Reddy, K. Yamaguchi, and T. J. Standiford.2001. Chemokine-dependent neutrophil recruitment in a murine model of Legionella pneumonia: potential role of neutrophils as immunoregulatory cells. Infect. Immun.69:2017-2024.
      32.
      van Gisbergen, K. P., T. B. Geijtenbeek, and Y. van Kooyk.2005. Close encounters of neutrophils and DCs. Trends Immunol.26:626-631.
      33.
      Varol, C., L. Lamdsman, D. K. Fogg, L. Grennshtein, B. Gildor, R. Margalit, V. Kalchenko, F. Geissmann, and S. Jung.2007. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J. Exp. Med.204:171-180.

      Information & Contributors

      Information

      Published In

      Infection and Immunity
      Volume 78Number 4April 2010
      Pages: 1564 - 1570

      History

      Received: 28 April 2009
      Revision received: 10 June 2009
      Accepted: 25 January 2010
      Published online: 9 February 2010

      Permissions

      Request permissions for this article.

      Contributors

      Authors

      Ildiko R. Dunay
      Department of Molecular Microbiology
      Department of Neuropathology, University of Freiburg, Breisacherstrasse 64, 79106 Freiburg, Germany
      Anja Fuchs
      Department of Medicine, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, Missouri 63110
      L. David Sibley [email protected]
      Department of Molecular Microbiology

      Notes

      Editor: J. F. Urban, Jr.

      Metrics & Citations

      Metrics

      Citations

      View Options

      Media

      Figures

      Other

      Tables

      Share

    • Infection and ImmunityArticle
      Bacillus anthracis Phospholipases C Facilitate Macrophage-Associated Growth and Contribute to Virulence in a Murine Model of Inhalation Anthrax

      Bacillus anthracis Phospholipases C Facilitate Macrophage-Associated Growth and Contribute to Virulence in a Murine Model of Inhalation Anthrax

      ABSTRACT

      Several models of anthrax pathogenesis suggest that early in the infectious process Bacillus anthracis endospores germinate and outgrow into vegetative bacilli within phagocytes before being released into the blood. Here, we define the respective contributions of three phospholipases C (PLCs) to the pathogenesis of B. anthracis. Genetic deletions of the PLCs were made in the Sterne 7702 background, resulting in the respective loss of their activities. The PLCs were redundant both in tissue culture and in murine models of anthrax. Deletion of all three PLC genes was required for attenuation of virulence in mice after intratracheal inoculation. This attenuation may be attributed to the inability of the PLC-null strain to grow in association with the macrophage. Complementation of these defects in both models of anthrax was achieved by expression of the PLC genes in trans. The functional redundancy between PLCs in the virulence of B. anthracis implies that their activities are important for anthrax pathogenesis.

      REFERENCES

      1.
      Burkholder, P. R., and N. H. Giles.1947. Induced biochemical mutations in Bacillus subtilis. Am. J. Bot.34:345-348.
      2.
      Camilli, A., L. G. Tilney, and D. A. Portnoy.1993. Dual roles of plcA in Listeria monocytogenes pathogenesis. Mol. Microbiol.8:143-157.
      3.
      Cendrowski, S., W. MacArthur, and P. Hanna.2004. Bacillus anthracis requires siderophore biosynthesis for growth in macrophages and mouse virulence. Mol. Microbiol.51:407-417.
      4.
      Dixon, T. C., A. A. Fadl, T. M. Koehler, J. A. Swanson, and P. C. Hanna.2000. Early Bacillus anthracis-macrophage interactions: intracellular survival and escape. Cell. Microbiol.2:453-463.
      5.
      Dixon, T. C., M. Meselson, J. Guillemin, and P. C. Hanna.1999. Anthrax. N. Engl. J. Med.341:815-826.
      6.
      Fisher, N., and P. Hanna.2005. Characterization of Bacillus anthracis germinant receptors in vitro. J. Bacteriol.187:8055-8062.
      7.
      Gilmore, M. S., A. L. Cruz-Rodz, M. Leimeister-Wächter, J. Kreft, and W. Goebel.1989. A Bacillus cereus cytolytic determinant, cereolysin AB, which comprises the phospholipase C and sphingomyelinase genes: nucleotide sequence and genetic linkage. J. Bacteriol.171:744-753.
      8.
      Gohar, M., O. A. Øksard, N. Gilois, V. Sanchis, A. B. Kolstø, and D. Lereclus.2002. Two-dimensional electrophoresis analysis of the extracellular proteome of Bacillus cereus reveals the importance of the PlcR regulon. Proteomics2:784-791.
      9.
      Goldfine, H., T. Bannam, N. C. Johnston, and W. R. Zückert.1998. Bacterial phospholipases and intracellular growth: the two distinct phospholipases C of Listeria monocytogenes. J. Appl. Microbiol.84:7S-14S.
      10.
      González-Zorn, B., G. Domínguez-Bernal, M. Suárez, M. T. Ripio, Y. Vega, S. Novella, and J. A. Vázquez-Boland.1999. The smcL gene of Listeria ivanovii encodes a sphingomyelinase C that mediates bacterial escape from the phagocytic vacuole. Mol. Microbiol.33:510-523.
      11.
      Guerout-Fleury, A. M., K. Shazand, N. Frandsen, and P. Stragier.1995. Antibiotic resistance cassettes for Bacillus subtilis. Gene167:335-336.
      12.
      Guidi-Rontani, C., M. Weber-Levy, E. Labruyère, and M. Mock.1999. Germination of Bacillus anthracis spores within alveolar macrophages. Mol. Microbiol.31:9-17.
      13.
      Guttmann, D. M., and D. J. Ellar.2000. Phenotypic and genotypic comparisons of 23 strains from the Bacillus cereus complex for a selection of known and putative Bacillus thuringiensis virulence factors. FEMS Microbiol. Lett.188:7-13.
      14.
      Haima, P., S. Bron, and G. Venema.1987. The effect of restriction on shotgun cloning and plasmid stability in Bacillus subtilis Marburg. Mol. Gen. Genet.209:335-342.
      15.
      Klichko, V. I., J. Miller, A. Wu, S. G. Popov, and K. Alibek.2003. Anaerobic induction of Bacillus anthracis hemolytic activity. Biochem. Biophys. Res. Commun.303:855-862.
      16.
      Koehler, T. M., Z. Dai, and M. Kaufman-Yarbray.1994. Regulation of the Bacillus anthracis protective antigen gene: CO2 and a trans-acting element activate transcription from one of two promoters. J. Bacteriol.176:586-595.
      17.
      Lyons, C. R., J. Lovchik, J. Hutt, M. F. Lipscomb, E. Wang, S. Heninger, L. Berliba, and K. Garrison.2004. Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect. Immun.72:4801-4809.
      18.
      Makino, S., C. Sasakawa, I. Uchida, N. Terakado, and M. Yoshikawa.1988. Cloning and CO2-dependent expression of the genetic region for encapsulation from Bacillus anthracis. Mol. Microbiol.2:371-376.
      19.
      McGaughey, C. A., and H. P. Chu.1948. The egg-yolk reaction of aerobic sporing bacilli. J. Gen. Microbiol.2:334-340.
      20.
      Mignot, T., M. Mock, D. Robichon, A. Landier, D. Lereclus, and A. Fouet.2001. The incompatibility between the PlcR- and AtxA-controlled regulons may have selected a nonsense mutation in Bacillus anthracis. Mol. Microbiol.42:1189-1198.
      21.
      Okinaka, R. T., K. Cloud, O. Hampton, A. R. Hoffmaster, K. K. Hill, P. Keim, T. M. Koehler, G. Lamke, S. Kumano, J. Mahillon, D. Manter, Y. Martinez, D. Ricke, R. Svensson, and P. J. Jackson.1999. Sequence and organization of pXO1, the large Bacillus anthracis plasmid harboring the anthrax toxin genes. J. Bacteriol.181:6509-6515.
      22.
      Palmer, B. R., and M. G. Marinus.1994. The dam and dcm strains of Escherichia coli: a review. Gene143:1-12.
      23.
      Pezard, C., P. Berche, and M. Mock.1991. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun.59:3472-3477.
      24.
      Pezard, C., E. Duflot, and M. Mock.1993. Construction of Bacillus anthracis mutant strains producing a single toxin component. J. Gen. Microbiol.139:2459-2463.
      25.
      Pomeramtsev, A. P., K. V. Kalnin, M. Osorio, and S. H. Leppla.2003. Phosphatidylcholine-specific phospholipase C and sphingomyelinase activities in bacteria of the Bacillus cereus group. Infect. Immun.71:6591-6606.
      26.
      Read, T. D., S. N. Peterson, N. Tourasse, L. W. Baillie, I. T. Paulsen, K. E. Nelson, H. Tettelin, D. E. Fouts, J. A. Eisen, S. R. Gill, E. K. Holtzapple, O. A. Okstad, E. Helgason, J. Rilstone, M. Wu, J. F. Kolonay, M. J. Beanan, R. J. Dodson, L. M. Brinkac, M. Gwinn, R. T. DeBoy, R. Madpu, S. C. Daugherty, A. S. Durkin, D. H. Haft, W. C. Nelson, J. D. Peterson, M. Pop, H. M. Khouri, D. Radune, J. L. Benton, Y. Mahamoud, L. Jiang, I. R. Hance, J. F. Weidman, K. J. Berry, R. D. Plaut, A. M. Wolf, K. L. Watkins, W. C. Nierman, A. Hazen, R. Cline, C. Redmond, J. E. Thwaite, O. White, S. L. Salzberg, B. Thomason, A. M. Friedlander, T. M. Koehler, P. C. Hanna, A. B. Kolsto, and C. M. Fraser.2003. The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature423:81-86.
      27.
      Reed, L. J., and H. Muench.1938. A simple method of estimating fifty per- cent endpoints. Am. J. Hyg.27:493-497.
      28.
      Ross, J. M.1957. The pathogenesis of anthrax following the administration of spores by the respiratory route. J. Pathol. Bacteriol.73:485-494.
      29.
      Ruthel, G., W. J. Ribot, S. Bavari, and T. A. Hoover.2004. Time-lapse confocal imaging of development of Bacillus anthracis in macrophages. J. Infect. Dis.189:1313-1316.
      30.
      Schmiel, D. H., and V. L. Miller.1999. Bacterial phospholipases and pathogenesis. Microbes Infect.1:1103-1112.
      31.
      Shannon, J. G., C. L. Ross, T. M. Koehler, and R. F. Rest.2003. Characterization of anthrolysin O, the Bacillus anthracis cholesterol-dependent cytolysin. Infect. Immun.71:3183-3189.
      32.
      Smith, G. A., H. Marquis, S. Jones, N. C. Johnston, D. A. Portnoy, and H. Goldfine.1995. The two distinct phospholipases C of Listeria monocytogenes have overlapping roles in escape from a vacuole and cell-to-cell spread. Infect. Immun.63:4231-4237.
      33.
      Smith, K., and P. Youngman.1992. Use of a new integrational vector to investigate compartment-specific expression of the Bacillus subtilis spoIIM gene. Biochimie74:705-711.
      34.
      Stewart, G. S., K. Johnstone, E. Hagelberg, and D. J. Ellar.1981. Commitment of bacterial spores to germinate: a measure of the trigger reaction. Biochem. J.198:101-106.
      35.
      Thorne, C. B.1968. Transduction in Bacillus cereus and Bacillus anthracis. Bacteriol. Rev.32:358-361.
      36.
      Thorne, C. B., and F. C. Belton.1957. An agar-diffusion method for titrating Bacillus anthracis immunizing antigen and its application to a study of antigen production. J. Gen. Microbiol.17:505-516.
      37.
      Titball, R. W.1998. Bacterial phospholipases. J. Appl. Microbiol.84:127S-137S.
      38.
      Tomita, M., R. Tagchi, and H. Ikezawa.1991. Sphingomyelinase of Bacillus cereus as a bacterial hemolysin. J. Toxicol. Tox. Rev.10:169-207.
      39.
      Weiner, M. A., and P. C. Hanna.2003. Macrophage-mediated germination of Bacillus anthracis endospores requires the gerH operon. Infect. Immun.71:3954-3959.
      40.
      Wei, Z., P. Schnupf, M. A. Poussin, L. A. Zenewicz, H. Shen, and H. Goldfine.2005. Characterization of Listeria monocytogenes expressing anthrolysin O and phosphatidylinositol-specific phospholipase C from Bacillus anthracis. Infect. Immun.73:6639-6646.
      41.
      Welkos, S. L., T. J. Keener, and P. H. Gibbs.1986. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect. Immun.51:795-800.
      42.
      Welkos, S. L., and R. Marrero.1996. Pathogenesis and host resistance to infection: a model system and an analysis of capsule synthesis and regulation by Bacillus anthracis, p. 209-256. In K. W. Adolph (ed.), Microbial genome methods. CRC Press, Inc., Boca Raton, Fla.
      43.
      Yanisch-Perron, C., J. Vieira, and J. Messing.1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene33:103-119.
      44.
      Zenewicz, L. A., Z. Wei, H. Goldfine, and H. Shen.2005. Phosphatidylinositol-specific phospholipase C of Bacillus anthracis down-modulates the immune response. J. Immunol.174:8011-8016.
      45.
      Zwartouw, H. T., and H. Smith.1956. Non-identity of the phospholipase of Bacillus anthracis with the anthrax toxin. J. Gen. Microbiol.15:261-265.

      Information & Contributors

      Information

      Published In

      Infection and Immunity
      Volume 74Number 7July 2006
      Pages: 3756 - 3764

      History

      Received: 23 February 2006
      Revision received: 27 March 2006
      Accepted: 7 April 2006

      Permissions

      Request permissions for this article.

      Contributors

      Authors

      Brian J. Heffernan
      Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109
      Brendan Thomason
      Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109
      Amy Herring-Palmer
      Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109
      Lee Shaughnessy
      Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109
      Rod McDonald
      Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109
      Nathan Fisher
      Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109
      Gary B. Huffnagle
      Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109
      Philip Hanna [email protected]
      Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109

      Notes

      Editor: D. L. Burns

      Metrics & Citations

      Metrics

      Citations

      View Options

      Media

      Figures

      Other

      Tables

      Share

    • Infection and ImmunityArticle
      Interleukin-17-Induced Protein Lipocalin 2 Is Dispensable for Immunity to Oral Candidiasis

      Interleukin-17-Induced Protein Lipocalin 2 Is Dispensable for Immunity to Oral Candidiasis

      ABSTRACT

      Oropharyngeal candidiasis (OPC; thrush) is an opportunistic fungal infection caused by the commensal microbe Candida albicans. Immunity to OPC is strongly dependent on CD4+ T cells, particularly those of the Th17 subset. Interleukin-17 (IL-17) deficiency in mice or humans leads to chronic mucocutaneous candidiasis, but the specific downstream mechanisms of IL-17-mediated host defense remain unclear. Lipocalin 2 (Lcn2; 24p3; neutrophil gelatinase-associated lipocalin [NGAL]) is an antimicrobial host defense factor produced in response to inflammatory cytokines, particularly IL-17. Lcn2 plays a key role in preventing iron acquisition by bacteria that use catecholate-type siderophores, and lipocalin 2−/− mice are highly susceptible to infection by Escherichia coli and Klebsiella pneumoniae. The role of Lcn2 in mediating immunity to fungi is poorly defined. Accordingly, in this study, we evaluated the role of Lcn2 in immunity to oral infection with C. albicans. Lcn2 is strongly upregulated following oral infection with C. albicans, and its expression is almost entirely abrogated in mice with defective IL-17 signaling (IL-17RA−/− or Act1−/− mice). However, Lcn2−/− mice were completely resistant to OPC, comparably to wild-type (WT) mice. Moreover, Lcn2 deficiency mediated protection from OPC induced by steroid immunosuppression. Therefore, despite its potent regulation during C. albicans infection, Lcn2 is not required for immunity to mucosal candidiasis.

      REFERENCES

      1.
      Fidel PL Jr. 2011. Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis. Adv. Dent. Res. 23:45–49.
      2.
      Glocker E and Grimbacher B. 2010. Chronic mucocutaneous candidiasis and congenital susceptibility to Candida. Curr. Opin. Allergy Clin. Immunol. 10:542–550.
      3.
      Huppler AR, Bishu S, and Gaffen SL. 2012. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res. Ther. 14:217.
      4.
      Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, and White TC. 2012. Hidden killers: human fungal infections. Sci. Transl. Med. 4:165rv13.
      5.
      Cassone A. 2013. Development of vaccines for Candida albicans: fighting a skilled transformer. Nat. Rev. Microbiol. 11:884–891.
      6.
      Milner J and Holland S. 2013. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nat. Rev. Immunol. 13:635–648.
      7.
      Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, Ho AW, Hai JH, Yu JJ, Jung JW, Filler SG, Masso-Welch P, Edgerton M, and Gaffen SL. 2009. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 206:299–311.
      8.
      Ho AW, Shen F, Conti HR, Patel N, Childs EE, Peterson AC, Hernandez-Santos N, Kolls JK, Kane LP, Ouyang W, and Gaffen SL. 2010. IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J. Immunol. 185:1063–1070.
      9.
      Farah CS, Hu Y, Riminton S, and Ashman RB. 2006. Distinct roles for interleukin-12p40 and tumour necrosis factor in resistance to oral candidiasis defined by gene targeting. Oral Microbiol. Immunol. 21:252–255.
      10.
      Puel A, Cypowji S, Bustamante J, Wright J, Liu L, Lim H, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman N, Al-Muhsen S, Galicchio M, Abel L, Picard C, and Casanova J-L. 2011. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332:65–68.
      11.
      Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, Cobat A, Ouachee-Chardin M, Toulon A, Bustamante J, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McConnell V, Cant AJ, Abinun M, Polak M, Bougneres PF, Kumararatne D, Marodi L, Nahum A, Roifman C, Blanche S, Fischer A, Bodemer C, Abel L, Lilic D, and Casanova JL. 2010. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207:291–297.
      12.
      Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, Ersvaer E, Perheentupa J, Erichsen MM, Bratanic N, Meloni A, Cetani F, Perniola R, Ergun-Longmire B, Maclaren N, Krohn KJ, Pura M, Schalke B, Strobel P, Leite MI, Battelino T, Husebye ES, Peterson P, Willcox N, and Meager A. 2010. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207:299–308.
      13.
      Gaffen SL. 2009. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9:556–567.
      14.
      Boisson B, Wang C, Pedergnana V, Wu L, Cypowyj S, Rybojad M, Belkadi A, Picard C, Abel L, Fieschi C, Puel A, Li X, and Casanova J-L. 2013. A biallelic ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 39:676–686.
      15.
      Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, and Banerjee S. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366:1190–1199.
      16.
      Patel DD, Lee DM, Kolbinger F, and Antoni C. 2013. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis. 72(Suppl 2):iii116–iii123.
      17.
      Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, and Baumgartner S. 2012. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366:1181–1189.
      18.
      Miossec P and Kolls JK. 2012. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11:763–776.
      19.
      Ford AC and Peyrin-Biroulet L. 2013. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am. J. Gastroenterol. 108:1268–1276.
      20.
      Shen F, Ruddy MJ, Plamondon P, and Gaffen SL. 2005. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-α-induced genes in bone cells. J. Leukoc. Biol. 77:388–399.
      21.
      Shen F, Hu Z, Goswami J, and Gaffen SL. 2006. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J. Biol. Chem. 281:24138–24148.
      22.
      Karlsen JR, Borregaard N, and Cowland JB. 2010. Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IκB-ζ but neither by C/EBP-β nor C/EBP-δ. J. Biol. Chem. 285:14088–14100.
      23.
      Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, and Barasch J. 2002. An iron delivery pathway mediated by a lipocalin. Mol. Cell 10:1045–1056.
      24.
      Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, and Strong RK. 2002. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell 10:1033–1043.
      25.
      Chan YR, Liu JS, Pociask DA, Zheng M, Mietzner TA, Berger T, Mak TW, Clifton MC, Strong RK, Ray P, and Kolls JK. 2009. Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. J. Immunol. 182:4947–4956.
      26.
      Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, and Aderem A. 2004. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432:917–921.
      27.
      Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, and Mak TW. 2006. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 103:1834–1839.
      28.
      Claudio E, Sonder SU, Saret S, Carvalho G, Ramalingam TR, Wynn TA, Chariot A, Garcia-Perganeda A, Leonardi A, Paun A, Chen A, Ren NY, Wang H, and Siebenlist U. 2009. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. J. Immunol. 182:1617–1630. http://www.jimmunol.org/content/182/3/1617.long.
      29.
      Solis NV and Filler SG. 2012. Mouse model of oropharyngeal candidiasis. Nat. Protoc. 7:637–642.
      30.
      Hernández-Santos N and Gaffen SL. 2012. Th17 cells in immunity to Candida albicans. Cell Host Microbe 11:425–435.
      31.
      Puel A, Picard C, Cypowyj S, Lilic D, Abel L, and Casanova JL. 2010. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines? Curr. Opin. Immunol. 22:467–474.
      32.
      Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, and Napolitani G. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8:639–646.
      33.
      Devireddy LR, Gazin C, Zhu X, and Green MR. 2005. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123:1293–1305.
      34.
      Devireddy LR, Teodoro JG, Richard FA, and Green MR. 2001. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 293:829–834.
      35.
      Raffatellu M, George MD, Akiyama Y, Hornsby MJ, Nuccio SP, Paixao TA, Butler BP, Chu H, Santos RL, Berger T, Mak TW, Tsolis RM, Bevins CL, Solnick JV, Dandekar S, and Baumler AJ. 2009. Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell Host Microbe 5:476–486.
      36.
      Liu JZ, Pezeshki M, and Raffatellu M. 2009. Th17 cytokines and host-pathogen interactions at the mucosa: dichotomies of help and harm. Cytokine 48:156–160.
      37.
      Liu Z, Petersen R, and Devireddy L. 2013. Impaired neutrophil function in 24p3 null mice contributes to enhanced susceptibility to bacterial infections. J. Immunol. 190:4692–4706.
      38.
      Holmes MA, Paulsene W, Jide X, Ratledge C, and Strong RK. 2005. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure 13:29–41.
      39.
      Guglani L, Gopal R, Rangel-Moreno J, Junecko BF, Lin Y, Berger T, Mak TW, Alcorn JF, Randall TD, Reinhart TA, Chan YR, and Khader SA. 2012. Lipocalin 2 regulates inflammation during pulmonary mycobacterial infections. PLoS One 7:e50052.
      40.
      Hu CJ, Bai C, Zheng XD, Wang YM, and Wang Y. 2002. Characterization and functional analysis of the siderophore-iron transporter CaArn1p in Candida albicans. J. Biol. Chem. 277:30598–30605.

      Information & Contributors

      Information

      Published In

      Infection and Immunity
      Volume 82Number 3March 2014
      Pages: 1030 - 1035
      Editor: G. S. Deepe Jr.

      History

      Received: 15 November 2013
      1 December 2013
      Accepted: 9 December 2013
      Published online: 16 December 2013

      Permissions

      Request permissions for this article.

      Contributors

      Authors

      Maria Carolina Ferreira
      Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
      Department of Clinical Pathology, Campinas State University, UNICAMP, SP, Brazil
      Natasha Whibley
      Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
      Anna J. Mamo
      Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
      Ulrich Siebenlist
      Laboratory of Immunoregulation, NIAID, National Institutes of Health, Bethesda, Maryland, USA
      Yvonne R. Chan
      Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
      Sarah L. Gaffen
      Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

      Editor

      G. S. Deepe Jr.
      Editor

      Notes

      Address correspondence to Sarah L. Gaffen, [email protected].

      Metrics & Citations

      Metrics

      Citations

      View Options

      Media

      Figures

      Other

      Tables

      Share

    • Infection and ImmunityArticle
      Inflammatory Monocytes and Neutrophils Regulate Streptococcus suis-Induced Systemic Inflammation and Disease but Are Not Critical for the Development of Central Nervous System Disease in a Mouse Model of Infection

      Inflammatory Monocytes and Neutrophils Regulate Streptococcus suis-Induced Systemic Inflammation and Disease but Are Not Critical for the Development of Central Nervous System Disease in a Mouse Model of Infection

      ABSTRACT

      Streptococcus suis is an important porcine bacterial pathogen and zoonotic agent responsible for sudden death, septic shock, and meningitis. These pathologies are a consequence of elevated bacterial replication leading to exacerbated and uncontrolled inflammation, a hallmark of the S. suis systemic and central nervous system (CNS) infections. Monocytes and neutrophils are immune cells involved in various functions, including proinflammatory mediator production. Moreover, monocytes are composed of two main subsets: shorter-lived inflammatory monocytes and longer-lived patrolling monocytes. However, regardless of their presence in blood and the fact that S. suis-induced meningitis is characterized by infiltration of monocytes and neutrophils into the CNS, their role during the S. suis systemic and CNS diseases remains unknown. Consequently, we hypothesized that monocytes and neutrophils participate in S. suis infection via bacterial clearance and inflammation. Results demonstrated that inflammatory monocytes and neutrophils regulate S. suis-induced systemic disease via their role in inflammation required for bacterial burden control. In the CNS, inflammatory monocytes contributed to exacerbation of S. suis-induced local inflammation, while neutrophils participated in bacterial burden control. However, development of clinical CNS disease was independent of both cell types, indicating that resident immune cells are mostly responsible for S. suis-induced CNS inflammation and clinical disease and that inflammatory monocyte and neutrophil infiltration is a consequence of the induced inflammation. In contrast, the implication of patrolling monocytes was minimal throughout the S. suis infection. Consequently, this study demonstrates that while inflammatory monocytes and neutrophils modulate S. suis-induced systemic inflammation and disease, they are not critical for CNS disease development.

      REFERENCES

      1.
      Gottschalk M, Xu J, Calzas C, Segura M. 2010. Streptococcus suis: a new emerging or an old neglected zoonotic pathogen? Future Microbiol 5:371–391.
      2.
      Wertheim HF, Nghia HD, Taylor W, Schultsz C. 2009. Streptococcus suis: an emerging human pathogen. Clin Infect Dis 48:617–625.
      3.
      Dominguez-Punaro M, Segura M, Plante MM, Lacouture S, Rivest S, Gottschalk M. 2007. Streptococcus suis serotype 2, an important swine and human pathogen, induces strong systemic and cerebral inflammatory responses in a mouse model of infection. J Immunol 179:1842–1854.
      4.
      Auger J-P, Fittipaldi N, Benoit-Biancamano M-O, Segura M, Gottschalk M. 2016. Virulence studies of different sequence types and geographical origins of Streptococcus suis serotype 2 in a mouse model of infection. Pathogens 5:48.
      5.
      Goyette-Desjardins G, Auger J-P, Xu J, Segura M, Gottschalk M. 2014. Streptococcus suis, an important pig pathogen and emerging zoonotic agent: an update on the worldwide distribution based on serotyping and sequence typing. Emerg Microbes Infect 3:e45.
      6.
      Segura M, Calzas C, Grenier D, Gottschalk M. 2016. Initial steps of the pathogenesis of the infection caused by Streptococcus suis: fighting against nonspecific defenses. FEBS Lett 590:3772–3799.
      7.
      Fittipaldi N, Segura M, Grenier D, Gottschalk M. 2012. Virulence factors involved in the pathogenesis of the infection caused by the swine pathogen and zoonotic agent Streptococcus suis. Future Microbiol 7:259–279.
      8.
      Reams RY, Glickman LT, Harrington DD, Thacker HL, Bowersock TL. 1994. Streptococcus suis infection in swine: a retrospective study of 256 cases. Part II. Clinical signs, gross and microscopic lesions, and coexisting microorganisms. J Vet Diagn Invest 6:326–334.
      9.
      Auger J-P, Benoit-Biancamano M-O, Bedard C, Segura M, Gottschalk M. 2019. Differential role of MyD88 signaling in Streptococcus suis serotype 2-induced systemic and central nervous system diseases. Int Immunol 31:697–714.
      10.
      Auger J-P, Santinón A, Roy D, Mossman K, Xu J, Segura M, Gottschalk M. 2017. Type I interferon induced by Streptococcus suis serotype 2 is strain-dependent and may be beneficial for host survival. Front Immunol 8:1039.
      11.
      Lecours MP, Gottschalk M, Houde M, Lemire P, Fittipaldi N, Segura M. 2011. Critical role for Streptococcus suis cell wall modifications and suilysin in resistance to complement-dependent killing by dendritic cells. J Infect Dis 204:919–929.
      12.
      Lecours MP, Segura M, Fittipaldi N, Rivest S, Gottschalk M. 2012. Immune receptors involved in Streptococcus suis recognition by dendritic cells. PLoS One 7:e44746.
      13.
      Graveline R, Segura M, Radzioch D, Gottschalk M. 2007. TLR2-dependent recognition of Streptococcus suis is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness. Int Immunol 19:375–389.
      14.
      Segura MA, Cleroux P, Gottschalk M. 1998. Streptococcus suis and group B Streptococcus differ in their interactions with murine macrophages. FEMS Immunol Med Microbiol 21:189–195.
      15.
      Segura M, Stankova J, Gottschalk M. 1999. Heat-killed Streptococcus suis capsular type 2 strains stimulate tumor necrosis factor alpha and interleukin-6 production by murine macrophages. Infect Immun 67:4646–4654.
      16.
      Segura M, Gottschalk M. 2002. Streptococcus suis interactions with the murine macrophage cell line J774: adhesion and cytotoxicity. Infect Immun 70:4312–4322.
      17.
      Meijerink M, Ferrando ML, Lammers G, Taverne N, Smith HE, Wells JM. 2012. Immunomodulatory effects of Streptococcus suis capsule type on human dendritic cell responses, phagocytosis and intracellular survival. PLoS One 7:e35849.
      18.
      Dale DC, Boxer L, Liles WC. 2008. The phagocytes: neutrophils and monocytes. Blood 112:935–945.
      19.
      Shi C, Pamer EG. 2011. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 11:762–774.
      20.
      Witter AR, Okunnu BM, Berg RE. 2016. The essential role of neutrophils during infection with the intracellular bacterial pathogen Listeria monocytogenes. J Immunol 197:1557–1565.
      21.
      Seele J, Tauber SC, Bunkowski S, Baums CG, Valentin-Weigand P, de Buhr N, Beineke A, Iliev AI, Brück W, Nau R. 2018. The inflammatory response and neuronal injury in Streptococcus suis meningitis. BMC Infect Dis 18:297.
      22.
      Benga L, Fulde M, Neis C, Goethe R, Valentin-Weigand P. 2008. Polysaccharide capsule and suilysin contribute to extracellular survival of Streptococcus suis co-cultivated with primary porcine phagocytes. Vet Microbiol 132:211–219.
      23.
      Chabot-Roy G, Willson P, Segura M, Lacouture S, Gottschalk M. 2006. Phagocytosis and killing of Streptococcus suis by porcine neutrophils. Microb Pathog 41:21–32.
      24.
      Segura M, Vadeboncoeur N, Gottschalk M. 2002. CD14-dependent and -independent cytokine and chemokine production by human THP-1 monocytes stimulated by Streptococcus suis capsular type 2. Clin Exp Immunol 127:243–254.
      25.
      Al-Numani D, Segura M, Doré M, Gottschalk M. 2003. Up-regulation of ICAM-1, CD11a/CD18 and CD11c/CD18 on human THP-1 monocytes stimulated by Streptococcus suis serotype 2. Clin Exp Immunol 133:67–77.
      26.
      Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. 2010. Development of monocytes, macrophages, and dendritic cells. Science 327:656–661.
      27.
      Geissmann F, Jung S, Littman DR. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19:71–82.
      28.
      Serbina NV, Pamer EG. 2006. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 7:311.
      29.
      Hanna RN, Carlin LM, Hubbeling HG, Nackiewicz D, Green AM, Punt JA, Geissmann F, Hedrick CC. 2011. The transcription factor Nr4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C monocytes. Nat Immunol 12:778–785.
      30.
      Sprangers S, de Vries TJ, Everts V. 2016. Monocyte heterogeneity: consequences for monocyte-derived immune cells. J Immunol Res 2016:1475435.
      31.
      Mildner A, Djukic M, Garbe D, Wellmer A, Kuziel WA, Mack M, Nau R, Prinz M. 2008. Ly-6G+CCR2 myeloid cells rather than Ly-6ChighCCR2+ monocytes are required for the control of bacterial infection in the central nervous system. J Immunol 181:2713–2722.
      32.
      Ribes S, Regen T, Meister T, Tauber SC, Schutze S, Mildner A, Mack M, Hanisch UK, Nau R. 2013. Resistance of the brain to Escherichia coli K1 infection depends on MyD88 signaling and the contribution of neutrophils and monocytes. Infect Immun 81:1810–1819.
      33.
      Biondo C, Mancuso G, Midiri A, Signorino G, Domina M, Lanza Cariccio V, Mohammadi N, Venza M, Venza I, Teti G, Beninati C. 2014. The interleukin-1beta/CXCL1/2/neutrophil axis mediates host protection against group B streptococcal infection. Infect Immun 82:4508–4517.
      34.
      Auray G, Lachance C, Wang Y, Gagnon CA, Segura M, Gottschalk M. 2016. Transcriptional analysis of PRRSV-infected porcine dendritic cell response to Streptococcus suis infection reveals up-regulation of inflammatory-related genes expression. PLoS One 11:e0156019.
      35.
      Dominguez-Punaro M, Segura M, Radzioch D, Rivest S, Gottschalk M. 2008. Comparison of the susceptibilities of C57BL/6 and A/J mouse strains to Streptococcus suis serotype 2 infection. Infect Immun 76:3901–3910.
      36.
      Dominguez-Punaro MC, Koedel U, Hoegen T, Demel C, Klein M, Gottschalk M. 2012. Severe cochlear inflammation and vestibular syndrome in an experimental model of Streptococcus suis infection in mice. Eur J Clin Microbiol Infect Dis 31:2391–2400.
      37.
      Lachance C, Gottschalk M, Gerber PP, Lemire P, Xu J, Segura M. 2013. Exacerbated type II interferon response drives hypervirulence and toxic shock by an emergent epidemic strain of Streptococcus suis. Infect Immun 81:1928–1939.
      38.
      Mishalian I, Ordan M, Peled A, Maly A, Eichenbaum MB, Ravins M, Aychek T, Jung S, Hanski E. 2011. Recruited macrophages control dissemination of group A Streptococcus from infected soft tissues. J Immunol 187:6022–6031.
      39.
      Verdrengh M, Tarkowski A. 1997. Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect Immun 65:2517–2521.
      40.
      Deniset JF, Surewaard BG, Lee W-Y, Kubes P. 2017. Splenic Ly6Ghigh mature and Ly6Gint immature neutrophils contribute to eradication of S. pneumoniae. J Exp Med 214:1333–1350.
      41.
      Tenenbaum T, Asmat TM, Seitz M, Schroten H, Schwerk C. 2016. Biological activities of suilysin: role in Streptococcus suis pathogenesis. Future Microbiol 11:941–954.
      42.
      Auffray C, Sieweke MH, Geissmann F. 2009. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27:669–692.
      43.
      Steinmetz O, Hoch S, Avniel-Polak S, Gavish K, Eli-Berchoer L, Wilensky A, Nussbaum G. 2016. CX3CR1hi monocyte/macrophages support bacterial survival and experimental infection-driven bone resorption. J Infect Dis 213:1505–1515.
      44.
      Zheng H, Punaro MC, Segura M, Lachance C, Rivest S, Xu J, Houde M, Gottschalk M. 2011. Toll-like receptor 2 is partially involved in the activation of murine astrocytes by Streptococcus suis, an important zoonotic agent of meningitis. J Neuroimmunol 234:71–83.
      45.
      Dominguez-Punaro M, Segura M, Contreras I, Lachance C, Houde M, Lecours MP, Olivier M, Gottschalk M. 2010. In vitro characterization of the microglial inflammatory response to Streptococcus suis, an important emerging zoonotic agent of meningitis. Infect Immun 78:5074–5085.
      46.
      Lampron A, Larochelle A, Laflamme N, Prefontaine P, Plante MM, Sanchez MG, Yong VW, Stys PK, Tremblay ME, Rivest S. 2015. Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J Exp Med 212:481–495.
      47.
      Diab A, Abdalla H, Li HL, Shi FD, Zhu J, Hojberg B, Lindquist L, Wretlind B, Bakhiet M, Link H. 1999. Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. Infect Immun 67:2590–2601.
      48.
      Aust V, Kress E, Abraham S, Schroder N, Kipp M, Stope MB, Pufe T, Tauber SC, Brandenburg LO. 2018. Lack of chemokine (C-C motif) ligand 3 leads to decreased survival and reduced immune response after bacterial meningitis. Cytokine 111:246–254.
      49.
      Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M. 2006. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 112:139–149.
      50.
      Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, Mack M, Charo IF. 2007. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 117:902–909.
      51.
      Shi C, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, Lipuma L, Leiner I, Li MO, Frenette PS, Pamer EG. 2011. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 34:590–601.
      52.
      Engel DR, Maurer J, Tittel AP, Weisheit C, Cavlar T, Schumak B, Limmer A, van Rooijen N, Trautwein C, Tacke F, Kurts C. 2008. CCR2 mediates homeostatic and inflammatory release of Gr1(high) monocytes from the bone marrow, but is dispensable for bladder infiltration in bacterial urinary tract infection. J Immunol 181:5579–5586.
      53.
      Slater JD, Allen AG, May JP, Bolitho S, Lindsay H, Maskell DJ. 2003. Mutagenesis of Streptococcus equi and Streptococcus suis by transposon Tn917. Vet Microbiol 93:197–206.
      54.
      Carr KD, Sieve AN, Indramohan M, Break TJ, Lee S, Berg RE. 2011. Specific depletion reveals a novel role for neutrophil-mediated protection in the liver during Listeria monocytogenes infection. Eur J Immunol 41:2666–2676.
      55.
      Wojtasiak M, Pickett DL, Tate MD, Londrigan SL, Bedoui S, Brooks AG, Reading PC. 2010. Depletion of Gr-1+, but not Ly6G+, immune cells exacerbates virus replication and disease in an intranasal model of herpes simplex virus type 1 infection. J Gen Virol 91:2158–2166.
      56.
      Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. 2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 83:64–70.
      57.
      Pösel C, Möller K, Boltze J, Wagner D-C, Weise G. 2016. Isolation and flow cytometric analysis of immune cells from the ischemic mouse brain. J Vis Exp 108:53658.
      58.
      National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.

      Information & Contributors

      Information

      Published In

      Infection and Immunity
      Volume 88Number 320 February 2020
      eLocator: e00787-19
      Editor: Guy H. Palmer
      Washington State University

      History

      Received: 3 October 2019
      23 October 2019
      Accepted: 4 December 2019
      Published online: 9 December 2019

      Permissions

      Request permissions for this article.

      KEYWORDS

      1. Streptococcus suis
      2. inflammation
      3. meningitis
      4. monocytes
      5. neutrophils
      6. sepsis

      Contributors

      Authors

      Jean-Philippe Auger
      Research Group on Infectious Diseases in Production Animals, University of Montreal, Saint-Hyacinthe, Quebec, Canada
      Swine and Poultry Infectious Diseases Research Center, University of Montreal, Saint-Hyacinthe, Quebec, Canada
      Department of Pathology and Microbiology, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, Quebec, Canada
      Serge Rivest
      CHU de Québec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, Quebec, Quebec, Canada
      Marie-Odile Benoit-Biancamano
      Research Group on Infectious Diseases in Production Animals, University of Montreal, Saint-Hyacinthe, Quebec, Canada
      Swine and Poultry Infectious Diseases Research Center, University of Montreal, Saint-Hyacinthe, Quebec, Canada
      Department of Pathology and Microbiology, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, Quebec, Canada
      Mariela Segura
      Research Group on Infectious Diseases in Production Animals, University of Montreal, Saint-Hyacinthe, Quebec, Canada
      Swine and Poultry Infectious Diseases Research Center, University of Montreal, Saint-Hyacinthe, Quebec, Canada
      Department of Pathology and Microbiology, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, Quebec, Canada
      Marcelo Gottschalk
      Research Group on Infectious Diseases in Production Animals, University of Montreal, Saint-Hyacinthe, Quebec, Canada
      Swine and Poultry Infectious Diseases Research Center, University of Montreal, Saint-Hyacinthe, Quebec, Canada
      Department of Pathology and Microbiology, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, Quebec, Canada

      Editor

      Guy H. Palmer
      Editor
      Washington State University

      Notes

      Address correspondence to Marcelo Gottschalk, [email protected].

      Metrics & Citations

      Metrics

      Citations

      View Options

      Media

      Figures

      Other

      Tables

      Share

    • Infection and ImmunityArticle
      The Paralogous Transcription Factors Stp1 and Stp2 of Candida albicans Have Distinct Functions in Nutrient Acquisition and Host Interaction

      The Paralogous Transcription Factors Stp1 and Stp2 of Candida albicans Have Distinct Functions in Nutrient Acquisition and Host Interaction

      ABSTRACT

      Nutrient acquisition is a central challenge for all organisms. For the fungal pathogen Candida albicans, utilization of amino acids has been shown to be critical for survival, immune evasion, and escape, while the importance of catabolism of host-derived proteins and peptides in vivo is less well understood. Stp1 and Stp2 are paralogous transcription factors (TFs) regulated by the Ssy1-Ptr3-Ssy5 (SPS) amino acid sensing system and have been proposed to have distinct, if uncertain, roles in protein and amino acid utilization. We show here that Stp1 is required for proper utilization of peptides but has no effect on amino acid catabolism. In contrast, Stp2 is critical for utilization of both carbon sources. Commensurate with this observation, we found that Stp1 controls a very limited set of genes, while Stp2 has a much more extensive regulon that is partly dependent on the Ssy1 amino acid sensor (amino acid uptake and catabolism) and partly Ssy1 independent (genes associated with filamentous growth, including the regulators UME6 and SFL2). The ssy1Δ/Δ and stp2Δ/Δ mutants showed reduced fitness in a gastrointestinal (GI) colonization model, yet induced greater damage to epithelial cells and macrophages in a manner that was highly dependent on the growth status of the fungal cells. Surprisingly, the stp1Δ/Δ mutant was better able to colonize the gut but the mutation had no effect on host cell damage. Thus, proper protein and amino acid utilization are both required for normal host interaction and are controlled by an interrelated network that includes Stp1 and Stp2.

      REFERENCES

      1.
      Pérez JC, Johnson AD. 2013. Regulatory circuits that enable proliferation of the fungus Candida albicans in a mammalian host. PLoS Pathog 9:e1003780.
      2.
      McManus BA, Coleman DC. 2014. Molecular epidemiology, phylogeny and evolution of Candida albicans. Infect Genet Evol 21:166–178.
      3.
      Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163.
      4.
      Perlroth J, Choi B, Spellberg B. 2007. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 45:321–346.
      5.
      Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch SM. 2005. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 26:540–547.
      6.
      Suleyman G, Alangaden GJ. 2016. Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin North Am 30:1023–1052.
      7.
      Trofa D, Gácser A, Nosanchuk JD. 2008. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 21:606–625.
      8.
      Lockhart SR, Berkow EL, Chow N, Welsh RM. 2017. Candida auris for the clinical microbiology laboratory: not your grandfather’s Candida species. Clin Microbiol Newsl 39:99–103.
      9.
      Wilson D, Naglik JR, Hube B. 2016. The missing link between Candida albicans hyphal morphogenesis and host cell damage. PLoS Pathog 12:e1005867.
      10.
      Mayer FL, Wilson D, Hube B. 2013. Candida albicans pathogenicity mechanisms. Virulence 4:119–128.
      11.
      Miramón P, Lorenz MC. 2017. A feast for Candida: metabolic plasticity confers an edge for virulence. PLoS Pathog 13:e1006144.
      12.
      Hube B, Stehr F, Bossenz M, Mazur A, Kretschmar M, Schafer W. 2000. Secreted lipases of Candida albicans: cloning, characterisation and expression analysis of a new gene family with at least ten members. Arch Microbiol 174:362–374.
      13.
      Leidich SD, Ibrahim AS, Fu Y, Koul A, Jessup C, Vitullo J, Fonzi W, Mirbod F, Nakashima S, Nozawa Y, Ghannoum MA. 1998. Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans. J Biol Chem 273:26078–26086.
      14.
      Hube B, Monod M, Schofield DA, Brown AJ, Gow NA. 1994. Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol Microbiol 14:87–99.
      15.
      Reuss O, Morschhäuser J. 2006. A family of oligopeptide transporters is required for growth of Candida albicans on proteins. Mol Microbiol 60:795–812.
      16.
      Danhof HA, Lorenz MC. 2015. The Candida albicans ATO gene family promotes neutralization of the macrophage phagolysosome. Infect Immun 83:4416–4426.
      17.
      Schaller M, Borelli C, Korting HC, Hube B. 2005. Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 48:365–377.
      18.
      Naglik JR, Challacombe SJ, Hube B. 2003. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67:400–428.
      19.
      Dunkel N, Hertlein T, Franz R, Reuß O, Sasse C, Schäfer T, Ohlsen K, Morschhäuser J. 2013. Roles of different peptide transporters in nutrient acquisition in Candida albicans. Eukaryot Cell 12:520–528.
      20.
      Lermann U, Morschhauser J. 2008. Secreted aspartic proteases are not required for invasion of reconstituted human epithelia by Candida albicans. Microbiology 154:3281–3295.
      21.
      Correia A, Lermann U, Teixeira L, Cerca F, Botelho S, Gil da Costa RM, Sampaio P, Gärtner F, Morschhäuser J, Vilanova M, Pais C. 2010. Limited role of secreted aspartyl proteinases Sap1 to Sap6 in Candida albicans virulence and host immune response in murine hematogenously disseminated candidiasis. Infect Immun 78:4839–4849.
      22.
      Sabina J, Brown V. 2009. Glucose sensing network in Candida albicans: a sweet spot for fungal morphogenesis. Eukaryot Cell 8:1314–1320.
      23.
      Singh P, Ghosh S, Datta A. 2001. Attenuation of virulence and changes in morphology in Candida albicans by disruption of theN-acetylglucosamine catabolic pathway. Infect Immun 69:7898–7903.
      24.
      Ramirez MA, Lorenz MC. 2009. The transcription factor homolog CTF1 regulates β-oxidation in Candida albicans. Eukaryot Cell 8:1604–1614.
      25.
      Ramirez MA, Lorenz MC. 2007. Mutations in alternative carbon utilization pathways in Candida albicans attenuate virulence and confer pleiotropic phenotypes. Eukaryot Cell 6:280–290.
      26.
      Barelle CJ, Priest CL, MacCallum DM, Gow NAR, Odds FC, Brown A. 2006. Niche-specific regulation of central metabolic pathways in a fungal pathogen. Cell Microbiol 8:961–971.
      27.
      Vylkova S, Carman AJ, Danhof HA, Collette JR, Zhou H, Lorenz MC. 2011. The fungal pathogen Candida albicans autoinduces hyphal morphogenesis by raising extracellular pH. mBio 2:e00055-11.
      28.
      Williams RB, Lorenz MC. 2020. Multiple alternative carbon pathways combine to promote Candida albicans stress resistance, immune interactions, and virulence. mBio 11:e03070-19.
      29.
      Gow NAR, van de Veerdonk FL, Brown AJP, Netea MG. 2011. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol 10:112–122.
      30.
      Danhof HA, Vylkova S, Vesely EM, Ford AE, Gonzalez-Garay M, Lorenz MC. 2016. Robust extracellular pH modulation by Candida albicans during growth in carboxylic acids. mBio 7:e01646-16.
      31.
      Naseem S, Araya E, Konopka JB. 2015. Hyphal growth in Candida albicans does not require induction of hyphal-specific gene expression. Mol Biol Cell 26:1174–1187.
      32.
      Vylkova S, Lorenz MC. 2014. Modulation of phagosomal pH by Candida albicans promotes hyphal morphogenesis and requires Stp2p, a regulator of amino acid transport. PLoS Pathog 10:e1003995.
      33.
      Miramón P, Lorenz MC. 2016. The SPS amino acid sensor mediates nutrient acquisition and immune evasion in Candida albicans. Cell Microbiol 18:1611–1624.
      34.
      Vesely EM, Williams RB, Konopka JB, Lorenz MC. 2017. N-acetylglucosamine metabolism promotes survival of Candida albicans in the phagosome. mSphere 2:e00357-17.
      35.
      Perez JC, Kumamoto CA, Johnson AD. 2013. Candida albicans commensalism and pathogenicity are intertwined traits directed by a tightly knit transcriptional regulatory circuit. PLoS Biol 11:e1001510.
      36.
      Klasson H, Fink GR, Ljungdahl PO. 1999. Ssy1p and Ptr3p are plasma membrane components of a yeast system that senses extracellular amino acids. Mol Cell Biol 19:5405–5416.
      37.
      Abdel-Sater F, Jean C, Merhi A, Vissers S, André B. 2011. Amino acid signaling in yeast: activation of Ssy5 protease is associated with its phosphorylation-induced ubiquitylation. J Biol Chem 286:12006–12015.
      38.
      Brega E, Zufferey R, Ben Mamoun C. 2004. Candida albicans Csy1p is a nutrient sensor important for activation of amino acid uptake and hyphal morphogenesis. Eukaryot Cell 3:135–143.
      39.
      Forsberg H, Gilstring CF, Zargari A, Martínez P, Ljungdahl PO. 2001. The role of the yeast plasma membrane SPS nutrient sensor in the metabolic response to extracellular amino acids. Mol Microbiol 42:215–228.
      40.
      Liu Z, Thornton J, Spirek M, Butow RA. 2008. Activation of the SPS amino acid-sensing pathway in Saccharomyces cerevisiae correlates with the phosphorylation state of a sensor component, Ptr3. Mol Cell Biol 28:551–563.
      41.
      Pfirrmann T, Heessen S, Omnus DJ, Andreasson C, Ljungdahl PO. 2010. The prodomain of Ssy5 protease controls receptor-activated proteolysis of transcription factor Stp1. Mol Cell Biol 30:3299–3309.
      42.
      Martinez P, Ljungdahl PO. 2005. Divergence of Stp1 and Stp2 transcription factors in Candida albicans places virulence factors required for proper nutrient acquisition under amino acid control. Mol Cell Biol 25:9435–9446.
      43.
      Martinez P, Ljungdahl PO. 2004. An ER packaging chaperone determines the amino acid uptake capacity and virulence of Candida albicans. Mol Microbiol 51:371–384.
      44.
      Kraidlova L, Van Zeebroeck G, Van Dijck P, Sychrová H. 2011. The Candida albicans GAP gene family encodes permeases involved in general and specific amino acid uptake and sensing. Eukaryot Cell 10:1219–1229.
      45.
      Lorenz MC, Bender JA, Fink GR. 2004. Transcriptional response of Candida albicans upon internalization by macrophages transcriptional response of Candida albicans upon internalization by macrophages. Eukaryot Cell 3:1076–1087.
      46.
      Lorenz MC, Fink GR. 2001. The glyoxylate cycle is required for fungal virulence. Nature 412:83–86.
      47.
      Andreasson C, Ljungdahl PO. 2004. The N-terminal regulatory domain of Stp1p is modular and, fused to an artificial transcription factor, confers full Ssy1p-Ptr3p-Ssy5p sensor control. Mol Cell Biol 24:7503–7513.
      48.
      Dabas N, Morschhäuser J. 2008. A transcription factor regulatory cascade controls secreted aspartic protease expression in Candida albicans. Mol Microbiol 69:586–602.
      49.
      Jimenez-Lopez C, Collette JR, Brothers KM, Shepardson KM, Cramer RA, Wheeler RT, Lorenz MC. 2013. Candida albicans induces arginine biosynthetic genes in response to host-derived reactive oxygen species. Eukaryot Cell 12:91–100.
      50.
      Rosenbach A, Dignard D, Pierce JV, Whiteway M, Kumamoto CA. 2010. Adaptations of Candida albicans for growth in the mammalian intestinal tract. Eukaryot Cell 9:1075–1086.
      51.
      Vylkova S, Lorenz MC. 2017. Phagosomal neutralization by the fungal pathogen Candida albicans induces macrophage pyroptosis. Infect Immun 85:e00832-16.
      52.
      Westman J, Moran G, Mogavero S, Hube B, Grinstein S. 2018. Candida albicans hyphal expansion causes phagosomal membrane damage and luminal alkalinization. mBio 9:e01226-18.
      53.
      Rubin-Bejerano I, Fraser I, Grisafi P, Fink GR. 2003. Phagocytosis by neutrophils induces an amino acid deprivation response in Saccharomyces cerevisiae and Candida albicans. Proc Natl Acad Sci U S A 100:11007–11012.
      54.
      Fradin C, De Groot P, MacCallum D, Schaller M, Klis F, Odds FC, Hube B. 2005. Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood. Mol Microbiol 56:397–415.
      55.
      Spiering MJ, Moran GP, Chauvel M, Maccallum DM, Higgins J, Hokamp K, Yeomans T, d’Enfert C, Coleman DC, Sullivan DJ. 2010. Comparative transcript profiling of Candida albicans and Candida dubliniensis identifies SFL2, a C. albicans gene required for virulence in a reconstituted epithelial infection model. Eukaryot Cell 9:251–265.
      56.
      Znaidi S, Nesseir A, Chauvel M, Rossignol T, d’Enfert C. 2013. A comprehensive functional portrait of two heat shock factor-type transcriptional regulators involved in Candida albicans morphogenesis and virulence. PLoS Pathog 9:e1003519.
      57.
      Tao L, Zhang Y, Fan S, Nobile CJ, Guan G, Huang G. 2017. Integration of the tricarboxylic acid (TCA) cycle with cAMP signaling and Sfl2 pathways in the regulation of CO2 sensing and hyphal development in Candida albicans. PLoS Genet 13:e1006949.
      58.
      Banerjee M, Thompson DS, Lazzell A, Carlisle PL, Pierce C, Monteagudo C, Lopez-Ribot JL, Kadosh D. 2008. UME6, a novel filament-specific regulator of Candida albicans hyphal extension and virulence. Mol Biol Cell 19:1354–1365.
      59.
      Martin R, Moran GP, Jacobsen ID, Heyken A, Domey J, Sullivan DJ, Kurzai O, Hube B. 2011. The Candida albicans-specific gene EED1 encodes a key regulator of hyphal extension. PLoS One 6:e18394.
      60.
      Bensen ES, Martin SJ, Li M, Berman J, Davis DA. 2004. Transcriptional profiling in Candida albicans reveals new adaptive responses to extracellular pH and functions for Rim101p. Mol Microbiol 54:1335–1351.
      61.
      Lu Y, Su C, Solis NV, Filler SG, Liu H. 2013. Synergistic regulation of hyphal elongation by hypoxia, CO2, and nutrient conditions controls the virulence of Candida albicans. Cell Host Microbe 14:499–509.
      62.
      Lu Y, Su C, Ray S, Yuan Y, Liu H. 2019. CO2 signaling through the Ptc2-Ssn3 axis governs sustained hyphal development of Candida albicans by reducing Ume6 phosphorylation and degradation. mBio 10:e02320-18.
      63.
      Banerjee M, Uppuluri P, Zhao XR, Carlisle PL, Vipulanandan G, Villar CC, Lopez-Ribot JL, Kadosh D. 2013. Expression of UME6, a key regulator of Candida albicans hyphal development, enhances biofilm formation via Hgc1- and Sun41-dependent mechanisms. Eukaryot Cell 12:224–232.
      64.
      Carlisle PL, Kadosh D. 2010. Candida albicans Ume6, a filament-specific transcriptional regulator, directs hyphal growth via a pathway involving Hgc1 cyclin-related protein. Eukaryot Cell 9:1320–1328.
      65.
      Pande K, Chen C, Noble SM. 2013. Passage through the mammalian gut triggers a phenotypic switch that promotes Candida albicans commensalism. Nat Genet 45:1088–1091.
      66.
      Fan D, Coughlin LA, Neubauer MM, Kim J, Kim MS, Zhan X, Simms-Waldrip TR, Xie Y, Hooper LV, Koh AY. 2015. Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization. Nat Med 21:808–814.
      67.
      Gantner BN, Simmons RM, Underhill DM. 2005. Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments. EMBO J 24:1277–1286.
      68.
      Kusch H, Engelmann S, Bode R, Albrecht D, Morschhauser J, Hecker M. 2008. A proteomic view of Candida albicans yeast cell metabolism in exponential and stationary growth phases. Int J Med Microbiol 298:291–318.
      69.
      Reuss O, Vik A, Kolter R, Morschhäuser J. 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341:119–127.
      70.
      Murad AM, Lee PR, Broadbent ID, Barelle CJ, Brown AJ. 2000. CIp10, an efficient and convenient integrating vector for Candida albicans. Yeast 16:325–327.
      71.
      Weyler M, Morschhauser J. 2012. Tetracycline-inducible gene expression in Candida albicans. Methods Mol Biol 845:201–210.
      72.
      Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. 2017. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14:417–419.
      73.
      Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550.
      74.
      Soneson C, Love MI, Robinson MD. 2015. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences [version 1; peer review: 2 approved]. F1000Research 4:1521.
      75.
      Zhu A, Ibrahim JG, Love MI. 2018. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics 35:2084–2092.

      Information & Contributors

      Information

      Published In

      Infection and Immunity
      Volume 88Number 520 April 2020
      eLocator: e00763-19
      Editor: Mairi C. Noverr
      Tulane School of Medicine

      History

      Received: 25 September 2019
      16 October 2019
      Accepted: 14 February 2020
      Published online: 24 February 2020

      Permissions

      Request permissions for this article.

      KEYWORDS

      1. Candida
      2. colonization
      3. virulence
      4. amino acids
      5. protein
      6. metabolism
      7. fungal pathogenesis
      8. nutrient regulation

      Contributors

      Authors

      Department of Microbiology and Molecular Genetics, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA
      Department of Microbiology and Molecular Genetics, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA
      Department of Microbiology and Molecular Genetics, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA
      Department of Microbiology and Molecular Genetics, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA

      Editor

      Mairi C. Noverr
      Editor
      Tulane School of Medicine

      Notes

      Address correspondence to Michael C. Lorenz, [email protected].

      Metrics & Citations

      Metrics

      Citations

      View Options

      Media

      Figures

      Other

      Tables

      Share

    • Infection and ImmunityArticle
      Sequencing and Functional Annotation of Avian Pathogenic Escherichia coli Serogroup O78 Strains Reveal the Evolution of E. coli Lineages Pathogenic for Poultry via Distinct Mechanisms

      Sequencing and Functional Annotation of Avian Pathogenic Escherichia coli Serogroup O78 Strains Reveal the Evolution of E. coli Lineages Pathogenic for Poultry via Distinct Mechanisms

      ABSTRACT

      Avian pathogenic Escherichia coli (APEC) causes respiratory and systemic disease in poultry. Sequencing of a multilocus sequence type 95 (ST95) serogroup O1 strain previously indicated that APEC resembles E. coli causing extraintestinal human diseases. We sequenced the genomes of two strains of another dominant APEC lineage (ST23 serogroup O78 strains χ7122 and IMT2125) and compared them to each other and to the reannotated APEC O1 sequence. For comparison, we also sequenced a human enterotoxigenic E. coli (ETEC) strain of the same ST23 serogroup O78 lineage. Phylogenetic analysis indicated that the APEC O78 strains were more closely related to human ST23 ETEC than to APEC O1, indicating that separation of pathotypes on the basis of their extraintestinal or diarrheagenic nature is not supported by their phylogeny. The accessory genome of APEC ST23 strains exhibited limited conservation of APEC O1 genomic islands and a distinct repertoire of virulence-associated loci. In light of this diversity, we surveyed the phenotype of 2,185 signature-tagged transposon mutants of χ7122 following intra-air sac inoculation of turkeys. This procedure identified novel APEC ST23 genes that play strain- and tissue-specific roles during infection. For example, genes mediating group 4 capsule synthesis were required for the virulence of χ7122 and were conserved in IMT2125 but absent from APEC O1. Our data reveal the genetic diversity of E. coli strains adapted to cause the same avian disease and indicate that the core genome of the ST23 lineage serves as a chassis for the evolution of E. coli strains adapted to cause avian or human disease via acquisition of distinct virulence genes.

      REFERENCES

      1.
      Barnes HJ, Vaiillancourt J-P, and Gross WB. 2003. Colibacillosis, p 631–656. In Saif YM, Barnes HJ, Glisson JR, Fadly AM, and McDougald LR (ed), Diseases of poultry, 11th ed. Iowa State University Press, Ames, IA.
      2.
      Pires-Dos-Santos T, Bisgaard M, and Christensen H. 2012. Genetic diversity and virulence profiles of Escherichia coli causing salpingitis and peritonitis in broiler breeders. Vet. Microbiol. pii:S0378–1135(12)00599-8. [Epub ahead of print.] doi:10.1016/j.vetmic.2012.11.008.
      3.
      Olsen RH, Chadfield MS, Christensen JP, Scheutz F, Christensen H, and Bisgaard M. 2011. Clonality and virulence traits of Escherichia coli associated with haemorrhagic septicaemia in turkeys. Avian Pathol. 40:587–595.
      4.
      Johnson TJ, Kariyawasam S, Wannemuehler Y, Mangiamele P, Johnson SJ, Doetkott C, Skyberg JA, Lynne AM, Johnson JR, and Nolan LK. 2007. The genome sequence of avian pathogenic Escherichia coli strain O1:K1:H7 shares strong similarities with human extraintestinal pathogenic E. coli genomes. J. Bacteriol. 189:3228–3236.
      5.
      Bauchart P, Germon P, Brée A, Oswald E, Hacker J, and Dobrindt U. 2010. Pathogenomic comparison of human extraintestinal and avian pathogenic Escherichia coli—search for factors involved in host specificity or zoonotic potential. Microb. Pathog. 49:105–115.
      6.
      Ewers C, Antão EM, Diehl I, Philipp HC, and Wieler LH. 2009. Intestine and environment of the chicken as reservoirs for extraintestinal pathogenic Escherichia coli strains with zoonotic potential. Appl. Environ. Microbiol. 75:184–192.
      7.
      Ewers C, Li G, Wilking H, Kiessling S, Alt K, Antáo EM, Laturnus C, Diehl I, Glodde S, Homeier T, Böhnke U, Steinrück H, Philipp HC, and Wieler LH. 2007. Avian pathogenic, uropathogenic, and newborn meningitis-causing Escherichia coli: how closely related are they? Int. J. Med. Microbiol. 297:163–176.
      8.
      Johnson TJ, Wannemuehler Y, Johnson SJ, Stell AL, Doetkott C, Johnson JR, Kim KS, Spanjaard L, and Nolan LK. 2008. Comparison of extraintestinal pathogenic Escherichia coli strains from human and avian sources reveals a mixed subset representing potential zoonotic pathogens. Appl. Environ. Microbiol. 74:7043–7050.
      9.
      Johnson TJ, Wannemuehler Y, Kariyawasam S, Johnson JR, Logue CM, and Nolan LK. 2012. Prevalence of avian pathogenic Escherichia coli strain APEC O1 genomic islands among extraintestinal and commensal E. coli isolates. J. Bacteriol. 194:2846–2853.
      10.
      Kariyawasam S, Scaccianoce JA, and Nolan LK. 2007. Common and specific genomic sequences of avian and human extraintestinal pathogenic Escherichia coli as determined by genomic subtractive hybridization. BMC Microbiol. 7:81. doi:10.1186/1471-2180-7-81.
      11.
      Mora A, López C, Dabhi G, Blanco M, Blanco JE, Alonso MP, Herrera A, Mamani R, Bonacorsi S, Moulin-Schouleur M, and Blanco J. 2009. Extraintestinal pathogenic Escherichia coli O1:K1:H7/NM from human and avian origin: detection of clonal groups B2 ST95 and D ST59 with different host distribution. BMC Microbiol. 9:132. doi:10.1186/1471-2180-9-132.
      12.
      Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, Pastorello I, Corea VA, Torricelli G, Cartocci E, Savino S, Scarselli M, Dobrindt U, Hacker J, Tettelin H, Tallon LJ, Sullivan S, Wieler LH, Ewers C, Pickard D, Dougan G, Fontana MR, Rappuoli R, Pizza M, and Serino L. 2010. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 107:9072–9077.
      13.
      Moulin-Schouleur M, Répérant M, Laurent S, Brée A, Mignon-Grasteau S, Germon P, Rasschaert D, and Schouler C. 2007. Extraintestinal pathogenic Escherichia coli strains of avian and human origin: link between phylogenetic relationships and common virulence patterns. J. Clin. Microbiol. 45:3366–3376.
      14.
      Tivendale KA, Logue CM, Kariyawasam S, Jordan D, Hussein A, Li G, Wannemuehler Y, and Nolan LK. 2010. Avian pathogenic Escherichia coli strains are similar to neonatal meningitis E. coli strains and are able to cause meningitis in the rat model of human disease. Infect. Immun. 78:3412–3419.
      15.
      Li G, Laturnus C, Ewers C, and Wieler LH. 2005. Identification of genes required for avian Escherichia coli septicemia by signature-tagged mutagenesis. Infect. Immun. 73:2818–2827.
      16.
      Mellata M, Dho-Moulin M, Dozois CM, Curtiss R III, Brown PK, Arné P, Brée A, Desautels C, and Fairbrother JM. 2003. Role of virulence factors in resistance of avian pathogenic Escherichia coli to serum and in pathogenicity. Infect. Immun. 71:536–540.
      17.
      Brown PK and Curtiss R III. 1996. Unique chromosomal regions associated with virulence of an avian pathogenic Escherichia coli strain. Proc. Natl. Acad. Sci. U. S. A. 93:11149–11154.
      18.
      Sabri M, Caza M, Proulx J, Lymberopoulos MH, Brée A, Moulin-Schouleur M, Curtiss R III, and Dozois CM. 2008. Contribution of the SitABCD, MntH, and FeoB metal transporters to the virulence of avian pathogenic Escherichia coli O78 strain χ7122. Infect. Immun. 76:601–611.
      19.
      Li G, Ewers C, Laturnus C, Diehl I, Alt K, Dai J, Antão EM, Schnetz K, and Wieler LH. 2008. Characterization of a yjjQ mutant of avian pathogenic Escherichia coli (APEC). Microbiology 154:1082–1093.
      20.
      Antão EM, Ewers C, Gürlebeck D, Preisinger R, Homeier T, Li G, and Wieler LH. 2009. Signature-tagged mutagenesis in a chicken infection model leads to the identification of a novel avian pathogenic Escherichia coli fimbrial adhesin. PLoS One 4:e7796. doi:10.1371/journal.pone.0007796.
      21.
      Antão EM. 2010. Identification of avian pathogenic E. coli (APEC) genes important for the colonization of the chicken lung and characterization of the novel ExPEC adhesin I. Ph. D. thesis. Humboldt-Universität zu Berlin, Berlin, Germany. http://edoc.hu-berlin.de/dissertationen/antao-esther-maria-2010-02-08/PDF/antao.pdf.
      22.
      Li G, Feng Y, Kariyawasam S, Tivendale KA, Wannemuehler Y, Zhou F, Logue CM, Miller CL, and Nolan LK. 2010. AatA is a novel autotransporter and virulence factor of avian pathogenic Escherichia coli. Infect. Immun. 78:898–906.
      23.
      Provence DL and Curtiss R III. 1994. Isolation and characterization of a gene involved in hemagglutination by an avian pathogenic Escherichia coli strain. Infect. Immun. 62:1369–1380.
      24.
      Dozois CM, Dho-Moulin M, Brée A, Fairbrother JM, Desautels C, and Curtiss R III. 2000. Relationship between the Tsh autotransporter and pathogenicity of avian Escherichia coli and localization and analysis of the Tsh genetic region. Infect. Immun. 68:4145–4154.
      25.
      Parreira VR and Gyles CL. 2003. A novel pathogenicity island integrated adjacent to the thrW tRNA gene of avian pathogenic Escherichia coli encodes a vacuolating autotransporter toxin. Infect. Immun. 71:5087–5096.
      26.
      Kariyawasam S and Nolan LK. 2009. Pap mutant of avian pathogenic Escherichia coli O1, an O1:K1:H7 strain, is attenuated in vivo. Avian Dis. 53:255–260.
      27.
      Marc D, Arné P, Brée A, and Dho-Moulin M. 1998. Colonization ability and pathogenic properties of a fim mutant of an avian strain of Escherichia coli. Res. Microbiol. 149:473–485.
      28.
      La Ragione RM, Sayers AR, and Woodward MJ. 2000. The role of fimbriae and flagella in the colonization, invasion and persistence of Escherichia coli O78:K80 in the day-old-chick model. Epidemiol. Infect. 124:351–363.
      29.
      Lymberopoulos MH, Houle S, Daigle F, Léveillé S, Brée A, Moulin-Schouleur M, Johnson JR, and Dozois CM. 2006. Characterization of Stg fimbriae from an avian pathogenic Escherichia coli O78:K80 strain and assessment of their contribution to colonization of the chicken respiratory tract. J. Bacteriol. 188:6449–6459.
      30.
      Ideses D, Gophna U, Paitan Y, Chaudhuri RR, Pallen MJ, and Ron EZ. 2005. A degenerate type III secretion system from septicemic Escherichia coli contributes to pathogenesis. J. Bacteriol. 187:8164–8171.
      31.
      Dozois CM, Daigle F, and Curtiss R III. 2003. Identification of pathogen-specific and conserved genes expressed in vivo by an avian pathogenic Escherichia coli strain. Proc. Natl. Acad. Sci. U. S. A. 100:247–252.
      32.
      Caza M, Lépine F, Milot S, and Dozois CM. 2008. Specific roles of the iroBCDEN genes in virulence of an avian pathogenic Escherichia coli O78 strain and in production of salmochelins. Infect. Immun. 76:3539–3549.
      33.
      Caza M, Lépine F, and Dozois CM. 2011. Secretion, but not overall synthesis, of catecholate siderophores contributes to virulence of extraintestinal pathogenic Escherichia coli. Mol. Microbiol. 80:266–282.
      34.
      Lamarche MG, Dozois CM, Daigle F, Caza M, Curtiss R III, Dubreuil JD, and Harel J. 2005. Inactivation of the pst system reduces the virulence of an avian pathogenic Escherichia coli O78 strain. Infect. Immun. 73:4138–4145.
      35.
      Germon P, Chen YH, He L, Blanco JE, Brée A, Schouler C, Huang SH, and Moulin-Schouleur M. 2005. ibeA, a virulence factor of avian pathogenic Escherichia coli. Microbiology 151:1179–1186.
      36.
      Wang S, Shi Z, Xia Y, Li H, Kou Y, Bao Y, Dai J, and Lu C. 2012. IbeB is involved in the invasion and pathogenicity of avian pathogenic Escherichia coli. Vet. Microbiol. 159:411–419.
      37.
      Bertrand N, Houle S, LeBihan G, Poirier É, Dozois CM, and Harel J. 2010. Increased Pho regulon activation correlates with decreased virulence of an avian pathogenic Escherichia coli O78 strain. Infect. Immun. 78:5324–5331.
      38.
      Crépin S, Lamarche MG, Garneau P, Séguin J, Proulx J, Dozois CM, and Harel J. 2008. Genome-wide transcriptional response of an avian pathogenic Escherichia coli (APEC) pst mutant. BMC Genomics 9:568. doi:10.1186/1471-2164-9-568.
      39.
      Cortes MA, Gibon J, Chanteloup NK, Moulin-Schouleur M, Gilot P, and Germon P. 2008. Inactivation of ibeA and ibeT results in decreased expression of type 1 fimbriae in extraintestinal pathogenic Escherichia coli strain BEN2908. Infect. Immun. 76:4129–4136.
      40.
      Herren CD, Mitra A, Palaniyandi SK, Coleman A, Elankumaran S, and Mukhopadhyay S. 2006. The BarA-UvrY two-component system regulates virulence in avian pathogenic Escherichia coli O78:K80:H9. Infect. Immun. 74:4900–4909.
      41.
      de Pace F, Nakazato G, Pacheco A, de Paiva JB, Sperandio V, and da Silveira WD. 2010. The type VI secretion system plays a role in type 1 fimbria expression and pathogenesis of an avian pathogenic Escherichia coli strain. Infect. Immun. 78:4990–4998.
      42.
      Mellata M, Ameiss K, Mo H, and Curtiss R III. 2010. Characterization of the contribution to virulence of three large plasmids of avian pathogenic E. coli χ7122 (O78:K80:H9). Infect. Immun. 78:1528–1541.
      43.
      Mellata M, Maddux JT, Nam T, Thomson N, Hauser H, Stevens MP, Mukhopadhyay S, Sarker S, Crabbé A, Nickerson CA, Santander J, and Curtiss R III. 2012. New insights into the bacterial fitness-associated mechanisms revealed by the characterization of large plasmids of an avian pathogenic E. coli. PLoS One 7:e29481. doi:10.1371/journal.pone.0029481.
      44.
      Mellata M, Touchman JW, and Curtiss R III. 2009. Full sequence and comparative analysis of the plasmid pAPEC-1 of avian pathogenic E. coli χ7122 (O78:K80:H9). PLoS One 4:e4232. doi:10.1371/journal.pone.0004232.
      45.
      Tivendale KA, Noormohammadi AH, Allen JL, and Browning GF. 2009. The conserved portion of the putative virulence region contributes to virulence of avian pathogenic Escherichia coli. Microbiology 155:450–460.
      46.
      Mellata M, Dho-Moulin M, Dozois CM, Curtiss R III, Lehoux B, and Fairbrother JM. 2003. Role of avian pathogenic Escherichia coli virulence factors in bacterial interaction with chicken heterophils and macrophages. Infect. Immun. 71:494–503.
      47.
      Provence DL and Curtiss R III. 1992. Role of crl in avian pathogenic Escherichia coli: a knockout mutation of crl does not affect hemagglutination activity, fibronectin binding, or curli production. Infect. Immun. 60:4460–4467.
      48.
      Simon R, Priefer U, and Pühler A. 1983. A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram negative bacteria. Nat. Biotechnol. 1:784–791.
      49.
      Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Berka J, Braverman MS, Chen YJ, Chen Z, Dewell SB, Du L, Fierro JM, Gomes XV, Godwin BC, He W, Helgesen S, Ho CH, Irzyk GP, Jando SC, Alenquer ML, Jarvie TP, Jirage KB, Kim JB, Knight JR, Lanza JR, Leamon JH, Lefkowitz SM, Lei M, Li J, Lohman KL, Lu H, Makhijani VB, McDade KE, McKenna MP, Myers EW, Nickerson E, Nobile JR, Plant R, Puc BP, Ronan MT, Roth GT, Sarkis GJ, Simons JF, Simpson JW, Srinivasan M, Tartaro KR, Tomasz A, Vogt KA, Volkmer GA, Wang SH, Wang Y, Weiner MP, Yu P, Begley RF, and Rothberg JM. 2005. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376–380.
      50.
      Chain PS, Grafham DV, Fulton RS, Fitzgerald MG, Hostetler J, Muzny D, Ali J, Birren B, Bruce DC, Buhay C, Cole JR, Ding Y, Dugan S, Field D, Garrity GM, Gibbs R, Graves T, Han CS, Harrison SH, Highlander S, Hugenholtz P, Khouri HM, Kodira CD, Kolker E, Kyrpides NC, Lang D, Lapidus A, Malfatti SA, Markowitz V, Metha T, Nelson KE, Parkhill J, Pitluck S, Qin X, Read TD, Schmutz J, Sozhamannan S, Sterk P, Strausberg RL, Sutton G, Thomson NR, Tiedje JM, Weinstock G, and Wollam A, Genomic Standards Consortium Human Microbiome Project Jumpstart Consortium, Detter JC. 2009. Genome project standards in a new era of sequencing. Science 326:236–237.
      51.
      Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream MA, and Barrell B. 2000. Artemis: sequence visualization and annotation. Bioinformatics 16:944–945.
      52.
      Berriman M and Rutherford K. 2003. Viewing and annotating sequence data with Artemis. Brief. Bioinform. 4:124–132.
      53.
      Riley M, Abe T, Arnaud MB, Berlyn MK, Blattner FR, Chaudhuri RR, Glasner JD, Horiuchi T, Keseler IM, Kosuge T, Mori H, Perna NT, Plunkett G III, Rudd KE, Serres MH, Thomas GH, Thomson NR, Wishart D, and Wanner BL. 2006. Escherichia coli K-12: a cooperatively developed annotation snapshot—2005. Nucleic Acids Res. 34:1–9.
      54.
      Hyatt D, Chen GL, Locascio PF, Land ML, Larimer FW, and Hauser LJ. 2010. Prodigal: prokaryotic gene recognition and translation initiation site identification. BMC Bioinformatics 11:119. doi:10.1186/1471-2105-11-119.
      55.
      Li L, Stoeckert CJ Jr, and Roos DS. 2003. OrthoMCL: identification of ortholog groups for eukaryotic genomes. Genome Res. 13:2178–2189.
      56.
      Carver TJ, Rutherford KM, Berriman M, Rajandream MA, Barrell BG, and Parkhill J. 2005. ACT: the Artemis Comparison Tool. Bioinformatics 21:3422–3423.
      57.
      Zerbino DR and Birney E. 2008. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res. 18:821–829.
      58.
      Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32:1792–1797.
      59.
      Liu K, Linder CR, and Warnow T. 2011. RAxML and FastTree: comparing two methods for large-scale maximum likelihood phylogeny estimation. PLoS One 6:e27731. doi:10.1371/journal.pone.0027731.
      60.
      Dziva F, van Diemen PM, Stevens MP, Smith AJ, and Wallis TS. 2004. Identification of Escherichia coli O157:H7 genes influencing colonization of the bovine gastrointestinal tract using signature-tagged mutagenesis. Microbiology 150:3631–3645.
      61.
      Barrow PA. 1983. A note on a method to aid sampling populations for characteristics. J. Appl. Bacteriol. 54:311–312.
      62.
      Datsenko KA and Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97:6640–6645.
      63.
      Ren CP, Chaudhuri RR, Fivian A, Bailey CM, Antonio M, Barnes WM, and Pallen MJ. 2004. The ETT2 gene cluster, encoding a second type III secretion system from Escherichia coli, is present in the majority of strains but has undergone widespread mutational attrition. J. Bacteriol. 186:3547–3560.
      64.
      Peleg A, Shifrin Y, Ilan O, Nadler-Yona C, Nov S, Koby S, Baruch K, Altuvia S, Elgrably-Weiss M, Abe CM, Knutton S, Saper MA, and Rosenshine I. 2005. Identification of an Escherichia coli operon required for formation of the O-antigen capsule. J. Bacteriol. 187:5259–5266.
      65.
      Korea CG, Badouraly R, Prevost MC, Ghigo JM, and Beloin C. 2010. Escherichia coli K-12 possesses multiple cryptic but functional chaperone-usher fimbriae with distinct surface specificities. Environ. Microbiol. 12:1957–1977.
      66.
      Brzuszkiewicz E, Brüggemann H, Liesegang H, Emmerth M, Olschläger T, Nagy G, Albermann K, Wagner C, Buchrieser C, Emody L, Gottschalk G, Hacker J, and Dobrindt U. 2006. How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains. Proc. Natl. Acad. Sci. U. S. A. 103:12879–12884.
      67.
      Lynne AM, Skyberg JA, Logue CM, and Nolan LK. 2007. Detection of Iss and Bor on the surface of Escherichia coli. J. Appl. Microbiol. 102:660–666.
      68.
      Binns MM, Davies DL, and Hardy KG. 1979. Cloned fragments of the plasmid ColV,I-K94 specifying virulence and serum resistance. Nature 279:778–781.
      69.
      Barondess JJ and Beckwith J. 1990. A bacterial virulence determinant encoded by lysogenic coliphage lambda. Nature 346:871–874.
      70.
      Skyberg JA, Johnson TJ, and Nolan LK. 2008. Mutational and transcriptional analyses of an avian pathogenic Escherichia coli ColV plasmid. BMC Microbiol. 8:24. doi:10.1186/1471-2180-8-24.
      71.
      Lynne AM, Skyberg JA, Logue CM, Doetkott C, Foley SL, and Nolan LK. 2007. Characterization of a series of transconjugant mutants of an avian pathogenic Escherichia coli isolate for resistance to serum complement. Avian Dis. 51:771–776.
      72.
      Li G, Tivendale KA, Liu P, Feng Y, Wannemuehler Y, Cai W, Mangiamele P, Johnson TJ, Constantinidou C, Penn CW, Nolan LK, and Payne SM. 2011. Transcriptome analysis of avian pathogenic Escherichia coli O1 in chicken serum reveals adaptive responses to systemic infection. Infect. Immun. 79:1951–1960.
      73.
      Badger JL, Wass CA, and Kim KS. 2000. Identification of Escherichia coli K1 genes contributing to human brain microvascular endothelial cell invasion by differential fluorescence induction. Mol. Microbiol. 36:174–182.
      74.
      Badger JL, Wass CA, Weissman SJ, and Kim KS. 2000. Application of signature-tagged mutagenesis for identification of Escherichia coli K1 genes that contribute to invasion of human brain microvascular endothelial cells. Infect. Immun. 68:5056–5061.
      75.
      Hill VT, Townsend SM, Arias RS, Jenabi JM, Gomez-Gonzalez I, Shimada H, and Badger JL. 2004. TraJ-dependent Escherichia coli K1 interactions with professional phagocytes are important for early systemic dissemination of infection in the neonatal rat. Infect. Immun. 72:478–488.
      76.
      Martindale J, Stroud D, Moxon ER, and Tang CM. 2000. Genetic analysis of Escherichia coli K1 gastrointestinal colonization. Mol. Microbiol. 37:1293–1305.
      77.
      Gonzalez MD, Lichtensteiger CA, and Vimr ER. 2001. Adaptation of signature-tagged mutagenesis to Escherichia coli K1 and the infant-rat model of invasive disease. FEMS Microbiol. Lett. 198:125–128.
      78.
      Bahrani-Mougeot FK, Buckles EL, Lockatell CV, Hebel JR, Johnson DE, Tang CM, and Donnenberg MS. 2002. Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic Escherichia coli virulence determinants in the murine urinary tract. Mol. Microbiol. 45:1079–1093.
      79.
      Tuntufye HN, Lebeer S, Gwakisa PS, and Goddeeris BM. 2012. Identification of avian pathogenic Escherichia coli genes that are induced in vivo during infection in chickens. Appl. Environ. Microbiol. 78:3343–3351.
      80.
      Shifrin Y, Peleg A, Ilan O, Nadler C, Kobi S, Baruch K, Yerushalmi G, Berdichevsky T, Altuvia S, Elgrably-Weiss M, Abe C, Knutton S, Sasakawa C, Ritchie JM, Waldor MK, and Rosenshine I. 2008. Transient shielding of intimin and the type III secretion system of enterohemorrhagic and enteropathogenic Escherichia coli by a group 4 capsule. J. Bacteriol. 190:5063–5074.
      81.
      Girón JA, Torres AG, Freer E, and Kaper JB. 2002. The flagella of enteropathogenic Escherichia coli mediate adherence to epithelial cells. Mol. Microbiol. 44:361–379.
      82.
      Erdem AL, Avelino F, Xicohtencatl-Cortes J, and Girón JA. 2007. Host protein binding and adhesive properties of H6 and H7 flagella of attaching and effacing Escherichia coli. J. Bacteriol. 189:7426–7435.
      83.
      Mahajan A, Currie CG, Mackie S, Tree J, McAteer S, McKendrick I, McNeilly TN, Roe A, La Ragione RM, Woodward MJ, Gally DL, and Smith DG. 2009. An investigation of the expression and adhesin function of H7 flagella in the interaction of Escherichia coli O157:H7 with bovine intestinal epithelium. Cell. Microbiol. 11:121–137.
      84.
      Masuda N and Church GM. 2002. Escherichia coli gene expression responsive to levels of the response regulator EvgA. J. Bacteriol. 184:6225–6234.
      85.
      Nishino K, Inazumi Y, and Yamaguchi A. 2003. Global analysis of gene regulation by EvgA of the two-component regulatory system of Escherichia coli. J. Bacteriol. 185:2667–2672.
      86.
      Low AS, Holden N, Rosser T, Roe AJ, Constantinidou C, Hobman JL, Smith DG, Low JC, and Gally DL. 2006. Analysis of fimbrial gene clusters and their expression in enterohaemorrhagic Escherichia coli O157:H7. Environ. Microbiol. 8:1033–1047.
      87.
      Spurbeck RR, Stapleton AE, Johnson JR, Walk ST, Hooton TM, and Mobley HL. 2011. Fimbrial profiles predict virulence of uropathogenic Escherichia coli strains: contribution of ygi and yad fimbriae. Infect. Immun. 79:4753–4763.
      88.
      Torres AG. 2009. The cad locus of Enterobacteriaceae: more than just lysine decarboxylation. Anaerobe 15:1–6.

      Information & Contributors

      Information

      Published In

      Infection and Immunity
      Volume 81Number 3March 2013
      Pages: 838 - 849
      Editor: J. B. Bliska

      History

      Received: 5 November 2012
      12 December 2012
      Accepted: 19 December 2012
      Published online: 28 December 2012

      Permissions

      Request permissions for this article.

      Contributors

      Authors

      Francis Dziva
      Enteric Bacterial Pathogens Laboratory, Institute for Animal Health, Compton, Berkshire, United Kingdom
      Present address: Francis Dziva, School of Veterinary Medicine, University of the West Indies, St Augustine, Trinidad and Tobago; Pauline M. van Diemen, Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Sabine Eckert, Oxford Nanopore Technologies, Edmund Cartwright House, Oxford, United Kingdom; Christa Ewers, Fachtierärztin für Mikrobiologie, Institut für Hygiene und Infektionskrankheiten der Tiere, Justus-Liebig-Universität, Giessen, Germany; Suman Mukhopadhyay, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
      Heidi Hauser
      Pathogen Genomics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom
      Thomas R. Connor
      Pathogen Genomics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom
      Pauline M. van Diemen
      Enteric Bacterial Pathogens Laboratory, Institute for Animal Health, Compton, Berkshire, United Kingdom
      Present address: Francis Dziva, School of Veterinary Medicine, University of the West Indies, St Augustine, Trinidad and Tobago; Pauline M. van Diemen, Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Sabine Eckert, Oxford Nanopore Technologies, Edmund Cartwright House, Oxford, United Kingdom; Christa Ewers, Fachtierärztin für Mikrobiologie, Institut für Hygiene und Infektionskrankheiten der Tiere, Justus-Liebig-Universität, Giessen, Germany; Suman Mukhopadhyay, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
      Graham Prescott
      Enteric Bacterial Pathogens Laboratory, Institute for Animal Health, Compton, Berkshire, United Kingdom
      Gemma C. Langridge
      Pathogen Genomics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom
      Sabine Eckert
      Pathogen Genomics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom
      Present address: Francis Dziva, School of Veterinary Medicine, University of the West Indies, St Augustine, Trinidad and Tobago; Pauline M. van Diemen, Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Sabine Eckert, Oxford Nanopore Technologies, Edmund Cartwright House, Oxford, United Kingdom; Christa Ewers, Fachtierärztin für Mikrobiologie, Institut für Hygiene und Infektionskrankheiten der Tiere, Justus-Liebig-Universität, Giessen, Germany; Suman Mukhopadhyay, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
      Roy R. Chaudhuri
      Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
      Christa Ewers
      Veterinary Faculty, Free University Berlin, Berlin, Germany
      Present address: Francis Dziva, School of Veterinary Medicine, University of the West Indies, St Augustine, Trinidad and Tobago; Pauline M. van Diemen, Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Sabine Eckert, Oxford Nanopore Technologies, Edmund Cartwright House, Oxford, United Kingdom; Christa Ewers, Fachtierärztin für Mikrobiologie, Institut für Hygiene und Infektionskrankheiten der Tiere, Justus-Liebig-Universität, Giessen, Germany; Suman Mukhopadhyay, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
      Melha Mellata
      The Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, Arizona, USA
      Suman Mukhopadhyay
      The Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, Arizona, USA
      Present address: Francis Dziva, School of Veterinary Medicine, University of the West Indies, St Augustine, Trinidad and Tobago; Pauline M. van Diemen, Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Sabine Eckert, Oxford Nanopore Technologies, Edmund Cartwright House, Oxford, United Kingdom; Christa Ewers, Fachtierärztin für Mikrobiologie, Institut für Hygiene und Infektionskrankheiten der Tiere, Justus-Liebig-Universität, Giessen, Germany; Suman Mukhopadhyay, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
      Roy Curtiss III
      The Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, Arizona, USA
      Gordon Dougan
      Pathogen Genomics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom
      Lothar H. Wieler
      Veterinary Faculty, Free University Berlin, Berlin, Germany
      Nicholas R. Thomson
      Pathogen Genomics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom
      Derek J. Pickard
      Pathogen Genomics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom
      Mark P. Stevens
      Division of Infection and Immunity, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian, United Kingdom

      Editor

      J. B. Bliska
      Editor

      Notes

      H.H. and T.R.C. contributed equally to this article.
      Address correspondence to Mark P. Stevens, [email protected].

      Metrics & Citations

      Metrics

      Citations

      View Options

      Media

      Figures

      Other

      Tables

      Share

    There are no results at this time

    American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
    FIND OUT MORE about the privacy policy